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Abstract 
 
Within the European Union the use of growth promoting agents in cattle fattening is 
prohibited according to Council Directive 96/22/EC. Interestingly, there is not a black list 
of substances, but 96/22/EC states that all substances having thyrostatic, estrogenic, 
androgenic or gestagenic activity are prohibited. Besides abuse of the “classical” synthetic 
steroids there is a tendency towards misuse of natural steroids and prohormones. 
Prohormones are compounds that exhibit limited or no hormonal activity but are direct 
precursors of bioactive hormones and are intended to be converted to full active hormones 
via enzymatic processes in the body. However, knowledge about metabolism, the mode of 
action and excretion profiles in cattle is often unclear, and methods to detect abuse of 
prohormones in livestock production are lacking. Therefore, the aim of this thesis was to 
get insight into the hormonal action of prohormones and to develop novel in vitro and in 
vivo screening methods allowing effective surveillance on the illegal use of prohormones 
in livestock production. Hereby the emphasis was on developing effect based approaches 
to better meet Council Directive 96/22/EC. 
The bioactivity of a wide variety of supplements which contained prohormones were 
tested using a yeast androgen bioassay. For supplements containing solely prohormones 
the value of this bioactivity based screening appeared to be limited as they require 
metabolism to become active. Therefore, screening methods for animal feed, supplements 
and preparations were set-up by using the same yeast androgen bioassay in combination 
with bovine liver models as well as enzymatic and chemical deconjugation procedures to 
mimic in vivo metabolic bioactivation. The use of either bovine liver S9, liver slices, pure 
enzymes or alkaline hydrolysis showed that prohormones could be activated, resulting in a 
significant increase in bioactivity as determined by the androgen yeast bioassay. 
For the detection of prohormone abuse at the farm and/or slaughterhouse the usefulness of 
‘omics’ based profiling techniques was investigated. Within this scope a comprehensive 
metabolomics based screening strategy for steroid urine profiling was developed. 
Comparison of urinary profiles revealed large differences between the profiles of controls 
and dehydroepiandrosterone (DHEA) as well as pregnenolone treated animals. Moreover 
this steroid urine profiling approach allowed identification of biomarkers for treatment by 
specific prohormones. This resulted in respectively 7 and 12 specific mass peak loadings 
which could potentially be used as biomarkers for pregnenolone and DHEA treatment. 
In addition, the feasibility of a liver gene expression profiling approach was investigated 
to monitor the effects of DHEA treatment at the transciptome level. It was shown that 
identification and application of genomic biomarkers for screening of DHEA abuse in 
cattle is substantially hampered by biological variation. On the other hand, it was 
demonstrated that comparison of pre-defined gene sets versus the whole genome 
expression profile of an animal allows to distinguish DHEA treatment effects from 
variations in gene expression due to inherent biological variation.  
Altogether the results of this thesis increase the knowledge about the metabolism and 
bioactivation of prohormones in vitro as well as in vivo. Based on this knowledge, a panel 
of new effect based concepts and screening methods was developed that complement and 
improve the current testing programs. These new concepts will facilitate better 
implementation of the European ban on growth promoters in livestock production as 
described in Council Directive 96/22/EC.  
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 1.1. History, legislation and monitoring  
In modern livestock production special meat producing breeds in combination with 
sophisticated feeding strategies are employed to assure optimal growth thereby 
maximizing economical benefits for the farmer. However, to further increase productivity, 
farmers are tempted to use illegal growth promoters like anabolic steroids, thyrostatics 
and ß-agonists.  
One of the first experiments with growth promoters in ruminants dates back from 1947 
showing improved growth and feed conversion in heifers as a consequence of 
diethylstilbestrol (DES) administration [1]. The recognition of the growth promoting 
properties of estrogens, either alone or in combination with androgens led to their 
introduction as a tool to increase meat production. In 1955, the USA allowed DES-
containing ear implants in cattle and since then, not only in the USA but also in Europe, a 
wide range of compounds came available for growth promoting purposes comprising 
synthetic as well as natural hormones. Because of the awareness that residues of growth 
promoters in meat may lead to disturbance of homeostatic hormone levels and might 
adversely affect consumers health [2,3], the use of anabolic agents for growth promoting 
purposes has been forbidden in The Netherlands since 1961 by a decree of the Commodity 
Board of Livestock and Meat (PVV) [4]. This consequently raised the need for effective 
methods to control and monitor abuse of growth promoters and since then various 
biological, histological, chemical and immunological based screening and detection 
methods were developed (Figure 1). One of the first screening methods to track abuse of 
estrogens was based on histological examinations of the prostate and Bartholin’s gland in 
veal calves [5,6]. When animals were found suspect the urine was checked by using more 
specific chemical and immunochemical methods like thin layer chromatography (TLC) 
and immunoassays (ELISAs and RIAs). In the beginning of the 1980s the illegal use of 
estrogens strongly reduced in favor of other anabolic compounds and cocktails. As a result 
it was harder to identify treated animals due to the fact that histological evaluations 
showed more variations and alterations were less pronounced [7]. Consequently, control 
measures shifted to the already existing detection/conformation methods like TLC and 
immunoassays later followed by more specific hyphenated techniques like gas 
chromatography (GC) and high performance liquid chromatography (HPLC) coupled to 
mass spectrometry [8]. These techniques allow targeted detection and quantification of a 
limited number of pre-selected analytes in one single run. Nowadays a typical analytical 
strategy for residue monitoring is in general a two-step approach. At first, a low cost 
screening method is applied which is optimized to prevent false negative results. 
Secondly, a confirmation method is used to confirm any positive screening result thereby 
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 preventing false positive results. For both screening as well as confirmation procedures 
gas and liquid chromatography in combination with mass spectrometric detection (GC- 
and LC-MS/MS) are used extensively and are considered state-of-the-art in veterinary 
control. Apart from screening by GC- and LC-MS, traditional methods such as ELISAs 
and RIAs are still used as well. Moreover, the last years a lot of effort is invested in 
development of novel effect based methods, like biosensors and receptor mediated 
bioassays which have shown to be very useful for screening groups of compounds with a 
similar mode of action [9]. In case of the illegal use of hormones this is of particular 
interest for the detection of new, possibly unknown compounds that can escape from 
detection by chemical analytical methods. 
Figure 1: In time evolvement of methods routinely used for monitoring growth promoter abuse. 
 
In The Netherlands, nowadays control is largely governed by European Union 
legislations. The oldest EU directives date back from 1970 specifying the additives that 
can be used in animal feeds [10]. Since then, EC legislation was continuously amended 
and updated until in 1988 EC legislation 88/146/EC became effective which totally 
prohibited the use of all hormonal growth promoting substances for fattening of farm 
animals [11]. The latter was replaced in 1996 by Council Directive 96/22/EC which states 
that; “Member states shall prohibit: the administering to a farm or aquaculture animal, by 
any means whatsoever, of substances having a thyrostatic, oestrogenic, androgenic or 
gestagenic action and of beta-agonists” [12]. Here it should be noted that the ban 
described in this directive does not comprise a black list of substances, but explicitly 
prohibits groups of substances based on their bioactivity. This bioactivity character is 
even more pronounced in the Dutch national legislation which prohibits the use of 
substances that exhibit any hormonal activity [13].  
To ensure compliance with EU legislations, requirements for residue analysis are 
described in Council Directive 96/23/EC [14]. This primarily includes sampling and 
investigation procedures, indications for sanctions in case of non compliance and rules for 
reporting of monitoring programmes. Also within the framework of Council Directive 
96/23/EC, technical guidelines and performance criteria are described in Commission 
Decision 2002/657/EC [15]. At a national level these EU legislations are implemented in 
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 residue monitoring programs regulating sampling of animal matrices and residue analysis 
therein. Analysis of the samples taken is performed by routine or field laboratories 
(RFLs). In each member state the RFLs are coordinated and controlled by a national 
reference laboratory (NRL) designated by the national government. The results of the 
implementation of these national residue monitoring plans in the EU Member states are 
included in European Commission annually reports [16]. Based on the result of these 
regulatory residue testing programs a realistic overall estimate of the misuse of 
compounds in the European Union can be made (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Number of bovine samples analyzed for steroids in the European Union. Shown are the total targeted 
and suspect samples analyzed as well as the number of samples found non-compliant in the period of 2005 up to 
2008 [16].  
 
For example in 2008, a total of 28171 targeted samples from bovine origin were taken for 
steroid analysis of which 0.31 % was found non-compliant (0.18% excluding cortico-
steroids) [16]. In absolute numbers these were 89 non-compliant samples for a total of 12 
substances. In addition, 2842 suspect samples were taken as part of the residue control 
which refers to samples taken as a consequence of either non-compliant results or a 
suspicion of illegal treatment. Of these 2842 samples 60 were found non-compliant for a 
total of 6 substances. Besides the classic synthetic steroids a trend is observed towards 
natural steroid hormones, used alone or in combinations. Moreover, inspections of 
livestock farms in the Netherlands occasionally turn up feed or herbal additives and 
preparations containing so-called prohormones. These compounds exhibit limited or no 
hormonal activity but are direct precursors of bioactive hormones and are intended to be 
converted to full active hormones via enzymatic processes in the body.  
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 Sport doping control faces similar problems and it appears that for muscle growth the 
same products are used by athletes as in cattle fattening. Until a few years ago 
prohormone containing supplements (e.g. dehydroepiandrosterone (DHEA), 4-androstene-
diol and 4-androstenedione) were sold as over the counter supplements in the USA and 
could be easily obtained by Dutch consumers via the internet. Since January 2005, when 
the Anabolic Steroid Control Act became effective in the USA, prohormones were added 
to the list of controlled substances [17]. From that time selling and possession of 
prohormones and prohormone containing supplements was banned and prohormones 
could only be obtained with a medical description [18]. Drug monitoring in sports is 
governed by the World Anti-Doping Agency (WADA) which, in contrast to Council 
directive 96/22/EC, publishes a list of prohibited substances which include all anabolic 
steroids as well as their precursors [19]. On this list however, there are closed and open 
classes. A closed class means that control laboratories must screen for only the 
compounds listed (e.g. endogenous anabolic steroids). An open class means that control 
laboratories must screen for compounds that have similar chemical structures or biological 
activity to those named in the list, this to avoid missing new designer steroids.  
Despite the observed increase in prohormone abuse in livestock production, knowledge 
about metabolism, the mode of action and excretion profiles of prohormones in cattle is 
limited. Moreover adequate screening and detection methods to prove prohormone abuse 
are lacking because biomarkers are most times not known or are not above highly 
fluctuating endogenous levels. The main purpose of this thesis research is to get insight in 
the hormonal action of assumed prohormones and to develop novel in vitro and in vivo 
screening methods allowing effective surveillance on the illegal use of prohormones in 
livestock production. Hereby the focus was on precursors of the natural anabolic steroid 
17ß-testosterone and on DHEA in particular.  
 
1.2. Steroid (pro)hormones 
 
Chemical structure and nomenclature of steroids 
The chemical structure of steroid hormones consists of a polycyclic C17 steran skeleton 
named cyclopentaneperhydrophenanthrene which has three condensed cyclohexane rings 
(A, B and C) and a cyclopentane ring (D). Depending on the presence and location of 
methyl and alkyl side chain groups the parental steroid structures are classified as 
pregnane (C21), androstane (C19) or estrane (C18) (Figure 3) [20]. For steroids, systematic 
as well as trivial names are widely used. Systematic names are applied according to the 
rules for steroid nomenclature formulated by the IUPAC (International Union of Pure and 
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 Applied Chemistry) [21]. Hereby, the parental steroid structure (preg-, androst- and estr-) 
is the basis for denomination and prefixes and/or suffixes are added to indicate the 
presence 
Figure 3: The cyclopentanoperhydrophenanthrene structure together with the parental structures of pregnane, 
androstane and estrane listed [20]. 
 
and location of substituents and double bonds. Any number of prefixes is allowed, while 
only one suffix may be used which is chosen according to the preference list: acid, 
lactone, ester, aldehyde, ketone, alcohol, amine and ether. Multiple prefixes are written in 
alphabetical order. For natural steroids the most frequently occurring substituents are the 
hydroxyl goup (-ol or hydroxyl-) and the oxo group (-one or oxo-). The atoms or side 
groups which are oriented in the direction below the plane of the paper are denoted with 
and α and these atom bonds are shown as broken 
lines in structural formulas. When the orientation 
is in the direction above the plane of the paper 
this is denoted with a ß and these atom bonds are 
depicted as thickened solid lines in structural 
formulas. If there are two groups attached to the 
same carbon atom, only the orientation of one of 
the groups is included in the systematic name. In 
unsaturated steroid molecules the parental suffix 
(-ane) is replaced by -ene (-adiene or -en) and the location of the double bond is indicated 
by the lower number of the two carbon atoms involved in the bond. If similar substituents 
exist, like two double bonds or two hydroxyl groups, the prefixes di, tri, etc. are added 
before the suffix or prefix. For example, the systematic name of the prohormone DHEA is 
3ß-hydroxy-5-androsten-17-one as the molecule exists of an androstane skeleton with one 
double bond between C5 and C6, a hydroxyl group at the C3 and an oxo group located at 
the C17 position respectively (Figure 4). However it should be noted that, similar to many 
other steroids, this compound is known by many other (trivial) names like prasterone, 
fidelin, androstenolone, anastar, dehydroisoandrosterone, 3ß-hydroxy-etioallocholan-5-
    Figure 4: Structure formula of  
    3ß-hydroxy-5-androsten-17-one (DHEA). 
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 ene-17-one, trans-dehydroandrosterone and 5,6-dehydroisoandrosterone. 
 
Biosynthesis and metabolism of natural steroids 
Natural sex steroid hormones are mainly produced in the gonads and adrenal glands and 
play an important role in growth, behavior, organ functioning and development of 
secondary sex characteristics. Testicular and ovarian steroid hormone production is 
controlled by the pituitary gonadotropins luteinizing hormone (LH) and follicle 
stimulation hormone (FSH). In this process prohormones like DHEA and 4-
androstenedione mainly serve as intermediates for the production of more potent sex 
hormones and only 10-25% of the DHEA and 5% of the DHEA-sulfate produced in the 
gonads are secreted directly in the blood [22]. Biosynthesis of prohormones like DHEA 
and 4-androstenedione also takes place in the adrenal cortex and is induced by 
corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) which stimulate 
the release of adrenocorticotropin (ACTH) from the pituitary gland [23]. 
In both gonads and adrenals, steroid synthesis is stimulated by binding of LH, FSH or 
ACTH to their corresponding receptors located at the cell surface. Upon receptor binding, 
conformational changes stimulate adenylyl cyclase and subsequently increased production 
of cyclic adenosine monophosphate (cAMP). cAMP activates protein kinase A (PKA) and 
phosphorylation of cholesteryl esterase which leads to an increase in intracellular 
concentrations of cholesterol. This extra-mitochondrial cholesterol is transported by 
steroidogenic acute regulatory (STAR) protein to the inner membrane of the mitochondria 
where side chain cleavage by CYP11A1 (or desmolase) turns cholesterol into 
pregnenolone. Secondly, cAMP affects long-term regulation of CYP11A1 by binding to 
cAMP regulatory elements on the CYP11A1 gene resulting in increased RNA 
transcription and increased levels of the CYP11A1 enzyme. Subsequent to CYP11A1 
activity, pregnenolone moves to the cytosol were further conversion takes place (Figure 
5). In addition ACTH stimulates the production of mineralocorticosteroids and 
glucocorticosteroids in respectively the zonae glomerulosa and reticularis [23]. This 
includes cortisol a glucocorticoid which provides the negative feedback on CRH, AVP 
and ACTH via the hypothalamo-pituitary system.  
Transformation of pregnenolone by 3ß-hydroxysteroiddehydrogenase (3ß-HSD) or 
CYP17A1 are competing reactions, and are respectively known as the Δ4- and Δ5-
pathway. Interestingly, in humans and bovines the Δ5-pathway is preferred while rodents 
mainly utilize the Δ4-pathway [24]. In the Δ5-pathway pregnenolone is hydroxylated by 
CYP17A1 to 17α-hydroxypregnenolone, and afterwards converted to DHEA via side 
chain cleavage by 17,20-lyase activity by the same CYP17A1 enzyme. 3ß-HSD completes 
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 the pathway by oxidation of DHEA to 4-androstenedione. In contrast, the Δ4-pathway 
starts with metabolism of pregnenolone by 3ß-HSD with progesterone as a product. 
Progesterone also serves as a substrate for CYP17A1 and can be metabolized to 17α-OH-
progesterone and further converted to 4-androstenedione by the 17,20 lyase activity of 
CYP17A1. 
Figure 5: Steroid biosynthesis pathway; a - Cytochrome P450 11A1 (CYP11A1) b - Cytochrome P450 17A1 
(CYP17A1) c - 3ß-Hydroxysteroid dehydrogenase/isomerase (3ß-HSD) d - 17ß-Hydroxysteroid dehydrogenase 
(17ß-HSD) e  - Cytochrome P450 19A1 (Aromatase) f  - Cytochrome P450 21 A1 (CYP21A1). 
 
Phase I metabolism 
Steroidal prohormones are extensively metabolized in vivo and after exogenous 
administration only small amounts of the parent substances are excreted via the urine. The 
most important metabolic phase I reactions include oxidation or reduction at the C3 and 
C17 position by hydroxysteroid dehydrogenases (HSDs), reduction of double bounds by  
5-reductases, aromatization of the A-ring by aromatase and hydroxylation at various 
positions of the parental steroid structure by cytochrome P450 (CYP) activity (Figure 5).  
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 3-Hydroxysteroid dehydrogenase (3-HSDs)  
3ß-HSDs are most abundantly present in steroidogenic tissues but are also found in 
various other tissues like liver, kidney, brain, skin, lung and adipose tissue. The 
widespread distribution of 3ß-HSD expression indicates that this enzyme plays an 
important role in the intracrine formation of sex steroids in large series of peripheral target 
tissues. Molecular cloning experiments have shown that at least three isoforms of 3ß-HSD 
are expressed in rat, six isoforms in mouse and two in humans (types I and II) [25]. 
Human 3ß-HSD type I is mainly found in the placenta and peripheral intracrine tissues, 
while type II is almost exclusively expressed in the adrenals and gonads [26]. In contrast 
to humans, up till now only one 3ß-HSD type has been identified in bovine species 
[26,27]. Under 3ß-HSD activity, 3ß-hydroxy-5-ene steroids are transformed into 3-oxo-4-
ene steroids. This two step transformation involves a dehydrogenase and an isomerase 
reaction. The first step in dehydrogenation of DHEA requires NAD+ as a cofactor 
resulting in 5-androstenedione and reduced NADH. Subsequently, this reduced coenzyme 
NADH, induces a conformational change in the enzyme protein that activates the 
isomerase reaction converting 5-androstenedione into 4-androstenedione [28]. Also 
NADP+ can serve as a cofactor in these reactions but was reported to be relatively 
ineffective [25].  
 
17-Hydroxysteroid dehydrogenases (17-HSDs) 
17ß-HSDs catalyze the interconversion of 17-ketosteroids into their corresponding 17ß-
hydroxy steroids. At present 14 different mammalian 17ß-HSDs have been identified [29] 
which are with the exception of 17ß-HSD type 5 all members of the short chain 
dehydrogenase/reductase (SDR) family. SDRs constitute a large protein family of 
oxidoreductases, present throughout species. 17ß-HSD enzymes are acting on a large set 
of substrates and are responsible for reduction or oxidation of hormones, fatty acids and 
bile acids in vivo. Although named as 17ß-HSDs, reflecting the major redox activity at the 
17ß-position of the steroid, several 17ß-HSDs are able to convert multiple substrates at 
multiple sites, such as at the C3 position of the steroid ring. Most of the 17ß-HSDs have 
bidirectional capabilities, catalyzing either the oxidative or reductive reaction in the 
presence of the cofactors NAD(P)+ or NAD(P)H respectively. The intracellular location of 
the enzymes is diverse and different 17ß-HSDs have found to be located in the cytosol, 
microsomes, mitochondria and peroxisomes. Also differences in enzymatic activity are 
observed across tissues and organs. These observations along with kinetic studies have 
demonstrated that although the enzymes have multifunctional capabilities, most have 
preferential substrate specificity and directionality in vivo [30].  
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 Epitestosterone, the 17α-epimer of testosterone, is abundantly present in the urine of men 
and equals the concentrations of testosterone. Although the exact pathway of formation is 
still a subject of research, it is believed that epitestosterone is formed by conversion of   
17-keto steroids by 17α-HSD activity. This is supported by a study where oral 
administration of hundreds of milligrams of 4-androstenedione showed an increase in the 
urinary excretion rate of epitestosterone [31] and a study in human embryonic kidney 
(HEK-293) cells showing conversion of 4-androstenedione to epitestosterone [32]. 
Another hypothesis is that epitestosterone is formed by 3ß-HSD oxidation of androst-5-
ene-3ß,17α-diol in the testes [33] this precursor in turn, might be formed as a by-product 
in the synthesis of androsta-5,16-dien-3ß-ol from pregnenolone [34]. In humans it has 
been shown that interconversion of testosterone and epitestosterone is negligible. As a 
result, the T/E ratio is utilized as a parameter for detecting abuse of 17ß-testosterone in 
human sports doping [35]. Compared to humans, other animal species such as rabbits, 
guinea pigs, mice and calves show great differences in excretion ratio of T and E [36, 37]. 
This is likely caused by the activity of 17α-hydroxysteroid which is much higher than in 
men and catalyses a conversion of 17ß-testosterone into epitestosterone. Similar as in 
humans, the pathway of epitestosterone formation in bovines is far from clear, and in spite 
of the fact that the testis was identified as a source of endogenous epitestosterone, no 
interconversion of testosterone and epitestosterone was observed in the testes of bulls, 
[37]. On the other hand, in castrated bovines it has been demonstrated that 37% of the 
conversion of testosterone in epitestosterone takes places in peripheral tissues like the 
blood and liver [38].  
 
5α- and 5ß-reductases 
The initial and rate limiting step in metabolism of 3-keto-4-ene steroids, such as 
testosterone, is the reduction of the C4-C5 double bond by 5α- or 5ß-reductase activity. 
Both 5α- and 5ß-reductases require NADPH as a cofactor and are located mainly in the 
liver but also in kidneys, adrenals, skin and testis. In humans, two isoenzymes of            
5α-reductase are identified, namely type 1 and type 2; the former exists predominantly in 
the skin whereas the latter is located mainly in the prostate [39]. Intracellular, 5α-
reductase is primarily located in the endoplasmatic reticulum while 5ß-reducatase is 
mainly located in the cytosol. The extent of 5α- and 5ß-isomers formed depends on the 
structure of the steroid such as differences in the D-ring structure. For example 
metabolism of testosterone to its 5α- and 5ß-isomers occurred in a ratio of 1:6 whereas for 
17-keto-metabolites (androsterone and etiocholanolone) the ratio was 1:1 [40]. In cattle 5α 
and 5ß metabolites of testosterone and its corresponding 17-keto metabolites are known, 
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 but no detailed information is available on their 5α/5ß ratio.  
In relation to bioactivity the orientation of these hydrogen atoms at the C5 position is very 
important. This can be illustrated by the relative androgenic potencies (RAP) of eight 
isomers of androstanediol which vary in α- and ß-configurations of the hydrogen atom at 
the C5 position and the hydroxyl-groups attached at the C3 and C17 position of the 
steroidal skeleton (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Eight isomers of androstanediol and their relative androgenic potencies (RAP) as determined in the 
RIKILT yeast androgen bioassay (extracted from Bovee et al. [41]) (nr = no response). 
 
It is shown that the more active compounds have a 5α-configuration which results in a 
more straightened steroidal structure which better fits the ligand binding pocket of the 
androgen receptor. Compared to 5α-androstane-3ß,17ß-diol, the 5ß-iosmer has a relative 
androgen potency (RAP) that is about 67 times lower than that of the 5α-isomer. In 
addition, it is shown that the ß-configuration of the  hydroxyl group located at C17 seems 
to play an important role in ligand binding, as all isomers with the hydroxyl group in the 
17α-position are not active [41].   
 
Hydroxylation by cytochrome P450 enzymes 
Endoplasmatic reticulum-bound cytochrome P450 enzymes play an important role in the 
oxidative metabolism of lipophilic compounds such as steroids [42]. In mammals the 
microsomal cytochromes are predominantly present in hepatic tissue where they catalyze 
NADPH-dependent mono-oxygenation reactions. In contrast to the extensive knowledge 
about human and rodent cytochrome P450 enzymes, the characterization of the 
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 cytochrome P450 system in livestock is still far from clear [43]. Although these reactions 
are highly species as well as compound specific, cytochrome P450 3A is considered to be 
the most important enzyme family involved in steroid hydroxylation.  
Within the scope of steroid urine profiling in humans, formation of hydroxy-metabolites 
upon DHEA and 4-androstenedione administration is extensively studied and reviewed by 
Van de Kerkhof [44]. For DHEA the main hydroxylation pathways are 7α-, 7ß- and 16α-
hydroxylation [45,46]. 16α-hydroxylation of DHEA to 16α-OH-DHEA is one of the most 
described hydroxylation reactions of DHEA as this metabolite is present in relatively high 
levels in urine [46, 47]. In addition to the hydroxy-metabolites also 7-keto-DHEA has 
been detected in human urine which is probably formed through dehydrogenation of the 
7α- or 7ß-OH-metabolites of DHEA. Based on in vitro as well as in vivo experiments the 
main reactions for 4-androstenedione are 4-, 6ß-, 16α-, 16ß- and 19-hydroxylation. The 
fact that for 4-androstenedione the same pathways are found as for hydroxylation of 
testosterone [48] suggests that these reactions are specific for androst-4-ene-3-one 
steroids. In cattle, data about hydroxylation of steroids is limited to experiments with 17ß-
testosterone [49].  
 
Aromatase 
Aromatase (CYP19) is also a cytochrome P450 enzyme which converts androgens into 
estrogens by aromatizing the steroidal A-ring using NADPH as a cofactor [50]. In most 
vertebrates aromatase enzyme activity is observed in the gonads, brain, placenta, adipose 
tissue, bone and various fetal tissues [51]. Among species the aromatase protein is highly 
conserved and compared to humans, bovine aromatase shows 86% homology in amino 
sequence identity and exhibits equal enzyme activity in the gonads [52]. 
 
Phase II metabolism 
Phase II reactions involve conjugation reactions of the polar functional groups formed as a 
result of phase I metabolism. These conjugation reactions occur at polar moieties like 
hydroxyl and carboxyl groups resulting in increased water solubility and consequently a 
more effective excretion via the urine. For steroids the main phase II reactions are 
sulfonation and glucuronidation which occur at the hydroxyl moiety at the C-3 and/or      
C-17 position of the steroid molecule. In humans, it is observed that 3α-hydroxy steroids 
are mainly conjugated with glucuronic acid while the 3ß-hydroxy steroids predominantly 
show sulfate conjugation [40]. Sulfoconjugation involves the transfer of a sulfonate (SO3-) 
from a donor molecule to the hydroxyl acceptor site. These reactions are catalyzed by 
sulfotransferases, which are located on the membranes of the Golgi complex and in the 
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 cytosol, and require the cofactor 3’-phosphoadenosine 5’-phosphosulfonate (PAPS) which 
is the sulfonate donor for all sulfotransferase reactions [53]. In humans sulfates of steroid 
precursors, especially DHEA-sulfate, play an important role as precursors in the 
peripheral biosynthesis of active steroid hormones. In order to become active the sulfate 
group is removed by sulfatase activity.  
The main site of glucuronidation is the liver, although glucuronidation also is observed in 
intestines, kidney and prostate tissue. The enzyme family responsible for catalyzing 
glucuronidation are called uridine diphosphate-glucuronosyltransferases (UGT) which 
include multiple isoforms and catalyze conversion of a wide variety of exogenous and 
endogenous compounds. The two families of UGT (UGT1 and UGT2) consist of more 
than 35 enzymes found in various species [54]. In humans, mainly the isoenzyme UGT1A 
and UGT2B subfamilies are involved in steroid hormone phase II metabolism [55] where 
UGT2B17 is one of the main human UGTB isoforms with a high affinity for C19 steroids 
such as DHEA, testosterone and dihydrotestosterone [56].  
 
Natural occurring levels of steroid prohormones  
The biological role and endogenous levels of prohormones, like DHEA, has been 
extensively studied in humans, primates and rodents and showed significant differences in 
blood plasma levels between species [57]. In most mammals plasma DHEA and DHEA-
sulfate levels are in the low nanomolar range. In humans, DHEA is also present in the 
nanomolar range while DHEA-sulfate is present at micromolar levels [58]. This is due to 
the high secretion rate of sex steroid precursors by the adrenal glands in humans which is 
completely different from laboratory animals like rats, mice and guinea pigs where no 
significant amounts of steroids are generated outside the gonads [59]. Also in bovines the 
adrenal contribution to plasma DHEA is believed to be limited [60]. Although the base 
levels of potent androgens and estrogens in cattle have been investigated intensively in the 
past, data describing endogenous levels of steroid precursors are limited (Table 1). In bull 
calves circulating DHEA plasma level were shown to be in the range of 100-1100 pg/ml 
[61,62] which is interestingly not significantly different from levels observed in heifers 
and dairy cows [61,63]. In cows levels of DHEA-sulfate were found to be significantly 
lower than those of DHEA [57,60] suggesting that DHEA (and not DHEA-sulfate) may be 
considered as the most important circulating precursor of androgens and estrogens in 
bovines. Steroid precursor levels in beef from bulls and steers are approximately 1000 
times lower than levels found in plasma. In beef from bulls median values were reported 
to be 670 pg/mg for pregnenolone, 10 pg/mg for 17α-hydroxyprogesterone, 240 pg/mg for 
DHEA and 390 pg/mg for 4-androstendione [64].   
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 Table 1: Plasma levels of steroid precursors (in pg/ml) observed in bulls and heifers as determined by 
radioimmunoassays (RIA).  
nd = not determined. 
 
Anabolic actions of prohormones 
Anabolic and androgenic actions of prohormones like DHEA appear to occur primarily 
through the metabolites formed in peripheral tissues. Hereby, the rate of formation of sex 
steroids strongly depends on the level of expression of specific androgen and estrogen 
synthesizing enzymes in the tissue. When the site of formation is the site of action this 
phenomena is described as ‘intracrinology’ [65]. Through this intracrine activity, locally 
produced androgens and estrogens exert their action in the same cell in which the 
synthesis takes place. [58]. Inside the cell these potent steroids exert their activity by 
binding to hormone specific receptors. After dimerization, the receptor-ligand complex 
undergoes conformational changes and is translocated to the nucleus. Upon binding to the 
DNA, hormone specific gene transcription is initiated and followed by translational 
processes and protein synthesis.  
In the illegal circuit and on the internet a wide variety of prohormone containing 
supplements and creams are marketed which claim to enhance active hormone levels in 
the body [18]. In principle the justification of these claims are based on the activity of 
steroid enzymes present in vivo which catalyze reactions such as:  
 
 Conversion of an - or -hydroxyl group attached to C3 by 3α-HSD or 3ß-HSD 
enzymes in a C3-oxo group.  
  Bulls (n=5) 
Bulls 
(n=10) 
Heifers 
(n=10) 
Heifers 
(n=6) 
Cows 
(n=12) 
Age 13-14 months 
9-11 
months Unknown 
12-14 
months 3-5 years 
Reference [62] [62] [61] [63] [63] 
Pregnenolone nd 250-1200 250-4000 nd nd 
17α-Hydroxyprogesterone nd 20-100 25-325 nd nd 
DHEA 557 (± 44) 100-1100 50-400 173-259 317-374 
4-Androstenedione nd 25-140 10-100 nd nd 
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  Conversion of the 5(6) double bond to a 4-C3-oxo group by 4,5-isomerase 
activity. This conversion probably also takes place under influence of the acidic 
environment in the stomach.  
 Combined conversion of a 5(6) double bond in combination with the 3ß-hydroxyl 
group by 3ß-HSD/4,5-isomerase in a 4 steroid with a C3-oxo group.  
 Conversion of a C17 oxo group by 17ß-HSD enzymes in a 17ß-hydroxyl group 
[66].  
 
In earlier days, only prohormones which are part of the testosterone biosynthesis pathway 
like DHEA, 5-androstenediol, 4-androstenedione and even pregnenolone were marketed. 
This however expanded to compounds which are not (directly) part of the steroid 
biosynthesis pathway like 4-androstene-3ß,17ß-diol (which exhibits also direct anabolic 
and androgenic activity) and precursors of synthetic steroids like boldione which can be 
easily converted to their active equivalents by 3ß-HSD or 17ß-HSD activity [67] (Figure 
5).  
Figure 7: Molecular structures of prohormones.  
 
But also compounds with saturated steroid nuclei like precursors and metabolites of 
dihydrotestosterone (DHT) are sold as prohormones. This in spite of the fact that DHT 
itself exhibits mainly androgenic activity and only limited anabolic activity. These 
compounds cannot serve as precursors of 17ß-testosterone, which is a more anabolic 
active compound, as the reduction of the double bond between C4 and C5 is irreversible. 
Also supplements containing herbs, herbal extracts and plant derived compounds are 
marketed for their prohormonal and subsequent anabolic activity. Compounds like 
diosgenin [68] (Figure 7) and fytosterols such as ß-sitosterol [69] are suggested to elevate 
androgen levels via the DHEA-pathway. However, the anabolic properties of these kinds 
of compounds are even more questionable and not much is known about the in vivo mode 
of action as well as metabolic transitions, especially not in bovines. 
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 1.3. Bioassays for androgen activity screening 
Although large differences in androgenic activities are observed between anabolic 
steroids, no  anabolic compound is known without any androgenic property. Therefore 
bioassays developed for screening for anabolic steroids mostly use androgenic effects 
(e.g. binding to the androgen receptor) as an endpoint.  In this paragraph a short overview 
is given of the types of bioassays used for screening on androgen activity and their 
response upon exposure to prohormones.    
 
In vivo bioassays 
The golden standard for evaluating androgen receptor (AR) agonistic and antagonistic 
properties of compounds is still the Hershberger assay [70]. This in vivo assay is 
employed by using either immature or castrated rats receiving the substance under 
investigation by oral gavage or subcutaneous injection for a period of ten consecutive 
days. When screening for potential anti-androgenic activity the rats are co-exposed to the 
test substance and testosterone propionate. The weights of five different androgen 
dependent tissues are determined: the ventral prostate, seminal vesicles, levator ani-
bulbocavernosus muscle, the paired Cowper’s glands and the glans penis. When, 
compared to a control group, the weight of two of these tissues are statistical significantly 
changed, the compound under investigation is scored positive for androgenic or anti-
androgenic activity. Data presented in Table 2 show androgenic activity, anabolic activity 
and the average anabolic/androgenic quotient (Q) of four steroidal precursors [71]. After 
subcutaneous injection of the test compound weights of the ventral prostate, seminal 
vesicles and levator ani muscle were determined using 17ß-testosterone as the biological 
standard of comparison which was set to 100. DHEA and 5-androstene-3ß,17ß-diol 
showed limited androgen and anabolic activity while the activity of 4-androstenedione 
was a factor 2-3 less than that of 17ß-testosterone and 4-androstene-3ß,17ß-diol however 
showed androgenic and anabolic effects comparable to 17ß-testosterone. 
 
Table 2: Androgenic and anabolic activity and average anabolic/androgenic quotient (Q) of steroidal precursors 
in rats. The standard of biological evaluation is expressed as 100% activity [71].  
  Androgenic activity Anabolic activity Q 
DHEA <10 <10 - 
4-Androstenedione 30-40 30-50 1 
5-Androstene-3ß,17ß-diol 20 10 0.5 
4-Androstene-3ß,17ß-diol 125 95 0.8 
17ß-Testosterone 100 100 1 
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 Application of such in vivo tests to measure androgenic activity has the advantage of 
including the ADME-parameters; absorption, distribution, metabolism and excretion and 
can also describe the disposition of a compound within an organism. However, these in 
vivo tests are slow, expensive, difficult, and not very sensitive due to differences in 
preparation and weighing of the tissue involved. As a result, and for obvious ethical 
reasons, this animal test is not suitable for routine high through-put screening.  
 
In vitro bioassays 
As an alternative for in vivo bioassays various in vitro bioassays have been developed for 
use in clinical practice as well as for screening purposes on (anti)androgenic activity of 
chemicals and environmental samples or when steroid hormone abuse is suspected [9,72]. 
In general, the principles of these in vitro bioassays are based on either receptor binding, 
cell proliferation (the A-screen) [73], or receptor binding in combination with 
transcription activation of reporter genes. Receptor binding assays using androgen 
receptor ligand binding domains are the most simple in vitro models to describe the 
affinity of a ligand for the androgen receptor [74-76]. The binding affinity of DHEA to the 
androgen receptor was observed to be 2000 times lower than that of 17ß-testosterone, 50 
times lower than that of 4-androstene-3ß,17ß-diol and 20 times lower than that of             
4-androstenedione and 5-androstene-3ß,17ß-diol (Table 3). In addition DHEA showed 
also affinity for the estrogen receptor. Hereby the ERß was preferred over the ERα [77]. 
 
Table 3: Relative androgen receptor binding affinity (RBA) of prohormones and 17ß-testosterone compared to 
DHT [74]. 
 
 
 
 
 
 
 
 
 
The main disadvantage of receptor binding assays is that they cannot distinguish agonistic 
from antagonistic properties as the transcription activation step is not included. For this 
purpose several receptor based transcription activation reporter gene assays have been 
developed, based on mammalian as well as yeast cells, each having their own advantages 
and disadvantages.  
  RBA 
DHEA 0.037 
4-Androstenedione 0.86 
5-Androstene-3ß,17ß-diol 0.79 
4-Androstene-3ß,17ß-diol 1.7 
17ß-Testosterone 69 
DHT 100 
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 To date, various stably transfected mammalian cell based reporter gene assays have been 
developed making use of different cell types and reporter genes [78-84]. The most 
frequently used reporter genes encode for proteins like ß-galactosidase, luciferase or 
chloramphenicol acetyl transferase which convert a specific substrate in metabolites with 
easily measurable luminescence or fluorescence signals. These kind of assays are shown 
to be very sensitive and considered as biologically relevant for screening on androgenic 
effects. However, in response to a given test substance not all bioassays show identical 
results due to differences in metabolic capacities or due to the presence/lack of co-
regulators (Table 4). Metabolism by reporter cells results in either activation or 
inactivation of hormones and subsequent alteration of the bioactivity read out. The latter is 
not necessarily a disadvantage, in particular when screening for compounds that need 
metabolic activation, like prohormones. In a recombinant Chinese hamster ovary (CHO) 
cell line, DHEA showed an EC50 of 1 nM and a relative androgenic potency (RAP) of 
0.015 compared to DHT [82] (Table 4). This response is mainly caused by the metabolites 
of DHEA formed by 3ß- and 17ß-HSD enzyme activity and does not represent the 
androgenic activity of DHEA. These results indicate that this cell line could be useful for 
prohormone screening purposes. Other mammalian reporter assays based on MDA human 
mammary carcinoma cells, human prostate adenocarcinoma PC-3 cells (PALM) and      
U2-OS bone cells (AR-CALUX) are showing consistent results for DHT, as only a factor 
2-3 difference in response is observed between these assays (Table 4). For 4-
androstenedione the responses are less consistent and EC50 values are observed between 
4.5 and 140 nM. The EC50 for 4-androstenedione as observed in the MDA and PALM 
cells is in the same order of magnitude as the response found in the A-screen [73,85]. The 
EC50 observed in the AR-CALUX is thus relatively low and this might be due to the 
conversion of 4-androstenedione into 17ß-testosterone. DHEA does not show a response 
in both the AR-CALUX and the MDA cell line which is probably representing its actual 
androgenic activity. Another androgen reporter assay is based on human embryonic 
kidney (HEK) 293 cells expressing the human AR and androgen responsive luciferase 
[80]. Although no exact EC50 values are reported for DHEA, 4-androstenedione and         
5-androstene-3ß,17ß-diol, all three compounds clearly showed transcription activation in 
the range of 0.3-100 nM, most likely again as a result of their enzymatic conversion. 
Another factor which may reduce specificity in mammalian cell lines is the presence of 
other endogenous receptors like the progesterone and glucocorticoid receptor (PR and 
GR). This crosstalk occurs due the fact that the consensus androgen responsive element 
(ARE) equals those of progesterone and glucocorticoids. As a consequence AREs are also 
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 activated upon binding by glucocorticoid and progesterone ligand-receptor complexes 
[86]. Alternatives are found in application of reporter gene assays using host cells which 
show no steroid metabolism and do not express any endogenous steroid receptors like for 
instance yeast. Most androgen yeast bioassays developed are based on a Saccharomyces 
cerevisae host strain using either ß-galactosidase, luciferase or enhanced green fluorescent 
protein (EGFP) as a reporter gene [87-91]. In general, it is shown that these yeast assays 
are a factor 10-100 less sensitive as compared to mammalian cell based assays (Table 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Schematic representation of the mechanism of action of the RIKILT Androgen yeast Assay (RAA). 
 
On the other hand, yeast assays are found to be more robust than mammalian cell assays 
and can be used for screening of complex biological samples like animal feed, without 
extensive clean-ups [92]. In this thesis work we used the RIKILT Androgen bioAssay 
(RAA) which is based on a Saccharomyces cerevisae host strain which constitutively 
expresses the human androgen receptor and possesses an androgen responsive element 
(ARE) coupled to an enhanced green fluorescent protein (EGFP) reporter system [91] 
(Figure 8). Upon exposure of this yeast, androgens bind to the human androgen receptor 
which is present in the cytosol of the cell. After dimerization, the ligand-receptor complex 
undergoes conformational changes, which enable binding to the androgen responsive 
element. After translocation to the nucleus, binding to the androgen responsive element 
results in transcription of the yEGFP reporter gene. The formation of EGFP can be 
quantified by measuring the fluorescence signal using excitation at 485 nm and emission 
at 530 nm. This activation of gene transcription takes up to several hours and results in a 
measurable response already after 6 hours of incubation. However, for practical reasons 
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 dose response curves are normally obtained after 24 hours of incubation, which is a time 
point that maximum response is reached enabling a more accurate determination of the 
EC50.   
 
1.4. Advanced mass spectrometry of steroids and metabolites 
In the field of residue analysis there is a tendency in moving from targeted methods, 
mainly based on liquid or gas chromatography (LC or GC) in combination with triple 
quadropole mass spectrometric (MS-MS) detection, towards full scan MS techniques such 
as Time-Of-Flight (TOF) and Fourier Transform (FT) Orbital Trap (Orbitrap) or Ion 
Cyclotron Resonance mass spectrometry [93]. Hyphenation with improved separation 
techniques like ultra performance liquid chromatography (UPLC) lead to increased 
chromatographic resolution, speed, peak capacity (number of peaks resolved per unit time 
in a gradient separation) and sensitivity which allows a more complete analysis of 
complex biological samples like cell extracts, urine and supplements [94]. Moreover 
compared to traditional GC- and LC/MS-MS methods which target only preset ions or ion 
transitions of known molecules, full scan accurate mass spectrometry offers additional 
possibilities such as retrospective analysis (e.g. determining the presence of newly 
identified compounds in previous analyses), development of multi-compound/multi-class 
techniques and the identifications of new (unknown) compounds by accurate mass 
measurement, elemental composition elucidation assessment and structure elucidation. 
 
Table 5: Number of elemental compositions obtained for the [M + H]+ ions of DHEA (m/z 289.2168) and  
DHEA-glucuronide (m/z 465.2488).   
*Elemental composition restrictions: C0–50, H0–100, O0–10, S0–5 and double bond equivalent −0.5 to 20, even 
number of electrons only.  
    Mass accuracy No. of 
Compound m/z [M+H]+ ppm mDa elemental compositions* 
DHEA 289.2168 5 1.4 1 
    20 5.8 2 
    50 14.5 3 
DHEA-gluc 465.2488 5 2.3 2 
    20 9.3 6 
    50 23.3 20 
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 Elemental composition searches limit the number of possible compound identities 
tremendously when searching in molecule databases such as Scifinder or the Merck index 
[97 ,98]. The accurate mass of an ion is calculated as the sum of the individual exact 
masses of all the atoms in the ionized molecule. For example the monoisotopic mass of 
1H=1.0078, 12C=12.0000 and 16O=15.9949. In natural steroid hormone analysis, masses of 
relevant compounds are typically in the range of 200-500 Da and elemental compositions 
include the atoms C, H, O occasionally S like as for steroid sulfates. When assuming that 
the mass spectrometer has been calibrated well a mass accuracy of < 5 ppm can point to a 
single elemental composition option as shown in Table 5 for the DHEA [M+H]+ ion at   
m/z 289.2168 (C19H29O2). A mass accuracy of 20 ppm yields only two elemental 
composition options (C19H29O2 and C16H33O2S) and 50 ppm already yields three elemental 
compositions (C19H29O2,C16H33O2S and C16H33S2). The number of possible formulae 
increases exponentially as the mass accuracy further decreases and as the molecular mass 
of a compound increases. As shown for DHEA-glucuronide (m/z 465.2488) already six 
possible elemental compositions within 20 ppm mass accuracy are obtained. The factors 
affecting mass accuracy typically include the design of the mass analyzer and (the 
stability of) its mass calibration. The TOFMS instrumentation used in this thesis research 
allowed the acquisition of accurate masses within 5 ppm, however occasionally only 20 
ppm could be achieved. 
Subsequent searches of the obtained elemental composition in comprehensive electronic 
databases such as Scifinder can narrow down the number of tentative identities 
significantly. In this case C19H28O2 (DHEA) initially gave 2439 possible compound 
options in Scifinder. After refining this search by only looking for C19 steroid structures 
and exclusion of isotopes, 136 options were remaining. Since accurate mass 
measurements as performed by high resolution TOFMS are specific and universal for 
every compound regardless of the instrumentation used, TOFMS enables the use of 
accurate mass databases in reducing the number of potential identities [99,100]. In this 
way accurate mass databases have been used for the identification of androgenic 
compounds in herbal mixtures and sport supplements [100]. In addition information about 
isotopic peak ratios, expected retention time and knowledge about the nature of the 
sample should be used to refine the search leading to the possible identity of the 
compound. Nevertheless it should be noted that one exact mass yields multiple structural 
formulas and that within one molecular formula multiple structural isomers are possible 
(as for example for 5-androstanediol, see Figure 6).  
Moreover, controlled MS-MS fragmentation studies in a quadropole-TOF or ion trap-
Orbitrap hybrid mass spectrometer can assist in defining substructures and further refine 
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 the number of molecule options. It should be noted however that mass spectrometric 
structure elucidations have a tentative character and should be preferably complemented 
by NMR studies. Unfortunately, in practice NMR is often not sensitive enough and the 
sample matrix too complex. Therefore in EU legislation for residue analysis mass 
spectrometric comparison with a pure reference standard is being used, thus providing a 
confirmation of a proposed structure. 
 
1.5. Metabolomics based urine profiling   
Historically, steroid urine profiling originates from the field of clinical endocrinology 
where it is used to detect enzyme deficiencies in newborns by monitoring levels of 
endogenous steroids in urine [101]. This methodology was adapted and introduced in 
human doping control in 1983 by Donike et al. [35] and since then has proven its value in 
detecting illegal use of endogenous steroids by determining levels and ratios of 
endogenous steroids in urine [35,102,103]. For the detection of these endogenous steroids 
statistically based threshold values for selected screening parameters have been set. This 
primarily concerns levels of the parent steroids or ratios such as 17ß-testosterone/17α-
testosterone (T/E ratio), androsterone/etiocholonalone, androsterone/17ß-testosterone and 
5α/5ß-androstane-3α,17ß-diol [104] but also monitoring of minor (phase I) metabolites 
are considered as valuable markers for the administration of endogenous steroids [105]. 
For screening purposes usually a set of endogenous urinary steroids or metabolites is 
quantified by GC/MS [106,107] offering a suitable basis for individual as well as 
population-based reference ranges and thus discrimination between undisrupted and 
altered steroid profiles.  
Although limited scientific publications are available regarding alteration of urinary 
steroid profiles as a consequence of DHEA administration, several urinary profiling 
parameters for DHEA abuse have been proposed [44,102,103,108,109]. These studies 
were most likely also the basis for setting the DHEA threshold value at 100 ng/ml for 
doping control purposes [110]. Recent studies however, demonstrated that urinary DHEA 
values higher than 100 ng/ml are observed in part of the normal human population 
[111,112] and therefore alternative threshold values of 200 ng/ml for both DHEA and the 
DHEA metabolite 3α,5-cyclo-5α-androstane-6ß-ol-7-one have been proposed [112].  
When an atypical steroid profile is observed, this usually is followed by confirmation 
techniques such as gas chromatography/combustion/isotope ratio mass spectrometry   
(GC/C/IRMS), a technique to differentiate between endogenous and exogenous steroids 
based on difference in carbon isotope ratios (13C/12C) [113]. Since this is a very complex, 
time consuming and costly methodology not all samples can be applied to GC/C/IRMS 
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 and hence screening techniques like steroid urine profiling still play a crucial role in 
detecting misuse of endogenous steroids in doping control.  
In livestock production however, misuse of natural occurring (pro)hormones is hard to 
prove; urinary metabolites are either unknown or profiling parameters which are relevant 
in humans are failing in cattle due to highly fluctuating endogenous steroid levels or 
differences in metabolism [114]. On the other hand, recent studies in calves showed that 
the endogenous steroid profiles were affected upon administration of nandrolone and 
estradiol [115]. In particular nandrolone administration lead to changes in estranediol 
profiles which may be used as screening parameters in this context [116]. These findings 
illustrate that steroid profiling methods have potential to be used as a screening tool in the 
field of veterinary growth promoter control.   
Nevertheless, to facilitate efficient control of anabolic practices there is a need for the 
development of new more comprehensive screening tools which are able to detect misuse 
of natural (pro)hormones as well as (new) synthetic steroids in urine. Therefore, as an 
alternative for targeted steroid profiling, a more comprehensive semi-targeted screening 
method has been described, which includes also detection of (new) synthetic designer 
steroids [117]. This LC-MS/MS screening approach is based on the fact that steroids with 
(partial) common structures show similar product ions in MS/MS analysis which can be 
monitored by precursor scan acquisition. This approach was refined by Pozo et al. who 
proposed the combined acquisition of the precursor ion scans of m/z 105, m/z 91 and m/z 
77 as a screening protocol for most anabolic steroids [118]. On the other hand, ongoing 
evolvements in chromatography, mass spectrometry (e.g. TOF and Orbitrap technology) 
and bioinformatics make it possible to obtain more complete chemical profiles of complex 
biological samples and enable unbiased profiling approaches which can be summarized in 
the term “metabolomics”. Application of metabolomics based techniques are providing a 
snap-shot of the metabolome of a cell, tissue, organ or organism at a certain time point. 
Unbiased holistic profiling of cellular metabolism products such as sugars, lipids and 
hormones is focused on measuring as many compounds as possible to generate metabolic 
fingerprints. Comparison of these fingerprints not only provides information on 
differences as a consequence of perturbations, e.g. a prohormone administration, but 
might also lead to identification of metabolites not previously reported to be affected by a 
treatment [119] (Figure 9).  
The last few years metabolomics has also emerged in the field of veterinary growth 
promoter control as a potential screening tool for untargeted urine steroid profiling [120]. 
From a historical point of view, nuclear magnetic resonance (NMR) is the most widely 
used technique for metabolomics purposes. Using NMR combined with multivariate 
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 statistics Dumas et al. [121] was one of the first showing how metabolic perturbations 
induced by hormonal treatment can be evidenced through characterization of bovine urine 
samples. However, because of higher performance in terms of sensitivity and specificity, 
mass spectrometry is becoming more and more used in the field of metabolomics [122]. In 
particular LC-based methods have shown to be good alternatives and are considered with 
great interest as a potential global screening tool in steroid metabolome profiling [123]. 
Recently, several studies in the field of growth promoter control have further demon-
strated the efficiency of mass spectrometry based fingerprinting to discriminate between 
treated and untreated animals [124-126].  
Figure 9: General overview of a metabolomics based strategy for anabolic steroid urine profiling in cattle.  
 
Because full scan mass spectrometric analysis of complex biological samples is 
generating enormous amounts of data, these approaches demand a highly automated and 
structured way of data processing. For this purpose several sophisticated bioinformatics 
tools, such as MetAlignTM have been developed to preprocess and align data allowing an 
efficient comparison of the obtained profiles [127]. In addition, multivariate statistical 
tools such as ANOVA, Principal Component Analysis (PCA) and Orthogonal Partial 
Least Squares analysis (OPLS) are employed to identify differences in urine steroid 
profiles. Besides highlighting metabolic disruptions upon anabolic treatment, these 
metabolomics based urine profiling approaches can also reveal new compound specific 
endpoints which can be used in targeted screening approaches. In this way Anizan et al. 
[124] demonstrated that PCA not only successfully discriminated between control and      
4-androstenedione treated bovines, but also identified 5α-androstane-3ß,17α-diol,           
5ß-androstane-3α,17α-diol, etiocholanolone and 5-androstene-3ß,17α-diol as potential 
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 parameters to prove 4-androstenedione abuse. Since these steroids are most likely direct 
metabolites of 4-androstenedione these findings are underlining the power of such an 
untargeted approach. Another approach was utilized by Courant et al. [126] using OPLS 
for both prediction of class membership as well as determination of potential biomarkers 
for clenbuterol administration. Again it was demonstrated that OPLS-DA statistical 
analysis permitted discrimination between treated and untreated animals during the 
treatment course as well as well as several days after the treatment. Among the ions 
pointed out by OPLS analysis, creatine and 18-hydroxycortisol could be identified as 
candidate biomarkers for clenbuterol treatment of calves. 
  
1.6. Transcriptome analysis  
The transcriptome is the set of total RNA (mRNA, tRNA, rRNA) produced in a cell or 
tissue at a given time. Analysis of these transcripts provides insight in ongoing processes 
and can provide detailed mechanistic information on the response to external stimuli. 
With respect to surveillance on growth promoter abuse, quantification of mRNA can be an 
attractive complement to the already established (bio)chemical screening and detection 
methods [128]. Several potential mRNA biomarkers for steroid hormone abuse have been 
reported for liver [129] or matrices like blood which can also be sampled in the farm 
phase [130]. Classical methods to determine mRNA levels are Northern blotting and real 
time RT-PCR. These are targeted techniques for gene expression analysis, using a limited 
number of preselected genes. Evolvement of the microarray technology however, allows 
the analysis of thousands of transcripts simultaneously which can describe the whole 
transcriptome of a cell or tissue in one single experiment. Application of DNA 
microarrays is therefore becoming more and more the common method to describe the 
effects of a treatment. After establishing microarrays for humans and classical laboratory 
test animals like rats and mice, rapid progress in veterinary genomics resulted in the 
development of commercially available farm animal microarrays, including those for 
bovines [131]. Although several types of microarrays exist, the most commonly used 
microarray platforms are those supplied by Affymetrix and Agilent and are based on 
oligonucleotide probes synthesized/spotted on a glass slide or silicon chip. The use of 
these bovine microarrays not only can provide detailed information about cellular 
processes as a consequence of a treatment, but also allow detection of (new) biomarkers 
which can be used to screen for illegal use of growth promoters [132]. After exposure of 
cells, tissues or animals to a compound, mRNA is extracted and transferred into 
fluorescent labeled cRNA (Figure 10). Hereby mRNA is first converted into cDNA using 
MMLV reverse transcriptase and oligo dT-promoter primer. Subsequently, cDNA is 
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 converted into cRNA by amplification using T7 RNA polymerase and labeled by 
incorporation of Cy3-CTP or Cy5-CTP. Upon loading of the fluorescent labeled sample 
onto the microarray, each specific cRNA will anneal to the complementary probe which is 
unique for a specific gene. By scanning the fluorescence signal intensity the amount of 
labeled cRNA hybridized to each probe can be determined and a ratio of expression can 
be calculated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Schematic overview of a microarray experiment using a common reference design.  mRNA is isolated 
from animal tissue, reverse transcribed and converted into fluorescent labeled cRNA using the Agilent 
microarray fluorescent cRNA synthesis procedure (Agilent Technologies).  Cy5 and Cy3 labeled samples are 
mixed and hybridized on the microarray slide. After scanning, the normalized fluorescence intensities of the Cy5 
channel are used to calculate the expression ratios between samples. 
Chapter 1 
 
  
36 
  
The microarray experiments performed in this thesis were using a so called common 
reference design; each sample (exposed as well as control) is individually labeled with 
Cy5 and a pool of all control samples is labeled with Cy3. The Cy3 fluorescence signals 
were only used to normalize the microarray data whereas the Cy5 fluorescence intensities 
were used to calculate the expression ratios between exposed and controls. Hybridization 
and scanning is followed by data analysis, starting with normalization [133] and removing 
of the low intensity spots. As the tissue under investigation does not express all the genes 
present on the microarray, also a so called ‘flooring’ procedure is applied. All spots below 
an arbitrary set threshold are set to that threshold. In this way the spots are not removed 
but identification of differentially regulated genes within background noise is prevented. 
In general, the next step is selection of differentially regulated genes by application of a 
threshold fold change together with a statistical derived p-value. To reduce the chance of 
false positives, most times also other statistical methods are applied to correct p-values for 
multiple testing e.g. by application of a false discovery rate (FDR) [134] or more 
comprehensive methods like Statistical Analysis of Microarrays (SAM) [135].  
Genes above the arbitrary set threshold values are selected for further biological 
interpretation which is often the most challenging part of microarray analysis. This largely 
depends on data available in literature, databases such as those at the National Center for 
Biotechnology Information (NCBI) and the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) [136,137], and a priori knowledge of the biologist who analyses the experimental 
data. In addition, several bioinformatics tools have been developed to get insight in the 
function of the genes found regulated and to get an overview of the pathways and 
processes affected [138,139]. 
Other approaches like principal component analysis (PCA) and cluster analysis [140] 
focus on identification of genes showing similar expression patterns. The multivariate 
statistics utilized by PCA allow a three dimensional visualization of gene expression 
profiles showing similarities and dissimilarities in the overall gene expression profiles. 
Alternatively, subsets of genes that contribute to differences between samples can be 
identified and compared to other gene expression profiles using tools like Gene Set 
Enrichment Analysis (GSEA) [141].  
 
1.7. Aim and objectives 
During inspections of livestock farms in The Netherlands a trend is observed towards 
abuse of feed and herbal additives and preparations containing prohormones. Up till now 
this primarily involves natural occurring prohormones like pregnenolone and DHEA, 
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 which are direct precursors of potent androgens and estrogens. However, sometimes also 
plant derived compounds such as diosgenin or plant extracts are found. Of most of these 
compounds the in vivo effects are unclear and the anabolic action is questionable. 
Interestingly Council Directive 96/22/EC is based on bioactivity and prohibits the use of 
compounds with thyrostatic, oestrogenic, androgenic or gestagenic activity. To fully meet 
this legislation screening should therefore be focused on detection of hormonal activity 
rather than on detection of the prohormones themselves.   
The main purpose of this thesis research is to get insight in the hormonal action of 
assumed prohormones and to develop novel (effect based) in vitro and in vivo screening 
methods allowing effective surveillance on the illegal use of prohormones in livestock 
production. This could be accomplished by monitoring in the farm phase, like sampling of 
animal feed, feed additives, urine and blood as well as sampling of tissues in the 
slaughterhouse phase. Within this scope the bioactivity of a wide variety of supplements, 
which contained assumed prohormones, were tested on bioactivity by using a yeast 
androgen bioassay (Chapter 2). For supplements containing solely prohormones the 
value of bioactivity based screening seems to be limited as prohormones show no direct 
bioactivity and need metabolism to become active. Therefore a screenings method was set
-up by using this same yeast androgen assay in combination with bovine liver S9 enzyme 
fractions to mimic in vivo metabolic transitions (Chapter 3). Also conjugated hormones 
like steroid glycosides and esters are not active and do not show any response in 
bioactivity based screening methods. In vivo however, deconjugation of the various 
groups results in the availability of the bioactive aglycon and subsequent anabolic action. 
This deconjugation is studied using in vitro enzymatic or chemical hydrolysis methods 
followed by bioactivity screening (Chapter 4).  
More comprehensive in vitro models like precision-cut bovine liver slices allow the 
combined study of primary hepatic metabolism of prohormones together with evaluation 
of the hormonal activity of the metabolites formed and their effects on the transcriptome 
(Chapter 5). Ultimately, these in vitro test methods could reduce the need for controlled 
animal studies with banned substances, hereby contributing to the 3 Rs: Reduction, 
Refinement and Replacement of animal tests.  
For detection of prohormone abuse at the farm and/or the slaughter phase we investigated 
the usefulness of ‘omics’ based profiling techniques to discriminate treated animals from 
controls. In human doping control (targeted) profiling of urinary steroid levels is an 
established method to detect steroid (pro)hormone abuse. However, application of such 
steroid profiling methods in veterinary control is thought to be of limited value due to 
highly fluctuating endogenous steroid levels. Chapter 6 describes a comprehensive 
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 untargeted metabolomics approach to identify the differential regulated metabolites as a 
consequence of pregnenolone and DHEA treatment. It was aimed to compare the overall 
urine profiles of treated animals versus controls using multivariate statistics. In the same 
way gene expression profiling offers the possibility to look at the effects of a prohormone 
treatment at the transcriptome level. In Chapter 7 the feasibility of DNA-microarrays as a 
screening tool for prohormone abuse was investigated at the slaughter phase. Hepatic gene 
expression profiles of bull calves treated with DHEA were compared with controls to 
determine differentially expressed genes and to identify biomarkers for DHEA treatment. 
Finally, the main results and findings are discussed in Chapter 8. Implications for further 
research, for effective surveillance on the illegal use of (pro)hormones and future 
perspectives are given in that chapter as well. 
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 Abstract 
Recently we constructed a recombinant yeast cell that expresses the human androgen 
receptor (hAR) and yeast enhanced green fluorescent protein (yEGFP), the latter in 
response to androgens. When exposed to testosterone, the concentration where half-
maximal activation is reached (EC50) was 50 nM. Eighteen different dietary supplements, 
already analysed by a liquid chromatography-tandem mass spectrometry method (LC-MS/
MS) for the presence of anabolic steroids, were screened for androgenic activity. Eleven 
samples containing at least one anabolic steroid, with a concentration that was around or 
above 0.01 mg unit−1 according to LC-MS/MS, were also positive in the bioassay. Seven 
samples did not contain any of the 49 compounds screened for in LC-MS/MS. In contrast 
two of them were positive in the bioassay. Bioassay-directed identification, using the 
bioassay as an off-line LC-detector and LC-time of flight-MS with accurate mass 
measurement was carried out in these two samples and revealed the presence of                
4-androstene-3β,17β-diol and 5α-androstane-3β,17β-diol in the first and 1-testosterone in 
the second supplement, showing the added value of the bioassay in comparison with a     
LC-MS/MS screening method alone. 
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 1. Introduction 
In order to achieve fair play and to fight doping, the World Anti-Doping Agency 
(WADA) prohibited the use of anabolic steroids in sports. This list of prohibited steroids 
has grown continuously and several steroids, especially designed to circumvent doping 
control, have been found. The use and misuse of these substances has been reviewed by 
Van Eenoo and Delbeke in 2006 and starts with the subcutaneous injections of a liquid 
obtained from the testis of animals in 1889 and finds its tentative culmination in the 
discovery of the designer steroid tetrahydrogestrinone (THG) in 2004 [1–3]. The rapid 
development of mass spectrometry resulted in specific screening methods for anabolic 
steroids in the 1980s, but the abuse of the endogenous steroid testosterone could not be 
detected until the testosterone to epitestosterone (T/E) ratio was introduced as a biomarker 
[4]. Unfortunately, naturally elevated levels of testosterone can occur in some cases and 
the biomarker ratio (T/E) is not a 100% trustworthy test [5]. In the 1990s several new 
steroids were commercialised as nutritional supplements. Initially these new steroids were 
precursors of testosterone, commonly referred to as prohormones, but later on a range of 
prohormones derived from other steroids than testosterone, including 19-nortestosterone, 
boldenone and 17α-alkylated steroids, also became available as over-the-counter 
preparations. The 17α-alkylated steroids were designed to block the metabolism of the 
17β-hydroxyl group, which is crucial for androgenic activity, and to improve the oral 
bioavailability. The 19-norandrogens were designed as anabolic steroids in order to 
minimise undesirable androgenic side effects. Although the ratio of anabolic versus 
androgenic activity of 19-norandrogens is improved, most 19-norandrogens have both 
greater anabolic and androgenic activities [6].  
Since 2005 there has been a ban on dietary supplements containing prohormones in the 
USA, but in order to improve their performance athletes, bodybuilders and even life 
stylers are tempted to use these kinds of nutritional supplements. Several investigations 
have shown that the information on the label of these supplements is often misleading or 
incomplete [7] or that supplements are contaminated with low concentrations of anabolic 
steroids such as testosterone and stanozolol [8]. In the light of these reports some dietary 
supplements that were ordered through the internet and intercepted by the Belgian 
pharmaceutical inspection at the post-office, were analysed by means of a liquid 
chromatography–tandem mass spectrometry method (LC-MS/MS) for the presence of 
prohibited anabolic steroids [9]. Results revealed the presence of active anabolic steroids 
in over 60% of these supplements and it was concluded that most likely the steroids were 
not deliberately added, but were by-products formed during the synthesis of the 
prohormones.  
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 Due to the great variety of chemicals with hormone-like activity, both immunochemical 
and analytical chemical methods have the drawback that they only detect target 
compounds and are not able to determine biological activity of unknown compounds and 
their metabolites, this in contrast to biological assays. Receptor-based transcription 
activation assays can be used to detect all compounds having affinity for a given receptor, 
both agonists and antagonists [10–13]. Recently we developed a yeast androgen bioassay 
that expresses yeast enhanced green fluorescent protein (yEGFP) as a measurable reporter 
protein in response to androgens [12]. This assay is sensitive and highly specific for 
androgens. Moreover, the assay was proven to be useful to detect the new designer steroid 
THG in human urine [13] while prohormones such as dehydroepiandrosterone (DHEA), 
are not active and need metabolic activation before they can be detected [14]. To 
investigate the performance of this new yeast androgen bioassay 18 dietary supplements, 
already analysed by an LC-MS/MS method for the presence of anabolic steroids [9], were 
screened for androgen activity in the bioassay and the outcomes of both methods were 
critically compared. 
 
2. Materials and methods 
 
2.1. Chemicals 
17β-Estradiol, 19-nortestosterone (nandrolone) and progesterone were obtained from 
Sigma (St. Louis, MO, USA) and 17β-boldenone, 1-testosterone, 4-androstene-3β,17β-
diol, 5-androstene-3β,17β-diol, 5α-androstane-3,17-dione, 5α-androstane-3α,17β-diol,     
5α-androstane-3β,17β-diol, 5β-androstane-3β,17β-diol, 17α-testosterone and 17β-
testosterone were obtained from Steraloids (Newport, RI, USA). Acetic acid, dimethyl 
sulfoxide (DMSO), sodium carbonate and sodium acetate trihydrate were obtained from 
Merck (Darmstadt, Germany). Acetonitrile and methanol were obtained from Biosolve 
(Valkenswaard, The Netherlands). Chemicals to prepare the growth media for yeast and 
the preparation of standard solutions in DMSO were as described previously [12]. Water 
used for LC/TOFMS was purified using a Millipore model Milli-Q system (Bedford, MA, 
USA). 
 
2.2. Extraction procedure 
A stock solution of 17β-testosterone was prepared in DMSO (50 µg mL−1). Supplement 
samples were grinded and two portions of 100 mg were weighted. One of the 100 mg 
portions was spiked with 10 µL of the 50 µg mL−1 17β-testosterone stock solution, 
resulting in a final spiked amount of 5 µg g−1. For extraction, 100 mg of the (un)spiked 
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 supplement samples were mixed with 4 mL methanol and 4 mL sodium acetate pH 4.8. 
Samples were sonicated for 10 min in an ultrasonic bath and subsequently mixed for 15 
min head over head. Samples were centrifuged at 3000 × g for 10 min and 4 mL of the 
upper liquid phase was brought into a glass tube. The pH was adjusted to 4.8 using 4N 
acetic acid and the extract was subjected to solid-phase extraction (SPE) on a C18 column 
(0.5 g Varian Bond Elut, Harbor City, CA, USA) previously conditioned with 3 mL 
methanol and 3 mL sodium acetate pH 4.8. Subsequently, this C18 column was washed 
with 1.5 mL sodium acetate pH 4.8, 2 mL water, 1.5 mL 10% (w/v) sodium carbonate 
solution, 2 mL water and finally with 2 mL methanol/water (50/50, v/v). The column was 
air-dried and eluted with 4 mL acetonitrile. The eluate was applied to a NH2-column    
(0.1 g IST, Hengoed, U.K.) that was previously conditioned with 4 mL acetonitrile. The 
eluate thus obtained was evaporated to dryness under a stream of nitrogen gas and 
reconstituted in 4 mL acetonitrile. Tenfold dilutions were made in acetonitrile and aliquots 
of 200 µL were transferred to a V-shaped 96-well plate in triplicate and 50 µL of a 4% 
DMSO solution was added to each well. To remove the acetonitrile, the plate was dried 
overnight in a fume cupboard and was then ready to be screened on androgenic activities 
with the yeast androgen bioassay. Aliquots of undiluted and diluted sample extracts were 
also investigated with 17β-testosterone spikes afterwards. These extracts spiked after the 
cleanup were prepared by the addition of 2 µL of a 30-µM 17β-testosterone stock, 
resulting in a final concentration of 300 nM in the well after adding the 200 µL of the 
yeast culture. In the same way and in each separate experiment a reagent blank, a negative 
feed, a negative supplement and corresponding spikes were prepared and used as negative 
and positive controls. 
 
2.3. Yeast androgen bioassay with fluorescence measurement 
The day before running the assay, a single colony from a MM/L agar plate was used to 
inoculate 10 mL of the selective MM/L medium [12]. This culture was grown overnight at  
30 °C with vigorous orbital shaking. At the late log phase, the yeast AR cytosensor was 
diluted in the selective MM/L medium to an OD value at 630 nm between 0.04 and 0.06. 
For exposure to standard compounds, aliquots of 200 µL of this diluted yeast culture were 
pipetted into each well of a 96-well plate and 2 µL of a 17β-testosterone or other stock 
solution in DMSO was added. DMSO and 17β-testosterone only controls were included in 
each experiment and each sample concentration was assayed in triplicate. For exposure of 
yeast to the sample extracts, aliquots of 200 µL of the diluted yeast culture were pipetted 
into each well already containing the dried extracts as described above. Exposure was 
performed for 24 h at 30 °C and orbital shaking at 125 rpm. Fluorescence and optical 
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 density (OD) were measured at 0 and 24 h in a SynergyTM HT Multi-Detection Microplate 
Reader (BioTek Instruments Inc., USA) using excitation at 485 nm and measuring 
emission at 530 nm. The fluorescence signal was corrected with the signals obtained with 
the MM/L medium containing DMSO solvent only. Densities of the yeast culture were 
determined by measuring the OD at 630 nm, but this was only done to check whether a 
sample was toxic for the yeast cells. 
 
2.4. Bioassay-directed identification of androgenic compounds using LC/TOFMS 
The experimental setup for the identification of androgenic compounds consisted of a 
gradient liquid chromatograph (LC), an autosampler, a dual 96-wells fraction collection 
system, the yeast androgen bioassay and a high resolution LC/TOFMS system. The 
gradient LC system consisted of two Knauer model WellChrom K-1001 Pumps (Berlin, 
Germany), a Knauer high pressure dynamic mixing chamber, a Gastorr model 154 
membrane degasser (Japan) and a Spark Holland model Endurance auto sampler (Emmen, 
The Netherlands). Liquid chromatography was performed using a Waters 150 mm × 3.0 
mm i.d. Symmetry column packed with 5 µm C18 material (Milford, MA, USA). The 
mobile phase consisted of (A) water/acetonitrile (90:10) and (B) water/acetonitrile (10:90) 
and a gradient elution was used at a flow rate of 0.4 mL min−1, starting at 35% B and 
linearly programmed to 100% B in 20 min. The column effluent was splitted towards two 
identical Gilson model FC203B 96-wells fraction collectors (Villiers-le-Bel, France). One 
96-wells plate was used for androgenic bioactivity detection using the yeast androgen 
bioassay. Subsequently, the bioassay suspect well numbers in the duplicate well plate 
were subjected to LC/TOFMS using a Waters model Acquity LC system equipped with a 
Waters 150 mm × 3.0 mm i.d. Symmetry column packed with 5-µm C18 material and a 
mobile phase consisting of (A) water/acetonitrile (90:10) and (B) water/acetonitrile 
(10:90). Gradient elution was performed at a flow rate of 0.4 mL min−1, starting at 35% B 
and linearly programmed to 100% B in 20 min. The LC column was directly interfaced to 
a Waters Micromass (Manchester, U.K.) model LCT Premier MS system equipped with a 
dual electrospray ionisation (ESI) probe and operated in the positive ion mode at a 
resolution of 10,000 (fwhm), source temperature 120 °C, desolvation temperature 350 °C, 
and a cone voltage of 50 V. The second LockSpray ESI probe provided an independent 
flow of leucine enkephalin lockmass calibrant (10 µL min−1). The lock calibrant data was 
acquired at a frequency of once per 5 s, using a cone voltage of 50 V. Data was acquired 
in the centroid mode from 100 to 1200 Da with a scan time of 0.1 s and processed using 
Masslynx v. 4.1 software. In-source collision-induced dissociation (CID) acquisitions 
were performed at an aperture voltage of 40, 50 or 60 V, to allow both identification of 
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 small neutral losses and the observation of diagnostic fragment ions. Some of the relative 
retention time data were obtained using the same LC setup but using a quadrupole MS 
instead of a TOFMS instrument. 
 
3. Results and discussion 
 
3.1. Bioassay performance 
Typical androgen bioassay dose-response curves for several natural and synthetic steroids 
are shown in Fig. 1. 17β-Testosterone, 19-nortestosterone and 17β-boldenone are potent 
androgens, but 17α-testosterone hardly gives a response. Fig. 1 shows that 17β-estradiol 
and progesterone also give some androgenic response in accordance with expectations 
since the latter two  compounds are known to exert also androgenic effects [15,16].  
Fig. 1 - Response of different steroids in the yeast androgen bioassay. Exposure to 17β-testosterone (17β-T),  
17α-testosterone (17α-T), 19-nortestosterone (19-norT), 17β-boldenone (Bold), 17β-estradiol (17β-E2) and 
progesterone (P) was started by adding an aliquot of 2 µL of a stock solution of the compound in DMSO to 200 
µL yeast culture. Fluorescence was determined after 24 h as described. Fluorescence signals are the mean of a 
triplicate with S.D. The dose-response curves were fitted using the equation y = a0 /(1 + (x/a1))ˆa2). Equal to: 
response = (max. response−min. response)/(1 + ([agonist]/EC50)) ^width of transition. 
 
Table 1 shows the calculated EC50, i.e. the concentration giving a half-maximum 
response, and the relative androgenic potency (RAP), defined as the ratio between the 
EC50 of 17β-testosterone and the EC50 of the compound, for several compounds. The yeast 
androgen bioassay showed good sensitivity towards all known androgens tested. The 
relative inactivity of 17α-testosterone was expected as the 17β-hydroxyl group is crucial 
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 for androgenic activity [17,18]. In a previous study we demonstrated that the RAPs for   
5α-dihydrotestosterone, methylboldenone, 17β-boldenone, stanozolol, 17α-methyl-
testosterone, tetrahydrogestrinone, 17β-trenbolone and 19-nortestosterone can be 
explained by their steroidal structure and show a good correlation with (Q)SAR model 
calculations, while steroid representatives for other hormone receptors, like estrone,     
17α-estradiol, 17α-ethynylestradiol and diethylstilbestrol for the estrogen receptor and 
corticosterone and dexamethasone for the glucocorticoid receptor, show no agonistic 
response [19]. 
 
Table 1. Determined EC50 concentrations and relative androgenic potencies (RAP) of compounds in the yeast 
androgen bioassay. 
n.r. = no response. 
a The EC50 is the concentration giving half-maximum response. The range in the EC50 of testosterone in the 
different experiments was from 40 to 75 nM. 
b The relative androgenic potency (RAP) is defined as the ratio between the EC50 of 17β-testosterone and the 
EC50 of the compound.  
c These compounds reach a maximum response that is lower than 70% of the maximum response obtained with 
17β-testosterone. The maxima obtained with 17β-estradiol, progesterone and 17α-testosterone are about 50, 20 
and 20% respectively. 
 
3.2. Bioassay analysis of supplements 
An overview of the ingredients declared on the labels of the supplement samples under 
investigation can be found in the research paper of Van Poucke et al. [9]. There was not 
enough material left from sample #11. According to the labels, 14 samples contained one 
to five prohormones. Nineteen different types of prohormones were mentioned on the 
various labels of these 14 supplements. Two supplements claimed to contain natural 
sterols, one to contain β-ecdysterone only and one to contain freeze-dried organs mainly.  
Compound EC50 [nM] in the RAAa RAP
b 
17β-Testosterone (17β-T) 40-75 1.0 
17α-Testosterone (17α-T) 8640 0.0063c 
19-Nortestosterone (nandrolone) 34 1.6 
17β-Boldenone 303 0.18 
1-Testosterone 38 1.9 
4-Androstene-3β,17β-diol 1020 0.049 
5-Androstene-3β,17β-diol n.r. n.r. 
17β-Estradiol (17β-E2) 2920 0.019c 
Progesterone 1430 0.038c 
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 Table 2. Bioassay and LC-MS/MS screening results of 18 dietary supplements. LC-MS/MS data adopted from 
Van Poucke et al. [9]. 
a,b Confirmed compounds and their concentration obtained by LC-MS/MS [9]. 
c Bioassay screening result. Negative (-) when the response of the undiluted and diluted extract in the yeast 
androgen bioassay is below 44 (CCα determined with 20 blank animal feed samples, data not shown). Positive 
(+) when the undiluted or one of the 10 to 10,000 fold diluted extracts gives a response above the CCα. 
 
Dietary 
supplement 
Weight of tablet or 
content of capsule [g] Confirmed compounds
a Concentration [mg unit-1]b 
Bioassay 
screening 
resultc 
1 1.0 17α-testosterone 
17β-testosterone 
0.02 
0.14 + 
2 0.55 17β-boldenone 
17β-testosterone 
<0.01 
0.08 + 
3 0.30 - - - 
4 0.50 17α-boldenone 
17β-boldenone 
17α-nortestosterone 
17β-nortestosterone 
<0.01 
0.13 
0.05 
0.58 
+ 
5 0.40 17α-boldenone 
17β-boldenone 
17β-testosterone 
<0.01 
0.06 
0.67 
+ 
6 Powder - - + 
7 cream (2 ml) 17α-nortestosterone 
17β-nortestosterone 
17β-testosterone 
0.23 
2.54 
<0.01 
+ 
8 0.60 17β-boldenone 
17β-testosterone 
<0.01 
<0.01 + 
9 0.70 estradiol 
17β-nortestosterone 
17β-testosterone 
1.26 
0.32 
<0.01 
+ 
10 0.60 - - - 
11 - - - Not analysed 
12 0.81 - - - 
13 0.45 - - - 
14 0.40 17β-testosterone 0.27 + 
15 0.90 17β-testosterone 0.06 + 
16 0.40 - - - 
17 0.50 17α-boldenone 
17β-boldenone 
<0.01 
0.19 + 
18 0.55 16-dehydroprogesterone 
17α-testosterone 
Progesterone 
17β-testosterone 
0.02 
0.11 
<0.01 
0.81 
+ 
19 0.50 - - + 
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 In addition, seven supplements also claimed to contain plant-derived compounds or plant 
extracts. Table 2 shows the LC-MS/MS confirmed compounds and their concentration as 
described by Van Poucke et al. [9].  
Recently, we validated the yeast androgen bioassay for the determination of androgen 
activity in animal feed and here we used a similar method for screening androgenic 
activity in supplement samples. Therefore, a feed sample that was screened negative was 
taken as a negative control. Fig. 2 shows the responses obtained in the yeast androgen 
bioassay with undiluted and diluted extracts of the negative feed control and some of the 
18 supplements.  
The negative feed control does not give a response, but the negative feed that was spiked 
with 5 µg 17β-testosterone per gram feed clearly gives a response in the bioassay. This 
signal decreases in the 10-fold diluted sample and after a 100-fold dilution the signal 
disappears. Assuming no recovery loss during the sample treatment, the undiluted extract 
of this spiked feed control would theoretically result in a final concentration of 217 nM 
17β-testosterone in the well. According to Fig. 1 this would result in a near maximal 
response. The 10- and 100-fold dilutions of the spiked feed control would thus 
theoretically result in well concentrations of 21.7 and 2.2 nM 17β-testosterone, 
respectively. According to Fig. 1 the 21.7 nM would still give a response while the 2.2 nM 
would not be able to show a response, thus explaining the observed responses of the 
spiked feed sample as shown in Fig. 2. The extracts that were spiked afterwards, result in 
a final concentration of 300 nM 17β-testosterone in the well. These “spike after” controls 
are performed in order to investigate whether there are disturbing or inhibiting 
(antagonist) compounds in the sample extract. According to Fig. 2, there are no such 
compounds present in the extract of the negative feed sample as all three dilutions of the 
extract give the same response with this “spike after” control. Moreover, the results 
indicate that the recovery of the cleanup procedure is acceptable as the “spike after” 
control (300 nM) only results in a little higher response compared to the response of the 
undiluted spiked feed control (217 nM). Fig. 2 shows that the LC-MS/MS negative 
supplements #3 and #10 are also negative in the yeast androgen bioassay. The spike 
controls prove that there are also no inhibiting compounds present in these negative 
supplements. Similar results were found for the LC-MS/MS negative supplements #12, 
#13 and #16. Moreover, no matrix effect was observed as the histogram patterns of the 
negative feed sample and the negative supplements #3, #10, #12, #13 and #16 were 
similar to that of the chemical blank (data not shown).  
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Fig. 2 – Responses obtained with undiluted and diluted extracts of the supplements in the yeast androgen 
bioassay. Fluorescence was determined after 24 h as described and signals are the mean of a triplicate with S.D. 
Chapter 2 
 
  
60 
 Fig. 2 also shows the responses of the LC-MS/MS positive supplements #1, #7 and #17. 
The main active compounds in these supplements are 17β-testosterone, 19-nortestosterone 
and 17β-boldenone, respectively (see Table 2 column 3). The histogram patterns obtained 
in the bioassay show that there is at least one potent agonist in the extract of these 
supplements. The extract of supplement #1 must be diluted more than 100 times before 
the response declines. After a 10,000-fold dilution the response of supplement #7 is still 
near maximum while the response of supplement #17 is declining. There is no evidence 
for the presence of any inhibiting compounds in these supplements. Similar results were 
obtained with the extracts of the LC-MS/MS positive supplements #2, #4, #5, #8, #9, #14, 
#15 and #18, showing responses that indicate that these supplements contain potent 
androgenic agonists.  
The bioassay results are included in Table 2 and show that the bioassay screening 
correlates very well with the LC-MS/MS screening (compare columns 3 and 5). The only 
differences observed are the LC-MS/MS negative screened supplements #6 and #19: in 
contrast both of these supplements are screened suspect in the yeast androgen bioassay. 
The histogram patterns of supplements #6 and #19 in Fig. 2 prove that there is at least one 
potent agonist in the extract of these supplements. There is no evidence for the presence of 
any inhibiting compounds. 
 
3.3. Bioassay-directed identification 
The bioassay-directed LC-TOFMS system as described in Section 2.4 was used to identify 
the responsible bioactive compound(s) in supplements #6 and #19. Fig. 3 shows the 
androgenicity biograms of both supplements obtained by LC-fractionation. The 
corresponding suspect well numbers in the duplicate 96-well plate were analysed by LC-
TOFMS. For supplement #6 we selected fractions 24 + 25, 27, 33 and 35 and for 
supplement #19 we analysed the combined fraction 31 + 32.  
LC-TOFMS analysis of the combined fraction 24 + 25 from supplement #6 resulted in a 
peak at a retention time of 6.69 min. The reconstructed ion chromatogram and mass 
spectra of fraction 24 + 25 are given in Fig. 4a and show abundant ions at m/z 255.2113, 
m/z 273.2208, and m/z 314.2484. The elemental composition of these ions was calculated 
from the accurate masses. The ion at m/z 273.2208 appeared to be [M+H−H2O]+ and 
originate from a C19H30O2 compound explaining the ions at m/z 255.2113 [M+H−2H2O]+ 
and the acetonitrile adduct ion at m/z 314.2484 [M+H−H2O+C2H3N]+. Searching 
elemental composition databases resulted in options like 4-androstene-3β,17β-diol and 5-
androstene-3β,17β-diol. However, only the first compound was found to be active in the 
yeast androgen bioassay (Table 1). After comparing retention times, the androgenic active 
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 compound in fraction 24 + 25 was indeed identified as 4-androstene-3β,17β-diol. Also 
400 MHz proton NMR analysis confirmed that supplement #6 contains mainly                  
4-androstene-3β,17β-diol (data not shown). Since no other steroids were observed by 
NMR, the remaining active fractions of supplement #6 probably contain quantitatively 
less abundant compounds. Elemental composition calculations and retention time 
comparison turned out that fraction 27 contained 17β-testosterone. Supplement #6 was 
found suspect on 17β-testosterone in the initial LC-MS/MS analysis. However, 
conformation results did not meet the criteria (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 – Androgenicity biogram of the suspect supplement samples #6 and #19. Extracts were separated on a 
C18-column and fractions of 20 s were collected and tested in the yeast androgen bioassay. For supplement #6 
the 100-fold diluted extract was used and for supplement #19 the 10-fold diluted extract. 
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Fig. 4b shows the reconstructed ion chromatogram of the less bioactive fraction 33, two 
peaks are observed at 8.76 and 9.08 min, both showing [M+H−2H2O]+ ions at m/z 257, 
[M+H−H2O]+ ions at m/z 275 and  [M+H−H2O+C2H3N]+ ions at m/z 316 (Fig. 4b, inserts 
1 and 2), suggesting the presence of, e.g. androstanediol. In total eight different isomers of 
androstanediol exist, however only 5α-androstane-3α,17β-diol, 5α-androstane-3β,17β-
diol, and 5β-androstane-3β,17β-diol show androgenic activity in the yeast androgen 
bioassay, with RAPs of 0.15, 0.22, and 0.0033, respectively [19]. LC/MS relative 
retention times of these three isomers of androstanediol are listed in Table 3 and are 1.26, 
1.22 and 1.08 for 5α-androstane-3α,17β-diol, 5α-androstane-3β,17β-diol, and 5β-
androstane-3β,17β-diol versus 17β-testosterone, respectively. Comparing this to fraction 
33 of supplement #6, the compound responsible for the response in the androgen 
biosensor is most likely 5α-androstane-3β,17β-diol.  
 
Table 3. Relative retention time of supplement fractions and reference standards by LC/TOFMS or LC/MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Relative retention time comparison of 17ß-testosterone vs. reference compounds or compounds present in 
supplement fractions, obtained, respectively by LC/TOFMS and LC/MS. 
 
  Retention times 
  relative against 17-T a 
  LC/TOFMS LC/MS 
Supplement #6     
Fraction 24 + 25 0.89 - 
Fraction 27 1.00 - 
Fraction 33 1.17 / 1.21 - 
Supplement #19     
Fraction 31 + 32 1.17 - 
Standards     
17β-Testosterone 1.00 1.00 
1-Testosterone - 1.17 
4-Androstane-3,17-dione - 1.46 
4-Androstene-3β,17β-diol - 0.92 
5a-Androstane-3a,17β-diol - 1.26 
5a-Androstane-3β,17β-diol - 1.22 
5β-Androstane-3β,17β-diol - 1.08 
Detection of anabolic steroids in dietary supplements 
  
63 
 Because two isomers of androstanediol are observed, the peak eluting at 8.76 min 
represents an androgenic inactive isomer of androstanediol. Probably 17β-testosterone and 
the isomers of androstanediol are by-products of 4-androstene-3β,17β-diol present in 
fraction 24 + 25 and formed during production or storage of the supplement. LC-TOFMS 
analysis of fraction 35 resulted in a similar mass spectrum as obtained by analysis of 
fraction 33 (Fig. 4b, insert 1 and 2). This suggests the presence of another androgenic 
active isomer of androstanediol, however this could not be confirmed by retention time 
comparison of reference standards using LC/MS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 – LC-TOFMS reconstructed ion chromatograms (mass window of 0.05 Da) of (a) fraction 24 + 25 and (b) 
fraction 33 of supplement #6 and (c) fraction 31 + 32 of supplement #19. Chromatogram inserts: the accurate 
mass spectra. 
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 Analysing fraction 31 + 32 of supplement #19 with LC-TOFMS, resulted in a peak at a 
retention time of 8.76 min with an abundant [M+H]+ ion at m/z 289.2166 (Fig. 4c). The 
elemental composition of this ion was calculated as C19H29O2, which is similar to the 
composition of 17β-testosterone, 1-testosterone and androstanedione. In-source CID 
spectra of fraction 31 + 32, 17β-testosterone, 1-testosterone and androstanedione using an 
aperture voltage of 50V are shown in Fig. 5. For 17β-testosterone (Fig. 5b), the [M+H]+ 
parent ion (at m/z 289), [M+H−H2O]+, [M+H−2H2O]+ ions and two important product 
ions were observed at m/z 97 and 107, which are typical for this compound [20]. In-source 
CID of androstanedione resulted in abundant product ions at m/z 213, 253 [M+H−2H2O]+ 
and 271 [M+H−H2O]+. The product ion spectra of 1-testosterone showed an abundant 
product ion at m/z 187 and less abundant ions at m/z 105, 131 and 205 which were also 
found previously by LC-ESI-MS/MS [21]. The obtained CID spectrum of fraction 31 + 32 
of supplement #19 (Fig. 5a) shows high similarities with the CID spectra of 1-
testosterone, suggesting the presence of the latter.  
 
Fig. 5 – In-source CID mass spectra of (a) fraction 31 + 32 of supplement #19, (b) 17β-testosterone,                 
(c) 1-testosterone and (d) androstanedione acquired at an aperture voltage of 50 V. 
 
Comparison of relative retention times of 1-testosterone, androstanedione and the 
unidentified compound present in fraction 31 + 32 is included in Table 3. Both fraction 31 
+ 32 and 1-testosterone showed a relative retention time of 1.17 versus 17β-testosterone. 
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 Therefore, it can be concluded that according to the obtained mass spectra, elemental 
composition, retention times and fragment ion patterns after in-source CID the androgenic 
compound in fraction 31 + 32 of supplement #19 is most likely 1-testosterone. 
 
3.4. Feasibility of quantification 
Although the bioassay has been validated and used as a qualitative screening method for 
the routine determination of androgenic activity in calf urine and animal feed, the 
response of sample extracts can be converted to concentrations using a 17β-testosterone 
standard dose-response curve. The fluorescence response of the undiluted extract of the 
negative feed sample that was spiked with 5 µg 17β-testosterone per g was 651 which 
corresponds with a concentration of 143 nM 17β-testosterone in the well. Assuming a 
final volume in the well of 200 µL, this semi-quantitative approach results in a              
17β-testosterone equivalent content of 3.3 µg g−1 indicating an overall recovery of 66%. 
In the same way the 1000 times diluted extract of supplement #1was calculated from the 
fitted 17β-testosterone standard dose-response curve and its fluorescence response of 110 
corresponds with a concentration of 11 nM 17β-testosterone in the well, or a 17β-
testosterone equivalent content of 0.3 mg g−1. This estimated content is in the same order 
of magnitude as the LC-MS/MS determined content of 0.14 mg 17β-testosterone per unit, 
as a unit of supplement #1 is a tablet of approximately 980 mg and as 17α-testosterone is 
almost inactive in the bioassay. Overall, this semi-quantitative approach resulted in 
estimated 17β-testosterone equivalent contents of the supplements that were in at least the 
same order of magnitude as the LC-MS/MS determined contents. 
 
4. Conclusions 
The only way to win the fight against doping is to be one step ahead of the abusers. The 
fight cannot be won by a strategy of checking urine samples only against a prohibited list 
(unknown compounds like THG were not found by that strategy). Bioactivity testing of 
dietary supplements used by athletes is one way to get in front. Here we mapped 18 
dietary supplements that might be used by athletes and showed that two supplements, 
shown negative in LC-MS/MS, were screened suspect in an androgen yeast bioassay. 
Analysing the bioassay-directed suspect fractions in the duplicate well by LC-TOFMS 
ultimately identified the responsible compounds showing that this androgen bioassay 
screening method has a surplus value in comparison with a LC-MS/MS screening method 
alone. 
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 Abstract 
Prohormones such as dehydroepiandrosterone (DHEA) are steroid precursors that do not 
show hormonal activity by themselves. Abuse of these prohormones in cattle fattening is 
hard to prove because of strong in vivo metabolism and the difficulty to detect metabolites 
which are not significantly above endogenous levels. The aim of the present work was to 
develop an in vitro assay capable of detecting the indirect hormonal activity of 
prohormones that might be present in feed supplements and injection preparations. 
Sample extracts were incubated with a bovine liver S9 fraction in order to mimic the in 
vivo metabolic activation. Subsequently incubated extracts were exposed to a highly 
androgen-specific yeast bioassay to detect hormonal activity. Metabolic activation of 
DHEA, 4-androstene-3,17-dione (4-adione) and 5-androstene-3,17-diol (5-adiol) resulted 
in an increased androgenic activity caused by the formation of the active androgen        
17β-testosterone (17β-T), as shown by ultra-performance liquid chromatography and time
-of-flight mass spectrometry with accurate mass measurement. The developed in vitro 
system successfully mimics the hydroxysteroid dehydrogenase (HSD)- and cytochrome 
P450-mediated in vivo metabolic transitions, thus allowing assessment of both bioactivity 
and chemical identification without the use of animal experiments. Screening of unknown 
supplement samples claimed to contain DHEA resulted in successful bioactivation and 
positive screening results according to the androgen yeast biosensor. 
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 Introduction 
Within the European Union the use of growth-promoting agents in cattle fattening is 
banned according to EC directive 96/22 [1]. Interestingly, there is not a black list of 
substances but EC 96/22 states that all substances having thyrostatic, estrogenic, 
androgenic or gestagenic activity are prohibited. A trend has been observed from the 
abuse of synthetic steroids towards natural steroid esters and prohormones. Feed 
supplements and preparations containing prohormones have the potential to enhance the 
levels of natural occurring steroids and can be misused in livestock production. After 
administration and uptake in the blood circulation, peripheral tissues are able to 
metabolize prohormones into more biologically active androgens and estrogens [2–4]. 
With respect to androgens this leads to anabolic action and subsequently to increased 
body weight, muscle strength and improved lean/fat ratios in farm animals [5].  
Abuse of prohormones in livestock production is hard to prove: urinary metabolites are 
unknown or not significantly above highly fluctuating endogenous levels [6]. Chemical 
methods have the drawback of detecting only targeted compounds of interest. Biological 
transcription activation assays, however, have the advantage of detecting compounds 
based on bioactivity. For screening of hormones a wide range of mammalian or yeast cell-
based bioassays have been developed [7–10]. These assays focus mainly on ligand-
receptor interactions in which activation of a specific receptor is linked to a transcription 
reporter mechanism. Assays based on mammalian cell lines are in general more sensitive; 
however, the metabolic capacity of both mammalian and yeast cell based assays is rather 
limited [11–13]. The latter are relatively easy to use and very robust, making them 
suitable for screening of samples from practice without complex sample cleanup 
procedures. In addition, yeast cells lack endogenous receptors and thus lack the potential 
cross talk from other receptor types [14]. As a result the signals obtained in the yeast 
androgen bioassay may be associated only with the androgenic properties of the 
compound or sample extract tested.  
In vivo, hepatic first pass metabolism of exogenous and endogenous compounds normally 
leads to inactivation by phase I and phase II enzymes and the subsequent excretion of the 
deactivated compounds. However, metabolism can also result in an increased biological 
activity of a given compound [15]. Prohormonal compounds can be activated by 
hydroxysteroid dehydrogenases (HSDs). Prohormones such as dehydroepiandrosterone 
(DHEA), 4-androstene-3,17-dione (4-adione) and 5-androstene-3,17-diol (5-adiol) are 
direct precursors of potent androgens like 17β-testosterone (17β-T) and dihydro-
testosterone (DHT). The 3β-hydroxysteroid dehydrogenase/isomerase (3β-HSD) enzyme 
catalyzes the two-step conversion of 3β-hydroxysteroids, like DHEA and 5-adiol, into      
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 4-adione and 17β-T, respectively. 17β-Hydroxysteroid dehydrogenase (17β-HSD) 
catalyzes the conversion of 17-ketosteroids, like DHEA and 4-adione, into their 
corresponding 17-hydroxysteroids, 5-adiol and 17β-T, respectively (Fig. 1). These 
conversions yield an increase of biological activity in vivo [2–4]. The action of 
biologically active androgens is mediated by the androgen receptor (AR). Upon ligand 
binding, the AR dissociates from its chaperone proteins and is translocated in its active 
state to the nucleus ready to bind to androgen-responsive elements (AREs) [16]. Binding 
results in recruitment of coactivators and enhanced transcription of target genes regulating 
androgenic-anabolic action. 
Fig. 1 - In vivo steroid hormone biosynthesis: side chain cleavage of cholesterol results in pregnenolone which 
is metabolized into DHEA under P450c17 activity. From DHEA, conversions are catalyzed by 3β-HSD and 17β-
HSD activity resulting in formation of potent androgens like 17β-T. Reversible reactions (marked by double 
arrows) depend on cofactor availability (e.g. NADP/NADPH ratios). Estrogens are formed from androgens      
(4-adione and 17β-T) by aromatase activity. 
 
In this context we explored the combined use of a bovine liver S9-based bioactivation 
model and a previously developed highly androgen-specific yeast assay based on the 
constitutive expression of the human androgen receptor (hAR) in combination with an 
androgen-responsive element coupled to an enhanced green fluorescent protein (EGFP) 
reporter system. A promising in vitro model for evidence of the indirect hormonal activity 
of prohormones, in accordance with the bioactivity-based legislation [1], has been 
developed. The results obtained were supported by chemical identification of the 
metabolites using ultra-performance liquid chromatography (UPLC) and time-of-flight 
mass spectrometry (TOFMS). 
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 Methods and materials 
 
Chemicals 
Dehydroepiandrosterone (DHEA), 5-androstene-3,17-diol (5-adiol), 4-androstene-3,17-
dione (4-adione), 17β-testosterone (17β-T), 17α-testosterone (17α-T), 5α-
dihydrotestosterone (DHT), 7α-hydroxy-DHEA (7α-OH-DHEA), 7β-hydroxy-DHEA (7β-
OH-DHEA), 16α-hydroxy-DHEA (16α-OH-DHEA), 16β-hydroxy-DHEA (16β-OH-
DHEA), 11β-hydroxy-DHEA (11β-OH-DHEA) and 19-hydroxy-DHEA (19-OH-DHEA) 
were obtained from Steraloids (Newport, RI, USA). Sodium acetate, sodium carbonate, 
sodium chloride, di-sodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate 
monohydrate, ammoniumsulphate, magnesium chloride, potassium chloride, tris
(hydroxymethyl)aminomethane (Tris), dimethylsulfoxide (DMSO), hydrochloric acid and 
acetic acid were purchased from Merck (Darmstadt, Germany). Glucose-6-phosphate, 
NADH disodium salt, NADP disodium salt and NADPH tetrasodium salt were from 
Roche Diagnostics (Almere, the Netherlands). Acetonitrile, methanol and isooctane were 
obtained from Biosolve (Valkenswaard, the Netherlands). Dextrose and yeast nitrogen 
base without amino acids and without ammonium sulphate were from Difco (Detroit, MI, 
USA). L-Leucine, bovine serum albumin (BSA), hydroxysteroid dehydrogenase 
originating from Pseudomonas testosteroni and NAD sodium salt were purchased from 
Sigma (St. Louis, MO, USA). Water used for LC/MS was purified using a Millipore 
(Bedford, MA, USA) Milli-Q system.  
 
Preparation of liver S9 fractions  
Four Frisian bovines (350-430 kg, 13-14 months old) that served as normally fed negative 
controls in a 6-week animal experiment were sacrificed at the end of the trial. At sacrifice, 
liver tissue was rinsed with ice cold 0.9% sodium chloride and snap-frozen in liquid 
nitrogen. Liver tissues were homogenized in twice their volume of Tris-HCl buffer (50 
mM, pH 7.4, 1.15% KCl), using a blender. Homogenates were pooled and centrifuged at 
10,000 g for 25 min at 4 °C. The supernatant was snap-frozen in liquid nitrogen and 
stored at -80 °C until use. Protein concentrations in this S9 fraction were determined 
according to Lowry [17], using the BioRad DC protein assay (BioRad, Veenendaal, the 
Netherlands) and BSA as a standard. The animal experiment referred to was approved by 
the Animal Ethics Committee of Gent University, Belgium, in accordance with local 
ethical requirements.  
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 Prohormone incubations  
Incubations of 50 μg (pro)hormones, or of 100 μl final SPE eluent from supplement 
samples (see Extraction of supplement samples), were carried out in a glass tube 
containing 0.1 M sodium phosphate buffer (pH 7.4), 10 mM glucose-6-phosphate, 33 mM 
KCl, 8 mM MgCl2, 2 mg/ml bovine S9 fraction and either 4 mM NAD, NADH, NADP or 
NADPH. The final volume was 1 ml and the mixtures were incubated at 37 °C in a water 
bath for 6 h. Single incubations of prohormones and of SPE eluents were performed. 
Blanks without bovine liver S9 and blanks without cofactor were included to check for 
nonenzymatic reactions during the incubation period. Reactions were terminated at t=0 
and t=6 h with 1 ml acetonitrile, and the reaction products were subsequently subjected to 
a cleanup, which is similar to a method described by Marwah et al. [18]. In summary, the 
mixture was centrifuged for 15 min at 3,000 g, and the supernatant was transferred to a 
fresh glass tube. The mixture was extracted again with 2 ml acetonitrile and centrifuged 
for 10 min at 3,000 g. The combined supernatants were evaporated under nitrogen at       
45 °C to approximately 0.5 ml. Next, the extract was diluted with 3 ml methanol, 
centrifuged for 15 min at 3,000 g and evaporated at 45 °C under nitrogen until dryness. 
The residue was dissolved in 200 μl methanol and, following the addition of 1.8 ml water, 
applied onto a preconditioned reversed-phase solid-phase extraction (SPE) cartridge 
(Waters Oasis™ HLB, 3 cc, 6 mg). The cartridge was washed twice with 2 ml water and 
eluted with 2 ml methanol. The SPE eluent was evaporated under nitrogen at 45 °C and 
reconstituted in 2 ml acetonitrile. Aliquots of 200 μl of this final acetonitrile extract plus 
50 μl 4% DMSO were pipetted in a conical 96-well plate (Greiner Bio-One, Germany) 
and evaporated overnight in a fume cupboard to leave only DMSO the next day.  
 
Extraction of supplement samples  
Two authentic supplement samples were extracted. According to the labels, each capsule 
of supplement A contained 50 mg DHEA and 10 mg vitamin C in a base of rice flour, and 
each capsule of supplement B contained 500 mg Tribulus terrestris, 100 mg 4-
androstenedione, 100 mg DHEA, 100 mg lysine and 15 mg zinc amine acid chelate. A 
100-mg aliquot of each capsule was extracted according to a method described by Bovee 
et al. [14]. In summary, sample aliquots were mixed with 4 ml methanol and 4 ml sodium 
acetate buffer (0.25 M, pH 4.8), sonicated for 10 min and mixed for 15 min in a head over 
head apparatus. Samples were then centrifuged for 10 min at 3,000 rpm, and 4 ml of the 
supernatant was collected. The pH of this supernatant was adjusted to pH 4.8 with 4 M 
acetic acid and applied onto an SPE cartridge (Varian, Bond Elut, C18, 500 mg, 3 ml), 
previously activated with 3 ml methanol and 3 ml sodium acetate buffer. Next, the SPE 
Indirect hormonal activity of prohormones 
  
75 
 cartridge was washed with respectively 1.5 ml sodium acetate buffer, 2 ml MilliQ water, 
1.5 ml sodium carbonate (10% w/v), 2 ml MilliQ water and 2 ml methanol/water (50:50  
v/v). The SPE cartridge was dried and eluted with 4 ml acetonitrile. The SPE eluent thus 
obtained was applied onto an NH2 SPE cartridge (Isolute, 100 mg, 3 ml) previously 
activated with 4 ml acetonitrile. The run through was collected and evaporated at 45 °C 
under nitrogen and reconstituted in 4 ml acetonitrile. At this point the SPE eluent is either 
measured directly in the androgen yeast biosensor or bioactivated according to the 
procedure as described in Prohormone incubations and then measured by the androgen 
biosensor. Two sets of spiked supplement samples were prepared to monitor the 
extraction recovery (“spike before samples”) and the potential presence of AR antagonists 
in the supplements (“spike after samples”). 17β-Testosterone was added to “spike before 
samples” (5 μg/g) before the sample preparation step and to “spike after samples” (30 μM 
in DMSO, 2 μl) prior to biosensor exposure. 
 
Recombinant yeast androgen bioassay 
Transformants of a Saccharomyces cerevisiae strain that express the human androgen 
receptor (hAR) and an yEGFP reporter system [10] were grown on selective minimal 
medium plates supplemented with L-leucine. Minimal medium consisted of yeast nitrogen 
base without ammonium sulphate or amino acids (1.7 g/l), dextrose (20 g/l), ammonium 
sulphate (5 g/l) and was supplemented with L-leucine (6 mg/l). At day 1, 10 ml minimal 
medium supplemented with L-leucine (MM/L) was inoculated with a single colony and 
cultured overnight at 30 °C, in a shaking incubator at 125 rpm. The next day, the 
overnight culture was diluted in MM/L to an optical density (OD) value between 0.04 and 
0.06 at 630 nm. Aliquots of 200 μl yeast suspension were added to each well of a 96-well 
plate, already containing the DMSO extract of samples and controls as described in 
Prohormone incubations. A standard dose-response curve of 17β-testosterone was 
included in each experiment. Plates were incubated at 30 °C for 24 h in a shaking 
incubator (125 rpm), and fluorescence was measured (485-nm excitation, 530-nm 
emission) using a Synergy™ HT multi-detection microplate reader (BioTek Instruments 
Inc., USA). The OD of the yeast was measured at 630 nm after 24 h to monitor for any 
cytotoxic effects on the yeast cells.  
 
UPLC-TOFMS assignment of substances formed in metabolic bioactivation  
Ultra-performance liquid chromatography (UPLC) was performed on a Waters (Milford, 
MA, USA) Acquity system containing a Waters Acquity BEH C18 1.7 μm, 2.1×50-mm 
column, with mobile phases (A) acetonitrile/water/formic acid (10:90:0.2, v/v/v) and (B) 
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 acetonitrile/water/formic acid (90:10:0.2, v/v/v), linearly increasing from 20 to 46% B in 
5 min at 0.7 ml/min. The column temperature was 45 °C, and the injection volume 20 μl. 
The column effluent was split 1:1 prior to mass spectrometry.  
Mass spectrometry was performed on a Waters QTOF micro instrument equipped with a 
dual electrospray ionization (ESI) probe and operated in the positive ion mode (ESI) at a 
source temperature of 120 °C, desolvation temperature 350 °C, desolvation gas flow 700 
l/h, ESI capillary voltage of 3,000 V and a cone voltage of 30 V. Phosphoric acid in 
acetonitrile/water (0.01:50:50, v/v/v) was used as reference solution in the LockSpray™ at 
a flow rate of 10 μl/min. TOF data were collected between m/z 80 and 1,200 and 
processed using Masslynx v 4.0 software.  
 
Results and discussion 
 
Direct androgen bioassay screening 
Androgen bioassay dose–response curves of DHEA and known in vivo metabolites 4-
androstene-3,17-dione (4-adione), 5-androstene-3,17-diol (5-adiol), 17β-testosterone    
(17β-T) and 5α-dihydrotestosterone (DHT) are shown in Fig. 2. Nonlinear regression 
curves were fitted through the data points, and the concentration giving half the maximum 
(EC50) was calculated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 - Dose-response curves of DHEA, 4-adione, 5-adiol, 17β-T and DHT after 24 h obtained in the androgen 
yeast biosensor. Fluorescence signals are the mean of an assay triplicate (± SD) and corrected for the signal at 
t=0 and the blank DMSO. 
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 Exposure of the androgen reporter-gene yeast bioassay to DHEA and 5-adiol did not 
result in a response of the cells, i.e. no direct hormonal activity was observed in vitro in 
accordance with expectations. In contrast a direct androgenic activity was observed for     
4-adione, 17β-T and DHT, with EC50 values of 6,900 nM, 92 nM and 26 nM, respectively. 
It should be noted that the obtained dose-response curve of 4-adione was also caused by a 
17β-T impurity (data not shown), apart from the androgenic activity of 4-adione itself.  
 
Incubation of prohormones with bovine liver S9 followed by androgen bioassay 
screening  
To study the bioactivation of prohormones, 50 μg of DHEA, 4-adione and 5-adiol were 
incubated with a bovine liver S9 mix in the presence of either NAD, NADH, NADP or 
NADPH. Initially, trials were performed with incubations of DHEA with NAD and pure 
hydroxysteroid dehydrogenase originating from Pseudomonas testosteroni containing 3α- 
and 3β-HSD activity. Incubation of DHEA for 1 h resulted in an increase of response in 
the androgen yeast assay, caused by formation of 4-adione and 17β-T (results not shown). 
However, further work was with bovine liver S9 to include the entire species specific liver 
metabolism.  
Results for sample extracts incubated with the S9 mix for 0 and 6 h in the presence of        
4 mM cofactor and subsequently screened for androgenic activity in the yeast androgen 
bioassay are shown in Fig. 3. The androgen assay showed no signal for DHEA at t=0, but 
after metabolic activation of DHEA with S9 in combination with either NAD, NADP or 
NADPH, an androgenic activity was measured (Fig. 3a). Application of NADH as a 
cofactor, however, caused only a slight increase in the bioactivity signal.  
Fig. 3 - Androgen bioassay responses of (a) DHEA, (b) 4-adione and (c) 5-adiol, before (t=0) and after (t=6) 
incubation with bovine liver S9 in the presence of different cofactors. Fluorescence signals are the mean of an 
assay triplicate (± SD) and corrected for the signal at t=0 and the reagent blank. 
 
Chapter 3 
 
  
78 
 The compound 4-adione is already androgenic without metabolic activation. Assuming 
100% recovery, the 50 μg 4-adione (containing the 17β-T impurity) without activation 
would result in a final concentration of 87,000 nM in the well, and in accordance with  
Fig. 2 this resulted in a maximal fluorescence response of about 800. After S9 treatment 
the signal increased up to maximal 1,200, suggesting that metabolites are formed that are 
more active than 4-adione itself (Fig. 3b). Figure 3c shows that 5-adiol can be activated by 
the S9/NAD combination, but no changes in response were found after using NADH, 
NADP and NADPH as a cofactor. Whether the differences in response found between 
NAD and NADP are caused by the high level of specificity of HSDs for either NAD or 
NADP cannot be stated from the present study. The blanks, without bovine liver S9 or 
cofactor, showed no increase in response after 6-h incubation (results not shown). 
 
Bioactivation plus androgen bioassay screening of supplement samples 
Two supplements, A and B, were extracted and screened directly in the yeast androgen 
bioassay (Fig. 4a and b). In addition, aliquots of both supplements were spiked before 
extraction with 5 μg 17β-T per gram sample in order to check the recovery. Assuming no 
losses, the 17β-T spike would result in a calculated concentration of 217 nM 17β-T in the 
well. After sample cleanup but prior to the androgen bioassay nonspiked sample aliquots 
were also spiked with 300 nM 17β-T in the well in order to investigate whether there are 
any interfering or antagonistic compounds in the extract. According to the dose-response 
curve shown in Fig. 2, both 17β-T spikes are expected to give maximal bioassay response. 
Supplement A, stated to contain mainly DHEA, did not give a direct androgen bioassay 
response, but also the 17β-T spike before and spike after controls failed to give a 
response. Dilution of the extract, however, resulted in an increase of the spike after 
control, suggesting that the extract of this preparation contains an antagonist, which could 
be DHEA. This is in line with earlier performed quantitative structure-activity relationship 
(QSAR) modeling approaches, where calculations of the free energy after ligand docking 
and energy minimization of the ligand–receptor complex were plotted against the relative 
androgenic potency (RAP) [13].  
DHEA showed no androgenic activity, but the calculated free energy is low, suggesting a 
good binding to the androgen receptor. Thus, DHEA shows affinity for the androgen 
receptor and might compete with bioactive androgens explaining its antagonistic 
properties. These antagonistic properties of DHEA were confirmed in the androgen yeast 
bioassay by coexposure of two concentrations of 17β-T, one concentration (70 nM) at half 
maximum and a concentration (1,000 nM) at full androgen bioassay response (data not 
shown).  
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Fig. 4 - Androgen bioassay responses of (a) supplement A and (b) supplement B as well as spiked with 17β-T 
before (217 nM in the well, calculated assuming 100% recovery) and after (300 nM added to the well) extraction 
and cleanup procedure. Fluorescence signals are the mean of an assay triplicate (± SD) and corrected for the 
signal at t=0 and the reagent blank.(c) Androgen bioassay results after incubation using bovine liver S9 and 
cofactor NAD. 
 
Figure 4b shows that supplement B gives a direct androgen bioassay response in 
accordance with the declared ingredient 4-adione. This response remains at the same level 
up to a 100-fold dilution of the extract, but at a 1,000-fold dilution the bioassay signal 
decreases. It should be noted that the “spike after” control does not reach its maximum 
fluorescence response of about 1,400 and that following dilution of the samples the signal 
of the “spike after” in the well increases. Again this is due to the antagonistic effects of 
DHEA, which is also a declared main compound in supplement B. Figure 4c shows the 
androgen bioassay responses of  supplement A and B in the yeast androgen bioassay 
without and after the metabolic activation with the S9/NAD combination. Supplement A 
does not give a signal without the activation; however, after 6 h of incubation with bovine 
liver S9/NAD the signal reaches near maximal response, indicating that bioactive 
androgenic metabolites have been formed. As mentioned before, supplement B already 
shows a response; however, after the S9/NAD treatment the signal increases from about 
600 to a near maximal response, again indicating that androgenic metabolites have been 
formed. From these results it can be concluded that supplement A contains pro-androgens 
showing anti-androgenic properties and supplement B contains both androgens and pro-
androgens containing androgenic and anti-androgenic properties. 
 
UPLC-TOFMS analysis 
UPLC-TOFMS analysis with accurate mass measurement was used for the identification 
of the metabolites formed after bovine S9 incubation. The metabolites were identified by 
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 exact mass measurement and elemental composition calculations thereof, followed by 
comparison of retention times and mass spectra with the data obtained from commercially 
available standards. Fifty-mDa window reconstructed ion chromatograms were used, 
being an appropriate window for elemental composition elucidation with a limited chance 
of false negative results due to mass shifts caused by coeluting isobaric compounds and/or 
detector saturation [19]. After metabolic activation of DHEA with bovine liver S9 and 
cofactor NAD (Fig. 5) the main metabolites of DHEA (X) appeared to be 4-adione (IX), 
7α-OH-DHEA (II) and metabolite III at a retention time of 0.95 min having an abundant 
ion at m/z 303 and minor ions at m/z 285 and m/z 267 suggesting a keto-metabolite of 
DHEA (e.g. 7-oxo-DHEA) or a hydroxy-metabolite of 4-adione. Several minor abundant 
metabolites eluted after 0.70, 1.07, 1.21, 1.52, 2.09 and 2.29 min of which the last two 
appeared to be 5-adiol (VII) and 17β-T (VIII), respectively. The identification of 17β-T 
and 4-adione confirm the bioactivation of DHEA into androgenic substances observed in 
the androgen bioassay.  
Metabolites I and IV are most likely hydroxy-metabolites of DHEA resulting in [M+H]+ 
ions at m/z 305 and [M-H2O+H]+ ions at m/z 287. V and VI most likely are keto-
metabolites of DHEA or hydroxylated metabolites of 4-adione, showing [M+H]+ ions at 
m/z 303 and [M-H2O+H]+ ions at m/z 285. According to ref. [20] metabolism of DHEA 
employing human liver S9 for 20 min (instead of bovine liver S9 for 6 h) resulted mainly 
in 7α-OH-DHEA, 7β-OH-DHEA, 7-oxo-DHEA, 16α-OH-DHEA and 5-adiol depending 
on the cofactor used; no androgenic metabolites like 4-adione and 17β-T were observed. 
The retention times of DHEA and its metabolites with corresponding exact masses have 
been summarized in Table 1. UPLC–TOFMS analysis showed that the spectra of 5-adiol, 
DHEA and hydroxy-metabolites generally were dominated by [M+H-H2O]+ and [M+H-
2H2O]+ ions, whereas the base peak in the mass spectra of 4-adione and 17β-T was the 
[M+H]+ ion, as expected for 3-keto-4-ene steroids [21].  
Metabolic activation of 4-adione, containing a 17β-T impurity, with bovine liver S9 
resulted in an increase of 17β-T, thereby confirming the increase in androgen bioactivity 
as observed in the bioassay. Interestingly 17α-T was also formed. For 5-adiol, only 
metabolic activation using NAD resulted in formation of small amounts 17β-T, in 
accordance with the bioassay results in Fig. 3b. The fact that DHEA is converted into 4-
adione and 5-adiol and the latter two into 17β-T supports that bovine liver S9 contains 3β-
HSD/isomerase and 17β-HSD activity. The observed hydroxy-metabolites of DHEA are 
due to P450 enzyme activity. Indeed in vitro bovine S9 treatment can mimic the in vivo 
conversions shown in Fig. 1. UPLC-TOFMS analysis showed that supplement A 
contained only DHEA which is in accordance with what is declared on the label. Apart 
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 from the claimed DHEA and 4-adione, supplement B contained 17β-T and traces of     
17α-T, which are possibly by-products formed during production or storage. Metabolic 
activation of the supplements showed similar metabolite profiles as obtained during 
activation of DHEA and 4-adione standards, resulting in higher levels of 5-adiol and the 
more potent androgens 4-adione and 17β-T (see Electronic Supplementary Material).  
 
Fig. 5 - UPLC-TOFMS total ion current (a) and reconstructed accurate mass chromatograms of DHEA          
(b), 4-adione (c), 5-adiol (d), 17α- and 17β-T (e), 7α-OH-DHEA (f) and a possible hydroxy-adione or keto-
DHEA metabolite (g) using the accurate mass of the [M+H]+ or  M+H-H2O]+ ion and a mass window of 0.05 
Da. Conditions: bovine liver S9 bioactivation using cofactor NAD and an incubation time of 6 h. 
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 Conclusions 
This work has outlined the concept of a bioactivity screening assay for prohormones using 
a combination of bovine liver S9 bioactivation with androgen bioactivity detection. The 
prohormone DHEA shows no direct androgenic activity in the androgen yeast biosensor 
but anti-androgenic properties. On the other hand, DHEA, but also 4-adione and 5-adiol, 
can be converted by bovine S9 into more potent androgens, resulting in an indirect 
androgenic hormonal activity. The developed in vitro bioactivation system successfully 
mimics the hydroxysteroid dehydrogenase (HSD)- and cytochrome P450-mediated in vivo 
metabolic transitions, thus allowing assessment of the indirect bioactivity and chemical 
identification without the use of animal experiments. UPLC-TOFMS analysis confirmed 
that the tested prohormones are metabolized into the androgenic active steroids 4-adione 
and 17β-T. In the same manner other prohormones of androgenic bioactive compounds 
requiring transformation by HSDs at the 3-position and 17-position can be screened for 
e.g. the prohormones 19-norandrostenedione and 19-norandrostenediol are expected to be 
converted into the potent anabolic androgenic steroid nandrolone by 3β-HSD/isomerase 
and 17β-HSD activity. In conclusion we can state that the androgen bioassay can be used 
for the screening of supplements for the presence of androgens, anti-androgens and 
prohormones, the last of these following liver S9 bioactivation. The system developed is 
expected to be equally applicable to prohormone preparations from sports doping.  
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 Abstract 
Receptor binding transcription activation bioassays are valuable tools for the screening of 
steroid hormones in animal feed and supplements. However, steroid derivatives often lack 
affinity for their cognate receptor and do not show any direct hormonal activity by 
themselves. These compounds are thus not detected by these kind of bioassays and need a 
bioactivation step in order to become active, both in vivo and in vitro. In this study a 
comparison was made between different in vitro activation methods for hormone esters 
and hormone glycosides. Testosterone acetate and testosterone decanoate were chosen as 
model compounds for the hormone esters, representing the broad range of steroid esters of 
varying polarities, while genistin was used as a substitute model for the steroid-
glycosides. Concerning bioactivation of the steroids esters, the efficiency for alkaline 
hydrolysis was 90-100% and much better as compared to enzymatic deconjugation by 
esterase. As a result 1 µg testosterone ester per gram of animal feed could easily be 
detected by a yeast androgen bioassay. When comparing different enzyme fractions for 
deglycosilation, genistin was shown to be deconjugated most efficiently by ß-glucuroni-
dase/aryl sulfatase from Helix pomatia, resulting in a significant increase of estrogenic 
activity as determined by a yeast estrogen bioassay. In conclusion, chemical and 
enzymatic deconjugation procedures for ester and glycoside conjugates respectively, 
resulted in a significant increase in hormonal activity as shown by the bioassay readouts 
and allowed effective screening of these derivatives in animal feed and feed supplements. 
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 1. Introduction 
The use of anabolic steroids as growth promoters in livestock production is banned within 
the European Union [1]. To ensure compliance with this ban, requirements for hormone 
residue analysis are described at the European level and implemented at national levels in 
residue monitoring programs [2]. Hormone abuse or incidents may be discovered by 
residue analysis in matrices such as urine, hair and feed. For screening animal feed and 
supplements reporter gene bioassays have proven their added value in detecting known 
and unknown steroidal compounds [3-5]. Oral administration of natural steroids via feed 
or supplements results in low bioavailability due to poor intestinal absorption and 
extensive hepatic first-pass metabolism. Alternatively, numerous derivatives have been 
synthesized with the goal to circumvent metabolism and prolong biological activity in 
vivo. Moreover, for efficient uptake, these compounds are often administered via 
injections, gels or implants. Intramuscular injection of hydrophobic testosterone esters for 
instance accounts for a slow release in the systemic circulation and by mixing short- and 
long-chain esters, both short and long term effects are obtained. In addition, steroid esters 
are also designed to improve the oral availability of steroids since esterification makes 
steroids sufficiently lipophilic to be incorporated in chylomicrons formed during lipid 
digestion in the intestine [6]. As a result, testosterone esters are absorbed by the intestinal 
lymphatic system and enter via this route the systemic circulation, thereby circumventing 
hepatic first-pass metabolism [7]. The oral bioavailability of testosterone undecanoate was 
estimated to be 7% and intake of 120-160 mg testosterone undecanoate equals the 
complete daily production of testosterone in males [8]. Apart from the lipophilicity of the 
compound, uptake and bioavailability also depend on the lipophilicity of the solvent used 
and might even be enhanced when taken together with food [6]. 
Steroidal glycosides constitute a structurally and biologically diverse class of molecules 
which have been isolated from a wide variety of both plant and animal species [9,10]. 
Similar to steroid esters, the glycoside group controls the pharmacokinetics and greatly 
modifies the biological activity of the steroid [11]. In vivo experiments with 
orchiectomised rats that received testosterone glycoside (Figure 1), either orally or 
intramuscularly, showed significant higher blood levels of testosterone compared to 
animals receiving oral testosterone [12]. This suggests that androgen glycosides taken 
orally are less susceptible to hepatic first pass metabolism than their corresponding 
unglycosilated androgens. 
Because the direct androgenic activity of steroid conjugates is often limited and binding to 
steroid receptors and subsequent biological effects only occur after deconjugation, there is 
a chance of missing the illegal use of these intact steroid conjugates when screening with 
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 bioassays based on receptor binding and the subsequent transcription activation of a 
marker gene. In the present work deconjugation steps were developed for steroid esters 
and glycosides in order to screen for their presence in animal feed and supplements with 
yeast based bioassays. Testosterone acetate and testosterone decanoate (Figure 1) were 
selected as model compounds for the development of an enzymatic or chemical hydrolysis 
method for steroid esters. Due to the lack of an androgen glycoside standard the 
glycosilated isoflavonoid genistin was used as a steroid-glycoside mimic compound, and 
combined with an estrogen bioassay screening in order to determine which enzymatic 
deconjugation was the most suited. 
Figure 1: Chemical structures of genistein, genistin, testosterone glycoside, testosterone acetate and 
testosterone decanoate. 
 
Because the direct androgenic activity of steroid conjugates is often limited and binding to 
steroid receptors and subsequent biological effects only occur after deconjugation, there is 
a chance of missing the illegal use of these intact steroid conjugates when screening with 
bioassays based on receptor binding and the subsequent transcription activation of a 
marker gene. In the present work deconjugation steps were developed for steroid esters 
and glycosides in order to screen for their presence in animal feed and supplements with 
yeast based bioassays. Testosterone acetate and testosterone decanoate (Figure 1) were 
selected as model compounds for the development of an enzymatic or chemical hydrolysis 
method for steroid esters. Due to the lack of an androgen glycoside standard the 
glycosilated isoflavonoid genistin was used as a steroid-glycoside mimic compound, and 
combined with an estrogen bioassay screening in order to determine which enzymatic 
deconjugation was the most suited. 
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 2. Materials and Methods 
 
2.1 Chemicals 
17ß-Testosterone, 17ß-estradiol, genistin, genistein, esterase (from porcine liver), ß-glucu-
ronidase type H5 from Helix pomatia, ß-glycosidase and L-leucine were purchased from 
Sigma (St. Louis, MO, USA). Testosterone acetate and testosterone decanoate were 
obtained from Steraloids (Newport, RI, USA). Sodium acetate, sodium carbonate, acetic 
acid, formic acid, hydrochloric acid, sodium hydroxide, dimethylsulfoxide (DMSO) and  
ß-glucuronidase/aryl sulfatase from Helix pomatia were purchased from Merck 
(Darmstadt, Germany). Dextrose, ammonium sulphate and yeast nitrogen base without 
amino acids and without ammonium sulphate were purchased from Difco (Detroit, MI, 
USA). HPLC grade acetonitrile and methanol were obtained from Biosolve 
(Valkenswaard, The Netherlands). Millipore water was obtained by using a Purelab Ultra 
system from Elga (Bucks, UK). 
 
2.2 Instrumentation 
2.2.1 HPLC analysis 
To determine levels of genistein, genistin and testosterone, HPLC analysis was performed 
on a Waters HPLC system (Waters, Milford, MA) consisting of two model 510 pumps, a 
model 717 plus auto injector and an automated gradient controller. Chromatographic 
separation was performed on a Supelcosil LC-18DB 5 µm, 4.6 x 2500 mm column 
(Supelco, Bellefonte, PA, USA) which was maintained at 40°C in a column oven. The 
mobile phases consisted of (A) 0.2% formic acid and (B) 0.2% formic acid in acetonitrile. 
A gradient was run at a flow rate of 1 mL min-1 starting at 20% B for 2 minutes followed 
by a linear increase to 80% B in 8 minutes. Next, the gradient remained 8 minutes at 80% 
B and returned linearly in 4 minutes to 20% B and remained 3 minutes at this level until 
the next injection. The injection volume was 50 µL and the column effluent was 
monitored by a Waters 996 photodiode array detector (Waters) at 200-400 nm and data 
was retrieved at a single wavelength of 260 nm. The HPLC system was equipped with 
Empower software (Waters). 
 
2.2.2 LC-MS analysis 
Levels of testosterone, testosterone acetate and testosterone decanoate were determined by 
LC-MS analysis. Liquid chromatography was performed on a Agilent Technologies 
1200series system (Agilent Technologies, Santa Clara, CA, USA) containing a Eclipse 
XDB-C8 5 µm, 3.0 x 150 mm column (Agilent Technologies) which was kept at 40 °C. 
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 The mobile phases consisted of (A) 0.1% formic acid and (B) 0.1% formic acid in 
acetonitrile. The injection volume was 50 µL and the flow was 0.4 mL min-1. A step-wise 
gradient was run starting with 30% B which was linearly increased to 100% B in 10 
minutes, kept at 100% B for 10 minutes. Then the gradient returned in 1 minute to 30% B 
and was kept at this level for 4 minutes until the next injection was started. The column 
effluent was directly introduced into a Waters model Micromass Quatro micro mass 
spectrometer operating in ESI positive ion mode. The capillary voltage of the ion source 
was set at 3000 V and the cone voltage was 30 V. The source temperature was 110 °C, 
desolvation temperature was 350 °C and the cone and desolvation gas flow were set on 30 
L h-1 and 600 L h-1 respectively. Data was recorded and processed using Masslynx v 4.1 
software (Waters).  
 
2.3 Procedures  
2.3.1 Alkaline and enzymatic hydrolysis of hormone esters 
For alkaline hydrolysis, 1 gram of sample was mixed with 6 mL methanol for 30 minutes 
in a head-over-head apparatus. The mixture was centrifuged at 3000 x g for 15 minutes 
and the supernatant was transferred to a fresh tube. The total supernatant volume was 
adjusted to 6 mL with methanol and deconjugation was performed by adding 750 µL 
sodium hydroxide (2.5 M) and incubation for 1.5 h at 60 °C in a water bath. After cooling 
to room temperature, 900 µL hydrochloric acid (2.5 M) was added to stop hydrolysis. 
Subsequently, 6 mL sodium acetate buffer (0.25 M, pH 4.8) was added and the pH was 
adjusted to pH 4.8 with acetic acid (4 M). Next, 6 mL of the extract was applied to the 
solid phase extraction (SPE) clean-up procedure as described below. 
For enzymatic hydrolysis, 1 gram of sample was shaken manually with 6 mL sodium 
phosphate buffer (0.2 M, pH 7.4) and 20 µL of esterase solution (300 U mL-1). Samples 
were incubated for 3 hours at 37 °C in a shaking water bath and enzymatic hydrolysis was 
stopped by adding 6 mL methanol. Samples were adjusted to pH 4.8 with hydrochloric 
acid (2.5 M). After centrifugation for 15 minutes at 3000 x g, 6 ml of supernatant was 
applied to the solid phase extraction (SPE) clean-up procedure as described below. 
SPE was performed on Bond Elute C18  SPE columns (Varian, 1000 mg, 6 mL) previously 
activated with 4 mL methanol and 4 mL methanol/sodium acetate buffer (50/50 v/v). The 
column was subsequently washed with 3 mL methanol/sodium acetate buffer (50/50 v/v), 
4 ml water, 3 ml sodium carbonate (10 % w/v), three times 4 mL water and two times       
4 mL methanol/water (50/50 v/v). After drying for 5 minutes under vacuum, the SPE 
columns were eluted with 2 times 4 mL acetonitrile followed by 2 mL ethylacetate. Next, 
the acetonitrile and ethylacetate eluate were applied to an Isolute NH2 column (IST, 500 
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 mg, 3 mL) previously conditioned with 4 mL acetonitrile. The effluent was collected 
separately, evaporated to dryness under a gentle stream of nitrogen gas and reconstituted 
in 3 mL of acetonitrile. Next, 200 µL aliquots of these final acetonitrile extracts were 
pipetted into a 96-well plate in triplicate and 50 µl of 4% DMSO was added. To remove 
the acetonitrile, plates were dried overnight in a fume hood, remaining only 2 µL of 
DMSO the next day. 
 
2.3.2 Enzymatic deconjugation of glycoside derivatives 
For enzymatic deconjugation of glycoside derivatives, 100 mg of sample was mixed with 
4 mL sodium acetate (0.2M, pH 5.2) and 30 µL of either Helix pomatia ß-glucuronidase/
aryl sulfatase, ß-glycosidase or ß-glucuronidase type H5 from Helix pomatia solution was 
added (each 24 U mL-1). Next, samples were incubated for 3 hours at 52°C in a shaking 
water bath. After cooling to room temperature, 4 mL methanol was added and samples 
were mixed head-over-head for 10 minutes. The mixture was centrifuged for 15 minutes 
at 3000 rpm and 4 mL supernatant was transferred to a fresh glass tube. The pH was 
adjusted to 4.8 with acetic acid (4 M) and the extracts were subjected to an Oasis HLB 
SPE column (Waters, 30 mg, 6mL) previously conditioned with 2 mL methanol followed 
by 2 mL water. Subsequently, the SPE cartridges were washed with 2 mL water and 2 mL 
methanol/water (50/50 v/v), dried under vacuum for 2 minutes and eluted with 4 mL 
methanol. A 500 µL portion of the eluate was evaporated to dryness under nitrogen gas at 
45°C and resuspended in 500 µL methanol/water (50/50 v/v) for analysis by HPLC. The 
remaining 3.5 mL eluate was evaporated to dryness under nitrogen gas at 45°C and 
resuspended in 1.5 mL acetonitrile. Next, 200 µL aliquots of this final acetonitrile extract 
were pipetted into a 96-well plate in triplicate and 50 µL of 4% DMSO was added. To 
remove the acetonitrile, plates were dried overnight in a fume hood, remaining only 2 µL 
of DMSO the next day. 
 
2.3.3 In vitro yeast androgen and estrogen bioassays 
Saccharomyces cerevisae transformants expressing either the human androgen receptor 
(hAR) or the human estrogen receptor alpha (hERα) were grown on selective minimal 
medium plates supplemented with L-leucine. Supplemented minimal medium (MM/L) 
consisted of yeast nitrogen base without ammonium sulphate or amino acids (1.7 g L-1), 
dextrose (20 g L-1), ammonium sulphate (5 g L-1) and was supplemented with L-leucine  
(6 mg L-1). The yeast androgen and estrogen bioassays were performed as described 
previously [3,14]. In short, 10 mL MM/L was inoculated with a single colony of the 
recombinant yeast and grown overnight at 30°C in an orbital shaking incubator at 125 
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 rpm. The next day, this yeast culture was diluted with MM/L until an optical density (OD) 
value at 630 nm between 0.04 and 0.06 was reached. For exposure to standard 
compounds, 200 µL aliquots of yeast culture were pipetted into each well of a 96-well 
plate and 2 µL stock solutions dissolved in DMSO were added. For exposure of the yeast 
to sample extracts, 200 µL aliquots of yeast culture were pipetted into each well of a 96-
well plate already containing the dried extracts as described in sections 2.2 and 2.3. 
Fluorescence was measured at 0 and 24 hours in a SynergyTM HT microplate reader 
(BioTek Instruments Inc., USA) using excitation at 485 nm and measuring emission at 
530 nm. Standards as well as samples were assayed in triplicate and each fluorescence 
signal was corrected for the signal at 0 hours and the reagent blank, containing DMSO 
solvent only. The OD at 630 nm was measured after 24 hours to check whether the yeast 
was grown well and to determine whether a sample extract was cytotoxic. 17ß-testoster-
one and 17ß-estradiol standard curves were included in each androgen and estrogen 
bioassay experiment respectively. Dose-response curves were fitted using the equation 
y=a0/((1+(x/a1))^a2). This is equal to: response= (max.response-min.response)/((1+
([agonist]/EC50))^width of transition).  
 
3. Results and Discussion 
 
3.1 Androgenic and estrogenic activities of model compounds 
The dose-response curves of 17ß-testosterone, testosterone acetate (TA) and testosterone 
decanoate (TD) as obtained in the yeast androgen bioassay are shown in Figure 2A. 
Curves were fitted through the data points by non-linear regression and the concentration 
giving half the maximum response (EC50) was calculated. As expected, TA showed no 
response in the yeast androgen bioassay. Surprisingly, TD showed a clear response and an 
EC50 value of 1.4*103 nM was calculated, resulting in a relative androgenic potency 
(RAP) of 0.063 compared to 17ß-testosterone (EC50 value of 88 nM). As TD most likely 
does not bind to the androgen receptor, the obtained response is most probably caused by 
minor 17ß-testosterone impurities formed during manufacturing and storage of TD or by 
hydrolysis of TD during sample clean-up or exposure of the yeast. Therefore a TD 
standard solution was fractionated by a previous described LC system [3] and the 
fractions were analysed by the yeast androgen bioassay. After fractionation no activity of 
TD was observed while a clear activity was observed in the yeast androgen bioassay 
caused by a 17ß-testosterone impurity which was about 1% of the starting amount of TD 
(data not shown). 
The glycosilated isoflavone genistin showed only limited estrogenic activity in the yeast 
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 estrogen bioassay (Figure 2B). Although the maximum response as observed for 17ß-
estradiol and genistein was not reached, the EC50 of genistin was calculated to be 3.8*104 
nM. Genistin was thus at least a factor 10 less potent than its deconjugated equivalent 
genistein (Figure 1), which showed an EC50 value of 2.7*103 nM. As both steroid esters as 
well as the glycoside conjugate are substantially less potent than their deconjugated 
equivalents, they can be used as model compounds for the development of deconjugation 
steps for hormone esters and glycosides prior to the use of yeast based bioassays. 
 
Figure 2: Dose-response curves of (A) 17ß-testosterone, testosterone acetate and testosterone decanoate 
obtained in the androgen yeast bioassay and (B) 17ß-estradiol, genistein and genistin obtained in the estrogen 
yeast bioassay. Fluorescence signals are the mean of an assay triplicate (±SD) and corrected for the signal at 
t=0 and blank DMSO.  
 
3.2 Alkaline and enzymatic hydrolysis of hormone esters 
A previously established SPE sample clean-up procedure for bioassay based screening of 
androgens in animal feed was used as a starting point for method development [4]. The 
new procedure included the addition of an extra ethyl acetate elution step in order to elute 
also the more lipophilic testosterone esters, as the original method was designed to extract 
the unconjugated steroids only. Academic standards of 17ß-testosterone, TA and TD were 
applied to this modified SPE clean-up and the eluate fractions were subsequently analysed 
in the yeast androgen bioassay. As expected, only testosterone showed a clear response, 
while no response was obtained for TA and TD (Figure 3, first 8 bars). However, a clear 
response was obtained in the acetonitrile fraction of TA spiked blanks and the ethyl 
acetate fraction of the blanks spiked with TD when esterase was added during the 
exposure of the yeast cells to these fractions (Figure 3, second series of 8 bars). These 
findings indicate hydrolysis of the testosterone esters by the added esterase and 
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 demonstrates that TA is eluted easily from the column with acetonitrile, just like the 
unconjugated steroids, while the more lipophilic TD is hardly eluted by acetonitrile and is 
mainly present in the ethyl acetate fraction. 
Figure 3: Androgen bioassay response of acetonitrile and ethyl acetate SPE fractions. Blanks (Bl) and standard 
solutions containing testosterone (T), testosterone acetate (TA) or testosterone decanoate (TD) were subjected 
either to enzymatic or alkaline hydrolysis prior to the SPE sample clean-up procedure or afterwards, by 
enzymatic hydrolysis in the well. Fluorescence signals are the average of an assay triplicate and corrected for 
the signal obtained at t=0 hours. 
 
Enzymatic or alkaline hydrolysis of TA and TD before the SPE sample clean-up, revealed 
strong responses in the acetonitrile fractions only (Figure 3, third and forth series of 8 
bars). These findings not only demonstrate both effective enzymatic and alkaline 
hydrolysis of the T-esters, but once more demonstrates that the unconjugated free 
testosterone is already completely eluted with acetonitrile. Moreover, on a semi-
quantitative level, the results indicate that the recovery for the T-esters is lower than that 
of the unconjugated testosterone and as a result it is better to perform the activation step 
before the sample clean-up. 
Next, animal feed samples from practice were spiked with 17ß-testosterone, TA or TD. 
After sample clean-up and exposure of the androgen yeast cells to the sample extracts, the 
enzymatic hydrolysis performed in the well, by the addition of esterase, showed no 
significant increase in the obtained responses and only the testosterone spiked feed 
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 samples gave clear positive responses compared to the blank sample (data not shown). 
However, enzymatic hydrolysis before SPE clean-up resulted in clear responses of all 
spiked feed samples (Figure 4A). Recoveries for the testosterone spikes were determined 
by LC-MS analysis and were between 60 to 80%, resulting in maximal responses in the 
yeast androgen bioassay. After enzymatic hydrolysis also all the TA and TD spiked 
samples showed a maximal or near maximal response in the yeast androgen bioassay, 
although only 10 to 20% of the esters were hydrolysed to 17ß-testosterone, as was 
determined by LC-MS. Moreover, while the recovery of the remaining 80 to 90% of intact 
ester was 90 to 130% for TA whereas it was only 10 to 30% for TD. This low recovery for 
TD is probably caused by poor elution of the intact TD ester from the SPE column and/or 
solubility issues during analysis. 
 
Figure 4: Androgen bioassay response of blank feed samples and feed samples spiked with 25 µg of testosterone 
(T), testosterone acetate (TA) or testosterone decanoate (TD) after (A) enzymatic and (B) alkaline hydrolysis. 
Fluorescence signals are the average of an assay triplicate and corrected for the signal obtained at t=0 hours. 
The percentage of TA and TD that remained intact (  ) and the percentage of free 17ß-testosterone () formed 
was determined by LC-MS analysis. 
 
Alkaline hydrolysis was shown to be more efficient as compared to enzymatic hydrolysis 
(Figure 4B). After hydrolysis, all spiked samples showed a maximal response in the yeast 
androgen bioassay. Recoveries of 17ß-testosterone were between 80 and 120% in animal 
feed 2, the milk replacer and the wet feed sample and surprisingly low for animal feed 1 
and the soy feed sample. In case of the TA and TD spiked samples nearly all of the ester 
was converted to 17ß-testosterone and only small traces of the intact esters were 
recovered. The applied alkaline hydrolysis procedure is therefore highly efficient, as LC-
MS analysis showed that 90 to 100% of the T-esters were hydrolysed. The detection limit 
of the alkaline hydrolysis procedure was shortly investigated by testing a concentration 
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 range of both the T-esters. This revealed that 1 µg of testosterone ester per gram of feed 
could easily be detected by the yeast androgen bioassay (data not shown).  
 
3.3 Enzymatic deconjugation of glycoside derivatives 
Three different enzyme fractions were assessed for their ability to convert genistin into 
genistein. Figure 5 shows the rates at which H5 ß-glucuronidase, ß-glycosidase and ß-
glucuronidase/aryl sulfatase from Helix pomatia convert genistin into genistein. ß-
glucuronidase/aryl sulfatase achieved full conversion within 1 h while the other two 
enzyme fractions required an overnight (16 h) digestion to achieve a full conversion. The 
negative control showed no conversion of genistin during the first 7 hours, but after 16 h 
17% of the genistin was deconjugated under formation of genistein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Genistin standards and feed samples enzymatically digested by H5 ß-glucuronidase (H5 ß-gluc.),       
ß-glycosidase (ß-glyc.) or ß-glucuronidase/arylsulfatase from Helix pomatia (ß-gluc/arylsulf.) (0.2 U mL-1). 
Shown is the enzymatic digestion of 25 µM genistin over a period of 16 hours measured by HPLC.  
 
After development of an efficient extraction procedure, which is described in section 2.3, 
the three different enzyme fractions were assessed for their ability to deconjugate genistin 
in real-life animal feed and feed supplement samples. The samples analysed consisted of 4 
different soy based feed samples and 2 herbal feed additives that were expected to contain 
isoflavones as well as glycosilated isoflavones like genistin [13]. Except for feed 
supplement 1, HPLC analysis confirmed that all sample extracts contained genistein in the 
range of 2 to 20 µM, which consequently resulted in an initial response in the yeast 
estrogen bioassay without the addition of an enzyme as shown by the first bars in figure 6. 
Incubation of the feed samples with ß-glucuronidase/aryl sulfatase for three hours resulted 
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 in a significant increase in estrogenic activity, while incubations with H5 ß-glucuronidase 
or ß-glycosidase resulted in no or a limited increase in estrogenic activity as compared to 
the control samples incubated without the addition of an enzyme. These observations were 
supported by the HPLC data, showing an increase of the genistein levels in the soy feed 
samples that were treated with the ß-glucuronidase/arylsulfatase enzyme mix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: The estrogen bioassay response of animal feed samples and supplements determined after enzymatic 
deconjugation. The samples spiked with genistin and genistein were deconjugated with ß-glucuronidase/
arylsulfatase. Bioassay fluorescence signals are the average of an assay triplicate and corrected for the signal 
obtained at t=0 hours. Mean response of the yeast exposed to the DMSO blank (_·_), the maximum response of 
the 17ß-estradiol standard curve (---) and genistein levels prior to deconjugation ( ) are included respectively.    
 
In addition, an attempt was made to get an impression of the conversion efficiency of the 
ß-glucuronidase/arylsulfatase enzyme mix in these animal feed samples. The samples 
were therefore spiked with 12.5 µM genistin or 12.5 µM genistein. Upon enzymatic 
deconjugation a near maximal response was obtained for all these spiked samples, 
showing almost no difference between the genistin and genistein spiked samples (Figure 
6). This indicates that genistin is almost completely converted into genistein and the 
obtained results are in accordance with the expectations for genistein, as 12.5 µM 
genistein showed a near maximal response in the yeast estrogen bioassay (Figure 2B). 
 
4. Conclusions 
The previously developed yeast based bioassay methods for the screening of estrogens 
and androgens in feed were not suited to detect inactive steroid conjugates [4, 14]. This 
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 study was intended to develop deconjugation methods in order to activate the inactive 
steroid conjugates. Testosterone acetate and testosterone decanoate were chosen as model 
compounds for steroid esters and genistin was chosen as a model compound for a 
glycoside conjugate. These conjugates were shown to be relatively inactive compared to 
their free aglycons, testosterone and genistein respectively. Subsequently, it was shown 
that the hormone esters were most efficiently activated by alkaline hydrolysis while the 
glycoside conjugate genistin could easily be activated by the ß-glucuronidase/arylsulfatase 
enzyme mix that is also used for the deconjugation of compounds in calf urine samples 
[4].  
Regarding the sensitivity, for free androgens in wet pulp feed and milk replacers the 
androgen yeast assay is fully validated according EC Decision 2002/657 [15] at a level of 
50 or 100 ng g-1 [4]. Although the present study demonstrated that after the alkaline 
hydrolysis it was still not possible to screen for the presence of testosterone esters as such 
low levels, 1µg g-1 feed could be easily detected by the androgen yeast assay for TA as 
well as TD. These levels are considered a relevant level for hormone esters to screen for. 
Together with a previous developed bioactivation protocol for prohormones like DHEA 
making use of a liver S9 mix [16], a panel of activation steps has been developed. 
Combined, this results in a comprehensive effect based screening strategy fully meeting 
EC directive 96/22, which states that all compounds having certain hormonal activity are 
prohibited [1]. 
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 Abstract 
Biotransformation of inactive prohormones like dehydroepiandrosterone (DHEA) can lead 
to the formation of potent androgens and subsequent androgenic responses in target 
tissues. In the present study a multi-functional in vitro bovine bioactivation model has 
been developed allowing to study the bioactivation of DHEA and resulting effects on the 
metabolite, transcript and androgenic activity level. Precision-cut bovine liver slices were 
exposed for 6 hours to various concentrations of DHEA. Changes in androgenic activity 
of DHEA containing cell culture media were measured using a yeast androgen bioassay 
and metabolites were identified using ultra performance liquid chromatography time-of-
flight mass spectrometry (UPLC-TOFMS). Furthermore, gene expression in the DHEA-
treated liver slices was examined using bovine microarrays and gene expression profiles 
were compared with those obtained with 17ß-testosterone (17ß-T). An increase in 
androgenic activity was observed in the bioassay upon testing of samples from 
incubations of DHEA with liver slices and the formation of 4-androstenedione (4-AD),    
5-androstene-3ß,17ß-diol, 17ß-T, 7α-hydroxy-DHEA, 7-keto-DHEA and 17α-T could be 
confirmed by UPLC-TOFMS analysis. Exposure of liver slices to DHEA and the strong 
androgen 17ß-T resulted in the identification of significantly up- and down-regulated 
genes and revealed similar gene expression profiles for both compounds. The results 
obtained indicate that DHEA itself is biologically not a very active compound, but is 
rapidly activated by liver slices in vitro. Moreover, the data presented successfully 
highlighted the multifunctional properties of bovine liver slices as an in vitro bioactivation 
model allowing the assessment of androgen activity or gene expression as effect-based 
endpoints for prohormone exposure.  
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 Introduction 
Steroidal sex hormones are potent compounds and play an important role in development, 
sexual maturation and behavior of both humans and animals. Human exposure to high 
levels of steroids results in disturbance of homeostatic hormone levels and is associated 
with an increased risk in the development of certain cancers (Pike et al., 1993; Hsing, 
2001). Especially homeostasis in sensitive populations, like young children, might be 
easily disrupted as exposure to exogenous hormones, e.g. dietary intake can be relatively 
high compared to extreme low endogenous hormone levels (Courant et al., 2007, 2008). 
Residues of hormones and growth promoters in food and feed are thus potential health 
hazards for consumers. Therefore, within the European Union, the use of growth 
promoters in animal production is strictly forbidden (EEC Directive 96/22, 1996). 
Despite the European ban, hormones are still surreptitiously used by farmers to improve 
weight gain and feed conversion efficiency. Albeit synthetic steroids are still used, the 
tendency is moving towards the use of natural steroids and their precursors such as the 
prohormone dehydroepiandrosterone (DHEA). Although DHEA lacks direct hormonal 
activity (Rijk et al., 2008), it has the potential to enhance levels of androgens and 
estrogens in vivo (Labrie et al., 1998). In order to prove and prevent fraudulent use of 
(pro)hormones, implemented monitoring programs focus on analyzing residues in 
matrices such as urine, feed and hair. For urine, feed and feed supplements, effect-based 
high throughput screening bioassays for hormones have proven their additional value 
(Bovee et al., 2009). However, inactive prohormones can not be detected by such 
screening assays and an additional bioactivation step is needed for these compounds (Rijk 
et al., 2008). 
Because the liver is an important site of metabolism of (pro)hormones, in vitro liver 
models are attractive tools to study biotransformation of (pro)hormones into more or less 
active metabolites. These models range from simple enzyme preparations like microsomes 
and liver S9 fractions (Merlanti et al., 2007; Rijk et al, 2008) up to models more close to 
the in vivo situation, like primary hepatocytes (Forsell et al. 1985; Donkin and Armentano, 
1993), liver slices (Zalko et al., 1998) and whole liver perfusions (Niles et al., 1961). Each 
model has its own advantages and disadvantages (Plant, 2004), while liver slices have the 
advantage that cell-cell interactions, cell heterogeneity and spatial arrangement are 
maintained. Moreover, liver slices allow investigation of a treatment effect at the gene 
expression level, as shown for rats (Elferink et al., 2008). Using the biotransformation 
capacity of liver slices together with gene expression analysis as an endpoint may provide 
an assay for effect-based screening for the presence of (pro)hormones in preparations and 
biological matrices. 
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 The aim of the present work was to investigate the potential of precision cut bovine liver 
slices as a multifunctional in vitro model to study bioactivation of DHEA and resulting 
effects on the metabolite, transcript and androgenic activity level. Following incubation of 
liver slices with different concentrations of DHEA, changes in androgenic activity of the 
DHEA containing incubation medium were monitored using a sensitive yeast androgen 
assay and ultra performance liquid chromatography in combination with time-of-flight 
mass spectrometry (UPLC-TOFMS) was used to identify the metabolites formed. 
Subsequently, liver slice gene expression profiles induced by DHEA were obtained using 
whole genome bovine oligonucleotide microarrays and were compared with profiles 
induced by the potent anabolic androgen 17ß-testosterone. 
 
Materials and Methods 
 
2.1. Chemicals 
17ß-testosterone was purchased from Steraloids (Newport, RI, USA). Dehydroepi-
androsterone (DHEA), bovine serum albumin and HEPES were obtained from Sigma (St. 
Louis, MO, USA). Sodium hydrogen carbonate, D-glucose, EDTA, tris(hydroxymethyl)
aminomethane (Tris), calcium chloride dehydrate, potassium chloride, sodium chloride, 
magnesium sulphate heptahydrate, potassium dihydrogen phosphate and dimethyl-
sulfoxide (DMSO) were obtained from Merck (Darmstadt, Germany). Williams’ medium 
E supplemented with Glutamax (WE) and charcoal-stripped fetal bovine serum were 
obtained from Invitrogen (Breda, The Netherlands). Acetonitrile and diethyl ether were 
purchased from Biosolve (Valkenswaard, The Netherlands). MilliQ-water used for UPLC-
TOFMS was purified using a Millipore MilliQ system (Bedford, MA, USA). 
 
2.2. Preparation and incubation of bovine liver slices 
Bovine liver tissue was obtained from the local slaughterhouse and originated from two 
male animals which were respectively 1.5 years old (380 kg) and 2.5 years old (420 kg). 
The caudate lobe was removed from the liver and flushed with ice-cold Krebs-Henseleit 
buffer (pH 7.4) containing 10 mM HEPES and 25 mM glucose. Liver tissue was stored in 
ice-cold Krebs-Henseleit buffer and transported to the laboratory where cylindrical cores 
with a diameter of 8 mm were taken out by use of a stainless steel drill press. Next, slices 
with a thickness of 250-300 mm were prepared using a Krumdieck tissue slicer (Alabama 
Research and Development Corp., Munford, AL, USA). The most uniform shaped slices 
were selected and transferred to 6-well culture plates. Each well contained 3.2 ml pre-
warmed (T = 39°C) WE medium supplemented with 25 mM D-glucose and 10% charcoal 
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 filtered-stripped fetal calf serum. DHEA and 17ß-testosterone stock solutions in DMSO 
were added to a final concentration of respectively 0.1, 1, 10, 50 and 100 mM in the well 
(final concentration of DMSO was 0.5%). Incubations were performed in triplicate, 
containing 3 slices per well. Control slices were incubated with DMSO-solvent only. 
Culture plates containing liver slices were incubated in a shaking water bath at 39 °C and 
continuously gassed with carbogen (95% O2/5% CO2). After 6 hours, slices for ATP 
determination were transferred to a tube containing 1 ml of sonication solution (70% 
ethanol, 2mM EDTA) and snap frozen in liquid nitrogen and stored at -80°C. For RNA 
extraction, slices were snap frozen in liquid nitrogen and stored at -80°C. Incubation 
media were stored at -20°C until analysis.  
 
2.3. ATP determination 
For ATP measurements, slices were homogenized by sonication and extracts were 
centrifuged at 13.000 rpm for 2 minutes. The supernatant was diluted ten times with 0.1 M 
Tris/HCl, 2 mM EDTA (pH 7.8) and ATP levels were determined by using the ATP 
Bioluminescence Assay kit CLS II (Roche, Mannheim, Germany) according to the 
manufacturer’s protocol. ATP analysis was performed in triplicate using slices from 3 
different wells. 
 
2.4. Extraction of incubation medium 
Aliquots of 3.2 ml incubation medium were thawed at room temperature, transferred to a 
glass tube and mixed with 6 ml diethyl ether. These samples were shaken head over head 
for 10 minutes, sonicated for 2 minutes in an ultrasonic water bath and centrifuged for      
5 minutes at 3000 xg. The organic upper layer was transferred to a fresh glass tube and the 
medium was extracted again with 3 ml diethyl ether. The combined organic phase was 
evaporated under nitrogen at 45°C until dryness and reconstituted in 1.5 ml acetonitrile. 
Next, aliquots of 200 µl acetonitrile extract plus 50 µl 4% DMSO were pipetted into a 
conical shaped 96-well plate. To remove the acetonitrile, the plate was air dried overnight 
in a fume hood. A similar procedure was used for samples for UPLC-TOFMS analysis. 
However, after extraction with diethyl ether and evaporation under nitrogen, samples were 
reconstituted in acetonitrile/water (10/90 v/v). 
 
2.5. Yeast androgen bioassay 
The yeast androgen bioassay procedure used was similar as the method described earlier 
(Bovee et al. 2007). In short, 10 mL of selective minimal medium supplemented with        
L-leucine (MM/L) was inoculated with a single androgen yeast colony and grown 
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 overnight at 30°C in a shaking incubator at 125 rpm. The next day, the yeast suspension 
was diluted with MM/L to an OD at 630 nm between 0.04 and 0.06 was reached. Aliquots 
of 200 µl yeast suspension were added to the 96-well plate containing samples and 
controls. Plates were incubated in a shaking incubator for 24 hours at 30°C, 125 rpm. 
Fluorescence (excitation at 485 nm and emission at 530 nm) was measured at 0 and 24h 
using a Synergy™ HT multi-detection microplate reader (Biotek Instruments Inc., 
U.S.A.). Fluorescence signals obtained at 24h were corrected with the signals from 0h and 
the blank, containing MM/L and DMSO only.  After 24h the OD of the yeast culture was 
measured at 630 nm to check whether the cells had grown well and to assure that the 
samples were not cytotoxic. In addition, aliquots of sample extracts were spiked with 2 µl 
of 30 µM 17ß-testosterone in DMSO just before androgen bioassay screening in order to 
test for androgen receptor antagonistic activity as well. 
 
2.6. UPLC-TOFMS analysis 
Ultra-performance liquid chromatography was performed on a Waters (Milford, MA, 
USA) Acquity system equipped with a Waters Acquity BEH C18 column (50 mm x 2.1 
mm i.d., 1.7 µm). The column temperature was kept at 45°C and the injection volume was 
20 µl. Mobile phases consisted of (A) acetonitrile/water/formic acid (10:90:0.2) and (B) 
acetonitrile/water/formic acid (90:10:0.2), linearly increasing from 20 to 46% B in            
5 minutes at a flow of 0.7 ml/min. The column effluent was split 1:1 prior to mass 
spectrometry. 
The UPLC was directly interfaced with a Waters LCT Premier mass spectrometer 
equipped with a dual electrospray ionisation probe operating in positive mode (ESI+). The 
source temperature was 120 °C, the desolvation temperature was set at 350 °C, the 
capillary voltage at 3000 V and the cone voltage at 50 V. The cone and desolvation gas 
flow were 50 and 600 l/h respectively. Leucine-enkephalin (1ng/µl) in water/acetonitrile 
(67:33 v/v) was used as a lock mass calibrant and continuously introduced in the mass 
spectrometer via the second ESI probe (Lockspray™) at a flow rate of 20 µl/min. Data 
were acquired between m/z 100-1000 and processed using MassLynx 4.1 software 
(Waters). 
 
2.7. RNA isolation and microarray hybridization 
Total RNA was extracted from liver slices by homogenization in Trizol (Invitrogen Life 
Technologies, Breda, The Netherlands). This homogenate was mixed with chloroform and 
centrifuged at 12000xg for 15 minutes at 4°C. The aqueous phase was transferred to a 
new tube, mixed with isopropanol, and centrifuged at 12000 xg for 10 minutes at 4°C. 
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 The pellet was washed with 75% ethanol and resuspended in RNase free water. Upon 
extraction, RNA was purified according to the RNeasy mini kit protocol (Qiagen, 
Westburg bv, Leusden, The Netherlands) and RNA concentration and quality was 
determined spectroscopically (Nanodrop technologies) and by automated electrophoresis 
using the BioRad Experion system (BioRad, Veenendaal, The Netherlands). Only RNA 
with A260/280 and A260/230 ratios above 1.8 was used for amplification. To generate 
fluorescently-labelled cRNA, the Agilent Low RNA Input Fluorescent Linear 
Amplification Kit (Agilent Technologies, Palo Alto, CA, USA) was used according to the 
manufacturer’s protocol. In short, 1 µg of total RNA was reverse transcribed using T7 
tagged oligo-dT primer and labelled with Cy3 or Cy5 (Perkin Elmer/NEN Life Sciences, 
Boston, MA, USA). RNAs of the control and treated liver slices were individually 
labelled with Cy5 and RNA of all control slices were pooled and labelled with Cy3. After 
purification with the RNeasy mini kit (Qiagen), label efficiency and yield were 
determined using a Nanodrop spectrophotometer (Nanodrop technologies). A mixture of  
1 µg of Cy3-labeled cRNA and 1 µg of Cy5-labeled cRNA was hybridized onto a 44k 
bovine oligo microarray (Agilent Technologies), using Agilent’s gene expression 
hybridization kit. Hybridization was performed at 65°C for 17 hours in a hybridization 
oven with rotation function (Agilent Technologies). Upon hybridization, microarrays were 
washed and dried according to Agilent’s instructions. Fluorescence measurements were 
performed using an Agilent Technologies G2565B microarray scanner. 
 
2.8. Microarray data analysis 
Fluorescence intensities were quantified using Feature Extraction 8.5 software (Agilent 
Technologies). Data were imported in GeneMaths XT 1.6 (Applied Maths, St. Martens-
Latem, Belgium) and signals below two times background were excluded from further 
analysis. Subsequently, the data were normalized as described by Pellis et al. (2003). This 
normalization included correction for the random error, with the median Cy3 signal for 
each individual spot. Secondly, correction for the systematic error was performed with the 
median value of the overall Cy5 signal. After normalization, principal component analysis 
(PCA) was performed to visualize differences between groups. Microarray data were 
floored by adjusting low intensity spots to a threshold value of 130, hereby reducing the 
number of less reliable genes. Next, data were 2log transformed and each gene was mean 
centred. Genes with statistically significant changes in expression were determined by 
Significance Analysis of Microarrays (SAM) (Tusher et al., 2001). A two class unpaired 
SAM analysis was performed using a fold change (FC) greater than 1.5 and a false 
discovery rate (FDR) of less than 0.2%. Hierarchical clustering of microarray data was 
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 performed using Cluster and Treeview (Eisen et al., 1998). 
 
Results 
 
3.1. ATP determination 
To assure the quality of the liver slices, ATP levels were determined after incubation of 
the slices with DHEA and 17ß-testosterone. Incubations with 100 µM DHEA showed a 
decrease up to 71% of the DMSO blank, while 10 and 1 µM DHEA or 17ß-testosterone 
showed a slight increase in ATP level compared to the blank (Figure 1). Based on these 
observations it was decided to use 10, 50 and 100 µM DHEA incubations for monitoring 
of both biological activity and metabolites formed and the 0.1, 1 and 10 µM DHEA and 
17ß-T incubations for gene expression profiling experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - ATP levels in bovine liver slices after 6h exposure to various concentrations of DHEA,                   
17ß-testosterone or DMSO solvent only (blank). ATP levels shown are the mean of a triplicate (±Stdev) using     
3 different liver slices. 
 
3.2. Yeast androgen bioassay 
After 6 hours exposure of the slices to DHEA, medium samples were extracted and 
subjected to the yeast androgen bioassay. Medium extracts of the 100 µM DHEA 
treatment showed a clear response in the androgen bioassay (grey bars in Figure 2). The 
response decreased in extracts of 50 µM DHEA incubations while incubations with 10 
µM DHEA or lower (1 and 0.1 µM DHEA, data not shown) as well as the control 
incubations of 10, 50, and 100 µM DHEA without slices, showed no response in the 
androgen yeast bioassay (Figure 2). 
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 To test the samples for androgen receptor antagonistic activity, aliquots of medium 
extracts were spiked with 17ß-testosterone to a final concentration of 300 nM (per well) 
and analysed in the androgen yeast bioassay. According to the 17ß-testosterone standard 
curve this concentration should result in a close to maximal fluorescence signal of 
approximately 700 (Figure 2). Although all spiked sample extracts gave a clear response, 
the maximal response was not reached (white bars in Figure 2). However, an increase of 
the signal was observed in 17ß-testosterone spiked medium extracts from incubations with 
decreasing concentrations of DHEA. A similar but even more pronounced, antagonistic 
effect was observed in DHEA incubations without slices. 
 
Figure 2 - Yeast androgen bioassay responses of 10, 50 and 100 µM DHEA incubated with and without bovine 
liver slices and a 17ß-testosterone standard curve. Fluorescence signals are the mean of an assay triplicate 
(±Stdev) and corrected for the signal at t=0 hours and the reagent blank. Grey bars represent the direct 
androgenic activity of the medium extracts and white bars represent the androgenic activity after addition of a 
300 nM 17ß-testosterone spike. 
 
3.3. UPLC-TOFMS analysis 
After DHEA incubation with liver slices, medium was extracted and analysed by UPLC-
TOFMS analysis with the goal to identify metabolites. Elemental compositions of  
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 metabolites were elucidated using accurate masses and the identity was confirmed by 
mass spectra and retention time comparison of commercially available standards. 
Retention times and m/z values of the most abundant ion of the analyzed standards are 
listed in Table S-1. 
The base peak intensity (BPI) chromatogram obtained from medium of liver slices 
incubated with 100 µM DHEA for 6 hours is shown in Figure 3A. The two most abundant 
peaks are DHEA at retention time 2.88 minutes and a peak at 0.53 minutes which could 
not be identified, but is most likely a medium component as it is also present in DHEA 
and 17ß-T incubations without slices (chromatograms not shown).  
 
Figure 3 - UPLC-TOFMS analysis of  medium following a 6 hours liver slice incubation with 100 µM DHEA. 
Shown is (A) the base peak intensity chromatogram and the reconstructed accurate mass chromatograms of (B) 
m/z 287.2011 (C) m/z 273.2218 + m/z 289.2168 and (D) m/z 303.1960 + m/z 305.2117 using a mass window of 
0.05 Da. For other conditions see Materials and Methods section. 
 
The main metabolite of DHEA is 4-AD which is observed at retention time 2.79 minutes 
showing a [M+H]+ ion at m/z 287.2011 (Figure 3B). Another ion with a m/z 287 is 
observed at retention time 0.96 which is most likely the [M+H-H2O]+ ion of 7α-hydroxy-
DHEA. Figure 3C, shows the reconstructed accurate mass chromatogram of m/z 273.2218 
+ m/z 289.2168 showing the [M+H-H2O]+ ion of 5-androstenediol and [M+H]+ ions of 
both 17α- and 17ß-T. Several, most likely, hydroxy- and oxo-metabolites of steroids are 
observed at retention time 0.60, 0.66, 0.91, 1.02, 1.28 and 1.63 minutes (Figure 3D) of 
which 7-keto-DHEA could be confirmed by retention time comparison. The relative levels 
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 of the identified metabolites were calculated versus the amount of DHEA observed at t=0 
incubations (11.1 µg/mL = 100%), by using the peak area of the extracted ion 
chromatogram and standard curves obtained by plotting the peak area versus the 
concentration of the standards (0, 0.1, 0.5, and 5 µg/mL). After liver slice incubation 17-
24% of the starting amount of DHEA remained unchanged, while summation of the levels 
of all observed steroidal phase I metabolites plus DHEA resulted in a yield of 33-43% 
relative to the starting amount of DHEA (Supplemental document S1).  
Although small differences in relative intensities were observed, the same metabolite 
profiles were detected in the 10 µM and 50 µM DHEA incubations in experiment 1 as 
well as in experiment 2 with slices prepared from a different liver. No metabolites were 
observed after incubation of 100 µM DHEA without liver slices (data not shown). 
 
3.4. Microarray analysis 
RNAs of slices from experiment 1 (0.1, 1 and 10µM DHEA and 17ßT; blank) and 
experiment 2 (10 µM DHEA; blank) were labeled and hybridized onto bovine arrays. 
After normalization of the microarray data, unsupervised principal component analysis 
(PCA) was performed. By reducing the complexity of the dataset, differences in gene 
expression can be visualized in 3 dimensions. Changes in the same direction are hereby 
indicative for changes of the same genes. Figure 4A shows the PCA-plot of the first three 
components covering 78.2% of the total variance. Control and exposed liver slices of 
experiment 1 as well as experiment 2 are mainly separated on the x-axis. The DHEA and 
17ß-T exposed slices of experiment 1 group closely together with the exception of all 
three slices incubated with 10µM 17ß-T and one 0.1 µM 17ß-T replicate. Based on this 
observation the 0.1 µM 17ß-T incubation was classified as an outlier and was excluded 
from further statistical analysis.  
Significant regulated genes (FC >1.5 and FDR <0.2%) were determined by Significance 
Analysis of Microarrays (SAM) and numbers of modulated transcripts are listed in Table 
1. The number of significantly regulated genes increased dose dependently, for DHEA as 
well as 17ß-testosterone, showing in general more down-regulated than up-regulated 
genes. The Venn diagrams in Figure 4B and C show the number of genes differentially 
expressed either in one group or in multiple groups of experiment 1. A total of 1048 genes 
were found to be modulated by at least one DHEA concentration, and a total of 152 genes 
were found modulated by each of the DHEA concentrations tested (Figure 4B). 
Figure 5 shows the outcome of the hierarchical cluster analysis of these 1048 regulated 
genes for the DHEA treated liver slices as well as for the DMSO blank and 17ß-T 
treatment groups. It should be noted that replica 3 of the 0.1µM 17ß-T incubation shows 
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 an expression profile which was highly similar to the blank DMSO incubations. This 
observation justifies again the exclusion of this replicate from the SAM analysis. The 
genes up-regulated by the DHEA treatment are clustered in area A, showing higher 
expression levels (increasing red intensity) as compared to the DMSO controls (green). 
For 17ß-T the same trend is observed, showing a more pronounced regulation at the 
highest concentration. In area B, genes down-regulated in the DHEA/17ßT treatment 
groups versus the DMSO controls are clustered together. In general, DHEA and 17ß-T 
exposed liver slices are showing similar expression profiles, particularly in the upper part 
of area B. However, a more pronounced down-regulation is observed for the 10 µM 17ß-T 
exposure. 
 
 
 
 
 
 
 
 
 
 
Figure 4. (A) Principal component analysis (PCA) of gene expression profiles in bovine liver slices. The 
principal components plotted cover 78.2% of the total variance. Spheres in the PCA are representing gene 
expression profiles observed in control (green) and DHEA (0.1 uM, yellow, 1 uM, blue and 10 uM, red) and 17ß
-testosterone (0.1 uM, purple, 1 uM, orange and 10 uM dark green) exposed liver slices of experiment 1. (B) 
Venn diagrams show the overlap between significantly regulated genes observed in bovine liver slices incubated 
with various concentrations DHEA and (C) 17ß-testosterone. 
A 
B C 
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Figure 5. Hierarchical cluster analysis of microarray probes that were significantly regulated (FC >1.5 and 
FDR <0.2%) by at least one of the DHEA treatments in experiment 1 (n = 1048). Shown are the responses of 
these modulated genes in all DHEA (experiment 1 and 2) as well as 17ß-testosterone exposed liver slices. Values 
are 2log transformed and mean centered followed by clustering on genes only using average linkage. Columns 
and rows represent liver slice incubations and genes respectively. Colors range from bright green (≥ 2log 0.8 
down regulated) to bright red (≥ 2log 0.8 up regulated).  
 
When determining the total number of significantly regulated genes upon treatment of 
liver slices with 10 µM DHEA in experiment 2, 621 and 789 genes were found to be up- 
and down-regulated respectively (Table 1), of which 35% overlapped with the genes that 
were found to be modulated by the 10 µM DHEA exposure in experiment 1 
(Supplemental document S2). 
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 Table 1. Number of transcripts significantly changed (Fold change ≥1.5 and FDR< 0.2%) after 6 hours exposure 
of bovine liver slices to DHEA or 17ß-testosterone. 
Discussion 
The main purpose of this study was to investigate the biotransformation of DHEA in 
bovine liver slices and to examine the feasibility of this model in combination with a yeast 
androgen bioassay and DNA microarrays for effect analysis. The viability of the liver 
slices was determined by measuring ATP-levels, as it was previously shown to be a valid 
quality parameter (Wang et al. 2010). Apart from the 100 µM DHEA incubation, no 
significant differences in ATP levels between DMSO blanks and treated slices were 
observed after 6 hours of exposure, thus indicating that with exception of 100 µM DHEA, 
the other DHEA and 17ß-T concentrations used were not cytotoxic for the liver cells. 
While DHEA itself is not active in the yeast androgen bioassay, exposure of bovine liver 
slices to 100 µM DHEA resulted in a significant increase in androgenic activity, 
suggesting formation of potent androgenic metabolites. However, medium extracts from 
incubations of DHEA with or without liver slices that were spiked afterwards with        
300 nM 17ß-T, showed a lower activity as expected. The response was lower than that 
from a 300 nM 17ß-T standard, showing a maximal response in the 17ß-T standard curve. 
This is likely due to the antagonistic properties of DHEA, as it was observed before that 
DHEA binds to the androgen receptor but shows no transcription activation in the 
androgen yeast bioassay (Bovee et al. 2008; Rijk et al. 2008). These antagonistic 
properties were confirmed by 6 hour control incubations of DHEA without liver slices, 
showing an increase in bioassay response of the 17ß-T spike with lower concentrations 
DHEA. Although exposure of liver slices to DHEA concentrations lower than 100 µM did 
not result in an androgenic response in the bioassay, a decrease in antagonistic activity 
was observed when comparing medium extracts of the 10 µM and 50 µM DHEA 
incubations with and without liver slices after spiking with 17ß-T. Here a higher bioassay 
Dose and compound Exp. No. Number Up Down 
0.1 µM DHEA 1 345 68 277 
1 µM DHEA 1 422 10 412 
10 µM DHEA 1 869 193 676 
0.1 µM 17ß-testosterone 1 142 0 142 
1 µM 17ß-testosterone 1 1130 416 714 
10 µM 17ß-testosterone 1 3543 1340 2203 
10 µM DHEA 2 1410 621 789 
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 response is observed in the DHEA incubations with liver slices as compared to DHEA 
incubations without liver slices (compare white bars with and without liver slices, Figure 
2), suggesting biotransformation of DHEA which results in a decreased antagonistic 
activity of the medium extracts and/or formation of androgenic metabolites. 
The biotransformation of DHEA was monitored by UPLC-TOFMS analysis showing the 
formation of 4-AD, 5-androstenediol, 17ß-T, 17α-T, 7α-hydroxy-DHEA, 7-keto-DHEA 
and at least 4 other metabolites that were not identified. According to the elemental 
composition these are most likely hydroxy- or oxo-metabolites of steroids (Figure 3). 
Quantification of DHEA and its metabolites resulted in 33-43% yield relative to the 
starting amount of DHEA. This incomplete yield could be explained by the performed 
liquid-liquid extraction using diethylether. Hereby the more water soluble phase II 
metabolites such as steroid glucuronides and sulphates are not extracted while most likely 
a substantial amount of the steroids is glucuronidated by the liver slices as e.g. shown for 
17ß-testosterone (Wang et al. 2010). Moreover, it is not reasonable to expect that all 
metabolites formed have similar ionization efficiencies in the UPLC-TOFMS analysis. 
For instance ionization of dihydrotestosterone, an androstane, is 5-10 times less efficient 
than that of its androstene equivalent 17ß-testosterone, but DHT is a two-fold more potent 
androgen than 17ß-testosterone (Bovee et al., 2008). Because other androstane steroids are 
not as potent as DHT, the increase in androgenic activity upon 6 h metabolism of DHEA 
by liver slices is expected to originate mainly from the formation of 17ß-T and 4-AD. 
Although 4-AD is approximately a 100 times less potent androgen than 17ß-T, the high 
levels formed contribute to the observed androgenic activity. Liver slice incubations with 
10 µM DHEA showed similar metabolite profiles, but no androgenic activity was 
perceived in the bioassay probably due to the antagonistic activity of DHEA itself and the 
low absolute levels of androgenic metabolites formed.  
Qualitatively, the bovine liver slice phase I metabolite profiles of DHEA determined in 
this study are similar to the profiles previously obtained with S9 mixtures prepared from 
bovine liver using NAD+ as a cofactor (Rijk et al., 2008). 4-AD and 7α-hydroxy-DHEA 
were the main metabolites formed, together with minor amounts of 17ß-testosterone,        
5-androstenediol and 7-keto-DHEA. Also in human liver S9 experiments the formation of 
7α-hydroxy-DHEA as well as of 7ß-hydroxy-DHEA, 16α-hydroxy-DHEA, 7-keto-DHEA 
and 5-androstenediol was observed (Chalbot and Morfin, 2005). Although 7α-hydroxyl-
lation of DHEA has been described as a major pathway in liver (Doostzadeh et al., 1998), 
metabolite profiles differ between species due to the stereospecificity of hydroxylation by 
the various P450 enzymes that metabolize DHEA (Miller et al., 2004). Moreover, 
metabolites observed in experiments using liver S9 fractions, strongly depend on the 
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 cofactor that is used (Chalbot and Morfin, 2005). Liver slices have the general advantage 
that all phase I and phase II enzymes are present together with their natural amounts of 
cofactors thus resembling the in vivo situation more closely. However, in this case 
incubation of liver slices with DHEA results in significant lower levels of androgen active 
compounds as compared to incubations with bovine liver S9 resulting in a lower response 
in the androgen bioassay (Rijk et al., 2008). This is probably due to the formation of 
androgen inactive steroid phase II metabolites and therefore liver slices are considered to 
be a less adequate bioactivation model to monitor the androgenic activity of prohormones.  
Regarding DNA microarray analysis, the present study with bovine liver slices shows that 
DHEA alters hepatic gene expression. This gene expression profile was qualitatively 
similar to that of the potent androgen 17ß-T. In comparison, in classical androgen-
sensitive tissues of gonadectomized mice, DHEA showed gene expression profiles that 
were highly similar to profiles of the potent androgens dihydrotestosterone (DHT) and 
tetrahydrogestrinone (THG) (Labrie et al., 2006). These results imply that exogenous 
DHEA can act as an androgen, but is most probably largely dependent on the expression 
levels of steroidogenic enzymes in the target cells (Labrie et al., 1991). The gene 
expression profile of DHEA is most likely caused by its more potent androgenic 
metabolites like 4-AD and 17ß-T. Similarly, these metabolites are responsible for the 
observed activity in the yeast androgen bioassay of medium extracts prepared from slices 
exposed to DHEA. Principal component analysis showed a clear separation in profiles 
between medium from control slices on the one hand and medium from DHEA or 17ß-T 
exposed slices on the other hand. For DHEA as well as 17ß-T the number of differentially 
regulated transcripts increased dose dependently and a significant overlap was observed 
between both compounds. However, a distinct separation was also shown between 
experiment 1 and 2, most probably due to obvious experimental and biological variation 
e.g. differences in origin and background of the bovines of which the livers were obtained.  
Rat in vivo as well as liver slice gene expression profiles induced by DHEA have been 
reported before (Depreter et al., 2002; Gu et al., 2003; Werle-Schneider et al., 2006). 
Although not always regulated in the same direction, in general the genes found regulated 
by DHEA in the rat liver slices (Werle-Schneider et al., 2006) are also regulated in the 
bovine liver slices (Figure 6). From these regulated genes, SAM analysis classified 
PSME1, RPL41, EHHADH, ALDH1A1 and HRG as significant regulated in at least one 
of the DHEA liver slice exposures. However, genes that were found to be down-regulated 
in DHEA treated rat liver slices, such as RPL41 and HRG were up-regulated in all DHEA 
treated bovine liver slices. 
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Figure 6. Heat map of expression in bovine liver slices of genes previously found regulated in rat liver slices 
treated with various concentrations DHEA [Werle-Schneider et al.]. Red and green colors indicate up regulated 
or down regulated vs the DMSO control average. Genes classified as significantly regulated by the SAM 
analysis are marked with an asterisk.    
 
In conclusion, the present study with bovine liver slices shows that biotransformation of 
DHEA not only results in an altered bioactivity, but also alters hepatic gene expression. 
Compared to metabolic conversions induced by bovine liver S9, bovine liver slices are a 
less efficient model for bioactivation in combination with androgenic reporter gene assays 
to screen for the presence of prohormones. Probably, this is mainly due to substantial 
phase II metabolism of DHEA as well as the lower levels of androgenic active metabolites 
formed. Moreover, preparation of liver slices is very laborious and thus less suitable to use 
in high through-put screening procedures. On the other hand, due to the fact that they 
exhibit also phase II metabolism liver slices can serve as an adequate in vitro model to 
study the species-specific metabolism of steroid (pro)hormones. Therefore a more feasible 
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 application of liver slices is foreseen in evaluation of both metabolism of (new) 
compounds as well as supplements showing up in the illegal circuit of which the in vivo 
mode of action is unclear. Currently, new compounds found in illegal preparations and 
supplements are tested in small scale animal experiments to obtain knowledge about 
absorption, distribution, metabolism and excretion kinetics in bovines, and to identify 
target urinary metabolites. In this process, liver slice models could be included to gather 
knowledge about metabolism and identification of (new) metabolite biomarkers that could 
be used for in vivo urine screening and hereby reduce the need for animal experiments.   
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 Abstract 
In livestock production, illegal use of natural steroids is hard to prove because metabolites 
are either unknown or not significantly above highly fluctuating endogenous levels. In this 
work we outlined for the first time a metabolomics based strategy for anabolic steroid 
urine profiling. Urine profiles of controls and bovines treated with the prohormones 
dehydroepiandrosterone (DHEA) and pregnenolone were analyzed with ultraperformance 
liquid chromatography in combination with time-of-flight accurate mass spectrometry 
(UPLC-TOFMS). The obtained full scan urinary profiles were compared using 
sophisticated preprocessing and alignment software (MetAlign) and multivariate statistics, 
revealing hundreds of mass signals which were differential between untreated control and 
prohormone-treated animals. Moreover, statistical testing of the individual accurate mass 
signals showed that several mass peak loadings could be used as biomarkers for DHEA 
and pregnenolone abuse. In addition, accurate mass derived elemental composition 
analysis and verification by standards or Orbitrap mass spectrometry demonstrated that 
the observed differential masses are most likely steroid phase I and glucuronide 
metabolites excreted as a direct result from the DHEA and pregnenolone administration, 
thus underlining the relevance of the findings from this untargeted metabolomics 
approach. It is envisaged that this approach can be used as a holistic screening tool for 
anabolic steroid abuse in bovines and possibly in sports doping as well.  
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 Introduction 
In livestock production, growth promoters are used to improve growth rates, feed 
conversion efficiency, and lean/fat ratios ultimately resulting in economical benefits for 
cattle fatteners. In contrast to regulations in, e.g., the U.S.A. and Australia, the use of all 
hormonal growth promoting substances is prohibited within the European Union [1]. To 
comply with this ban, mandatory monitoring and surveillance programs, based on 
screening and confirmation concepts, are implemented at a national level [2]. In order to 
circumvent regulations certain farmers are continuously in search for new growth 
promoting substances, such as prohormones, of which misuse in cattle fattening is hard to 
prove. Prohormonal substances do not exhibit hormonal action by themselves, however 
they are precursors of bioactive steroid hormones. The main precursor of all natural sex 
steroid hormones, androgens as well as estrogens, is dehydroepiandrosterone (DHEA) [3]. 
In vivo synthesis of DHEA occurs mainly in the adrenal gland where side chain cleavage 
of cholesterol results in pregnenolone which is metabolized by P450 17α-hydroxylase 
(P450c17) into DHEA. The compound DHEA itself was not found to exhibit direct 
androgenic action [4]; however, conversion by peripheral tissues under 3β-hydroxysteroid 
dehydrogenase/isomerase (3β-HSD) and 17β-hydroxysteroid dehydrogenase (17β-HSD) 
activity is yielding more potent androgens like testosterone (Figure 1).  
Routine urine screening is largely performed by using gas chromatography (GC) or liquid 
chromatography (LC) combined with mass spectrometry (MS) [5]. In order to obtain 
sufficient sensitivity and specificity, GC/MS and LC-MS/MS screening methods are in 
general based on monitoring of a limited number of ions or MS/MS transitions of known 
compounds. However, application of these targeted methods do not detect new unknown 
anabolic steroids or compounds which are absent in the preselected list of target analytes. 
Moreover, there is a chance of missing abuse of natural compounds, like pregnenolone 
and DHEA, which might not be significantly above highly fluctuating endogenous levels 
due to extensive metabolism.  
For urine screening including detection of new designer steroids, several more 
comprehensive screening concepts have been developed. Thevis et al. [6] proposed an LC
-MS/MS screening protocol based on the fact that steroids with (partially) common 
structures show similar product ions, which can be monitored by precursor ion scan 
acquisition. This idea has been refined by Pozo et al. [7] who stated that the combined 
acquisition of the precursor ion scan of m/z 105, m/z 91, and m/z 77 might be applicable as 
a screening protocol for most anabolic steroids. Another concept for screening is 
implemented by using a yeast androgen bioassay for screening calve urine on androgenic 
bioactivity [8]. In addition, that bioassay was successfully used as an offline LC detector 
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 followed by LC-QTOF identification for screening urine on synthetic or unknown 
designer steroids such as tetrahydrogestrinone (THG) [9].  
Figure 1 - In vivo androgen biosynthesis: pregnenolone is converted into DHEA under P450c17 activity; 
subsequently 17β-testosterone is formed via 5-androstenediol or 4-androstenedione due to 3β-hydroxysteroid 
dehydrogenase/isomerase (3β-HSD) and 17β-hydroxysteroid dehydrogenase (17β-HSD) enzyme activity; and 
17β-testosterone is converted into unsaturated metabolites under 5α- and β-reductase, 3α-hydroxysteroid 
dehydrogenase (3α-HSD), and 17βHSD activity. 
 
In human antidoping control, steroid profiling has proven its usefulness by comparing 
levels and ratios of endogenous produced steroids in urine [10]. Significant variations of 
endogenous steroid levels and ratios are observed after administration of (pro)hormones 
[11] including alterations as a consequence of DHEA administration [12,13]. For 
screening on DHEA abuse in humans, threshold values of 200 ng/mL have been proposed 
for both DHEA and the DHEA-metabolite 3α,5-cyclo-5α-androstane-6β-ol-7-one [14]. 
However, because of large differences in metabolism and excretion, a steroid profiling 
approach using parameters that proved its value in humans, such as testosterone/
Metabolomics approach to anabolic steroid urine profiling 
  
125 
 epitestosterone (T/E) ratios, does not seem to be feasible in cattle [15].  
Recent developments in LC-MS and bioinformatics allow untargeted and unbiased urine 
profiling approaches which can be adopted from metabolomics research [16]. 
Ultraperformance liquid chromatography (UPLC) [17] combined with full-scan high-
resolution MS such as time-of-flight (TOF) and Fourier transform (FT) ion cyclotron 
resonance or Orbitrap MS allows more complete chemical profiles of complex biological 
samples like urine. In addition, the mass accuracy provided by TOFMS and Fourier 
transform mass spectrometry (FTMS) allows calculation of elemental compositions [18]. 
Recent performed work by Werner et al. [19] combined UPLC with TOFMS to analyze 
urine samples from rats treated with phenobarbital. Subsequent comparison of urinary 
profiles from treated and untreated rats under well-defined laboratory conditions resulted 
in identification of 14 phenobarbital metabolites not previously reported.  
The aim of the present work was to develop a metabolomics based screening strategy for 
prohormone abuse in real-life urine samples from farm bovines. An untargeted approach 
is used for detection of differentially accumulating metabolites as a consequence of 
treatment with the prohormones pregnenolone and DHEA. Urine samples were analyzed 
by UPLC-TOFMS with the aim to obtain constant and reproducible results, leading to 
detection of relevant metabolites. Within this context, the a priori focus during 
development was to ensure method applicability at least for phase I and phase II 
glucuronide metabolites of steroid hormones but of course also other nonsteroidal 
metabolites might be picked up. Urine profiles generated by UPLC-TOFMS were 
processed by in-house developed MetAlign software [20,21]. Through data reduction and 
alignment, complex chemical profiles were used for various comparisons and searches. 
Data were analyzed using multivariate statistics followed by identification of signals 
differential in urine of prohormone-treated versus untreated animals. The mass peak 
loadings obtained by this untargeted approach were statistically tested for its biomarker 
potential for DHEA and pregnenolone misuse in bovines. Finally, potential biomarkers 
were identified based on accurate mass derived elemental composition and retention time 
comparison with commercially available standards or by LC-LTQ-Orbitrap tandem MS. 
 
Experimental section 
 
Chemicals  
DHEA was obtained from Sigma (St. Louis, MO) and was dissolved in Miglyol 812 
(Certa SA, Braine-l’Alleud, Belgium) for intramuscular injection. Testosterone-d3 was 
purchased from NMI (Pymble, Australia) and testosterone-d3-glucuronide from NARL 
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 reference materials (Pymble, Australia). Pregnenolone and all other steroidal compounds 
used were obtained from Steraloids (Newport, RI). Acetic acid, formic acid, ammonia, 
and sodium acetate were of analytical grade and obtained from Merck (Darmstadt, 
Germany). Methanol and acetonitrile were purchased from Biosolve (Valkenswaard, The 
Netherlands). Milli-Q-water was purified using a Millipore Milli-Q system (Bedford, 
MA). 
 
Animals, treatments, and urine sampling  
In a time span of 1½ years, three independent bovine DHEA treatment experiments were 
performed using identical treatment and sampling schedules. For obvious ethical reasons 
it was chosen to perform three small scale treatment experiments, hereby deliberately 
including inherent biological variations like differences in, e.g., age, origin, nutrition, and 
disease history. Male Frisian bovines were purchased at the local market and housed for   
2-3 weeks before the start of each experiment. Each of the three experiments consisted of 
two animals of which one was orally (PO) administered capsules containing 1000 mg of 
DHEA and the other was injected intramuscularly (IM) with 1000 mg of DHEA dissolved 
in 10 mL of Miglyol 812. Untreated control animals were included in all three 
experiments, respectively, three animals in the first, one in the second, and two in the third 
experiment. The pregnenolone experiment consisted of four control animals and four 
animals which were treated orally with capsules containing 500 mg of pregnenolone. For 
the DHEA as well as the pregnenolone trial, repeated dose administrations were 
performed seven times at 24 h intervals. An overview of the experimental setup, including 
the age and weights of the animals, is shown in Table 1. Before the start of the treatment 
urine collections were made, and during the animal trials urine was sampled at days 2, 5, 
and 7 between 08.00 and 17.00 h. The animal study was approved by the Ethical 
Committee of Ghent University and performed in agreement with local ethical 
requirements. 
 
Table 1: Experimental setup, age and weights of bovines included in the DHEA and pregnenolone animal 
treatment experiments 
 Experiment No. of treated animals  (age and weight) 
No. of control animals  
(age and weight) 
DHEA no. 1 1 PO and 1 IM  (8-9.5 months, 253-290 kg)  
3  
(6 months, 153-174 kg) 
DHEA no. 2 1 PO and 1 IM  (8,5-9 months, 253-290 kg) 
1  
(8.5 months, 275 kg) 
pregnenolone 4 PO  (7.5- 10.5 months, 190-215 kg)  
4  
(8-9.5 months, 195-240 kg) 
DHEA no. 3 1 PO and 1 IM  (12.5-13.5 months, 355-410 kg)  
2  
(13.5-14 months, 350-386 kg) 
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 Sample preparation  
Prior to sample preparation, 5 mL aliquots of each urine sample were lyophilized to 
determine the dry weights. Next, the volume of nonlyophilized urine aliquots were 
normalized to 40 mg/mL dry weight by the addition of 0.11-5.83 mL of Milli-Q water. 
Aliquots of 3 mL were fortified with 20 μL of internal standard (1.5 ng/μL testosterone-d3 
and testosterone-d3- glucuronide in methanol). Samples were prepared in triplicate on 
separate days, and if a sample contained less than 40 mg/mL dry residue, a larger sample 
volume representing 120 mg dry weight was subjected to the following solid phase 
extraction (SPE) cleanup procedure. To each sample 3 mL of sodium acetate (0.25 M, pH 
4.8) was added, and the pH was adjusted to 5.0 ± 0.3 with 4 M acetic acid if necessary. 
Urine samples were then applied on a reversed phase SPE cartridge (Phenomenex Strata 
X, 200 mg, 33 μm, 6 mL), previously activated with 12 mL of methanol and 6 mL of  
Milli-Q water. The cartridge was washed with 6 mL of 0.17 M acetic acid in methanol/
water (40:60 v/v) and 6 mL of 0.13 M ammonia in methanol/water (20:80 v/v), dried 
under vacuum, and eluted with 6 mL of methanol. The SPE eluent was evaporated at 45 °
C under a gentle stream of nitrogen and reconstituted in 100 μL of methanol followed by 
adding 400 μL of mobile phase A. Before injection, samples were centrifuged for 10 min 
at 2000 g. To include between-day variation, each of the replicates was analyzed in a 
different measurement series.  
 
Ultraperformance liquid chromatography coupled to time-of-flight mass 
spectrometry  
Ultraperformance liquid chromatography was performed on a Waters (Milford, MA) 
Acquity system equipped with a Waters Acquity BEH C18 column (150 mm × 2.1 mm 
i.d., 1.7 μm) which was kept in a column oven at 50 °C. The injection volume was 25 μL, 
and the mobile phases consisted of (A) 20 mM formic acid in water and (B) 20 mM 
formic acid in water/acetonitrile (10/90 v/v) at a flow rate of 0.4 mL/min. An isocratic 
period of 1 min at 100% A was followed by a linear change from 0 to 20% B in 2 min, 20 
to 70% B in 20 min, and 70 to 100% B in 2 min. Next, the gradient remained 10 min at 
100% B and returned linearly in 1 min to 100% A, remaining at this level for 4 min until 
the next injection.  
The UPLC was directly interfaced with a Waters LCT Premier mass spectrometer 
equipped with a dual electrospray ionization probe operating in the positive mode (ESI+). 
The source temperature was set at 120 °C, the desolvation temperature at 400 °C, the 
capillary voltage at 2500 V, and the cone voltage at 50 V. The cone and desolvation gas 
flow were 50 and 500 L/h, respectively. A lock mass calibrant of leucine-enkephalin        
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 (1 ng/μL) in water/acetonitrile (67:33 v/v) was continuously introduced in the mass 
spectrometer via the second ESI probe (Lockspray) at a flow rate of 20 μL/min. Data were 
acquired between m/z 80-1000 and processed further in MassLynx 4.1 software (Waters).  
 
Ultraperformance liquid chromatography coupled to LTQ Orbitrap mass 
spectrometry  
Identification of a pregnenolone metabolite was carried out on a Thermo Fisher Scientific 
(San Jose, CA) Accela series U-HPLC system using the same column and identical 
elution conditions as used in the UPLC-TOFMS experiments, only the injection volume 
was changed to 20 μL. The LC system was directly coupled to a LTQ Orbitrap XL 
(Thermo Fisher Scientific) mass spectrometer equipped with an electrospray ionization 
probe operated in the positive ion mode. The electrospray voltage was 4000 V, capillary 
temperature 250 °C, sheath and auxiliary gas flow of 40 and 20 arbitrary units, 
respectively. Precursor ions were isolated in the linear ion trap (LTQ) section at a width of 
2.0 m/z and collisionally dissociated. Dissociation of m/z 317.3 was carried out at a 
normalized collision energy of 40% and scan ranges were m/z 85-400. In the case of m/z 
285.3, the collision energy was 30% for scan event 1 and 50% for scan event 2, scan 
ranges were m/z 85-350. Data were recorded and processed using Xcalibur software 
(Thermo Fisher Scientific). 
 
Processing of data files  
UPLC-TOFMS data generated in MassLynx format were directly imported in an accurate 
mass version of MetAlign [20,21]. Basically this software performs a baseline correction, 
accurate mass calculation, data smoothing and noise reduction, followed by alignment 
between chromatograms, generating data files which are 100-1000 times reduced in size. 
Next, data were imported in GeneMaths XT (Applied Maths, St. Martens-Latem, 
Belgium) and 2log transformed. A one-way analysis of variance (ANOVA, p < 0.01) with 
Bonferroni correction was performed to test for differences between groups, days, and 
routes of administration. To visualize these differences, principal component analysis 
(PCA) was performed and ANOVA selected mass peak loadings were exported in txt-
format to Excel. In search for robust potential biomarkers, additional selection criteria 
were applied. Fold changes were calculated by comparing the mean of all samples from 
treated animals versus the mean of all controls. For the DHEA and pregnenolone 
experiment, mass peaks with respectively a 10- and 5-fold change were selected. Mass 
peak loadings fulfilling this criteria but with a mean treated signal lower than 200 counts 
were considered too close to background noise and therefore removed from the selection. 
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 Subsequently data were mean centered and hierarchical clustering was done using Cluster 
and Treeview software [22]. Each of the selected mass peak loadings were evaluated 
using univariate statistics to determine if they can be used as a biomarker for prohormone 
detection. A detailed description of univariate modeling can be found in the Supporting 
Information. 
 
Results and discussion  
 
Quality of analytical data  
Urine samples were analyzed in triplicate, distributing each replicate in random order in a 
different analysis series. In total, three series containing 109-113 samples each were 
analyzed by UPLC-TOFMS during a time span of 3 weeks. These series included 15-20 
urine samples not belonging to the DHEA and pregnenolone treatment experiments and 
therefore not considered further in this paper. After every 20 samples, a mixed urine 
sample was injected to check for consistency during analysis. In addition, each urine 
aliquot was spiked before SPE cleanup with 30 ng of testosterone-d3 and testosterone-d3-
glucuronide internal standard. This allowed assessment of retention time stability, 
consistency of signal intensities, and mass accuracy within and between measurement 
series. Normalized and 2log transformed mass amplitudes of testosterone-d3 and 
testosterone-d3-glucuronide during measurement series are shown in Figure 2. For 
testosterone-d3, differences in mass amplitudes varied between a -2.02 and 1.60-fold 
change. Mass amplitudes of testosterone-d3-glucuronide showed higher variability and 
ranged between a -3.54 and 2.07-fold change. Although some fluctuations are observed, 
the UPLC-TOFMS system is considered extremely stable: most mass amplitude 
fluctuations are within a factor 2 without showing up- or down-going trends during the 
analysis series.  
Mass errors of the observed MetAlign calculated accurate mass of testosterone-d3 and 
testosterone-d3-glucuronide were in general below 10 ppm (Figure S-1 in the Supporting 
Information). Again testosterone-d3-glucuronide displayed higher variability throughout 
all measurement series, where testosterone-d3 showed only in the first analysis series a 
few outliers above 10 ppm mass error. Overall, it is concluded that the applied full scan 
analysis of urine samples with high-resolution UPLC-TOF mass spectrometry revealed 
highly stable and reproducible results.  
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Figure 2 - Normalized and 2log transformed accurate mass amplitudes of deuterium labeled internal standards, 
testosterone-d3 and testosterone-d3-glucuronide (30 ng spike added to urine samples before the SPE procedure) 
observed during UPLC-TOFMS measurements. 
 
 
Data processing and selection of potential biomarkers 
For the DHEA treatment experiment, aligned UPLC-TOFMS data of all samples were 
compared by one-way ANOVA (p < 0.01) with Bonferroni correction in order to correct 
for multiple testing. Supervised principal component analysis was applied on the output   
(n = 1565 mass peak loadings) to visualize differences between urine obtained from the 
control and DHEA treated animals. The projection of the three largest principal 
components, which represent 44% of the total variance, is shown in Figure 3. Control and 
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 treated groups are mainly separated on the x-axis. Whereas urine samples from IM and 
PO treated animals show separation on the y-axis. However, potential application in 
control and enforcement programs is performed without a-priori knowledge about the 
route of administration. As a result, it is more relevant and desirable to determine potential 
biomarkers for DHEA treatment independent from the route of administration. The 1565 
mass signals obtained after ANOVA were converted back in a Masslynx format.  
 
Figure 3 - PCA plot of urine samples from control animals (green) and DHEA treated animals (IM and PO at 
days 2, 5, and 7) after UPLC-TOFMS measurement and ANOVA (p value < 0.01) with Bonferroni correction. 
 
A comparison of urine profiles in total ion chromatogram (TIC) format displaying the 
average peak amplitude of the controls (A) versus the DHEA treated animals (B) for each 
of the 1565 selected mass signals is shown in Figure 4. Huge differences are observed 
between these profiles and because many signals are also observed at lower levels in urine 
from control animals, they most likely relate to endogenous metabolites, in accordance 
with expectations following administration of naturally occurring prohormones like 
DHEA.  
In order to identify the most abundant and robust biomarkers, ions with a fold change 
greater than 10 were selected by comparing the mean of all controls versus the mean of all 
samples originating from DHEA treatment. In addition, the mean signal of ions following 
DHEA treatment must exceed 200 counts in order to obtain measurable signals. In total, 
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 180 mass peak loadings (listed in Table S-1 in the Supporting Information) met these 
additional criteria and together with the top 10 of mass peak loadings found down-
regulated, hierarchical clustering (HCA) was performed. First, data were converted in 2log 
mean centered values followed by HCA on mass peak loadings only. Results of HCA are 
presented in Figure 4C, where >16 times regulation gets a maximal red or green intensity, 
representing respectively up- and down-regulation versus the signal average of all 
samples. The HCA-plot visualizes the presence of discriminating ions which are present 
in urine originating from both IM and PO DHEA treated animals (area A in Figure 4C). 
An increase in signal intensity of DHEA IM urine samples at days 2, 5, and 7 is observed. 
This most likely indicates that repeated treatment of animals with DHEA results in 
accumulation of metabolites in urine. In Figure 4C, area B, a cluster of ions is shown 
which are not differentially expressed at day 2, however, showing abundant dis-
criminating signals at days 5 and 7. Mass peak loadings characteristic for DHEA 
treatment per PO are found in area C, again observing an increasing trend during 
treatment. No signals were meeting the additional criteria for down regulation (>10-fold 
change), nevertheless the top 10 (area D) has been included in the HCA of Figure 4C, 
showing regulation from -1.85 to -7.14.  
For selection of potential biomarkers for pregnenolone abuse, a strategy similar to the one 
followed in the DHEA treatment experiment was applied. Again, data were aligned and 
ANOVA with Bonferonni correction was performed. Next, mass peak loadings with a      
p-value < 0.01 and a fold change > 5 were selected (n = 163) and applied to HCA (Figure 
5). Highly variable signals among samples are observed in area A of the HCA plot, where 
more robust discriminating markers are found in area B (listed in Table S-2 in the 
Supporting Information). Moreover, 16 signals were observed to be down regulated >5 
times in urine from pregnenolone treated animals (area C in Figure 5 and listed in Table   
S-3 in the Supporting Information). 
 
Univariate statistical analysis    
Each of the selected mass peaks, obtained as described in the data processing section (180 
for DHEA and 163 for pregnenolone), were evaluated individually in order to determine if 
they can be used as a biomarker for prohormone detection. For DHEA, all control samples 
from this experiment are used to estimate the probability density functions of each of the 
180 selected mass peaks. In addition, all samples from the DHEA treated bovines are used 
to determine the number of false negatives. As an example, the probability density 
function of m/z 255.2078 (RT = 10.98 min) is presented in Figure S-2 in the Supporting 
Information. The same methodology was applied to pregnenolone data.  
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Figure 4 - Mass peak loadings with a p value < 0.01 after ANOVA with Bonferroni correction, back converted to 
total ion chromatogram (TIC) data. Shown is (A) the average of all controls and (B) the average of the DHEA 
treated group. The insert at chromatogram A shows a 10 times magnification between 4 and 20 min. (C) 
Hierarchical clustering of  2log transformed and mean centered mass peak loadings showing more than a         
10-fold up-regulation. Additionally, the top 10 of mass peak loadings, which are down-regulated is shown (area 
D). Fold changes were obtained by comparing mean signals of all urines originating from DHEA treated 
animals versus the mean of all control urines. 
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Figure 5 - Hierarchical cluster analysis of 2log transformed and mean centered mass peak loadings showing 
more than a 5-fold increase (areas A and B) or decrease (area C) in signal. Fold changes were obtained by 
comparing mean signals of all urines originating from pregnenolone treated animals versus the mean of all 
control urines. 
 
The number of mass peak loadings yielding no or only a limited number of false negatives 
for prohormone treatment versus the controls is presented in Table 2. Corresponding mass 
peak loading for DHEA and pregnenolone are listed in Tables S-4 and S-5 in the 
Supporting Information, respectively. For screening purposes, a false negative rate of 5% 
is considered acceptable according to Commission Decision 2002/657/EC [23]. Already 
seven mass peak loadings from the DHEA treatment comply with this Decision.  
From the DHEA and pregnenolone experiment, subsets of mass peaks were selected and 
tested for false positives using an independent control test set, i.e., respectively, the 
control samples from the pregnenolone and DHEA experiments. Again the number of 
false positives was observed to be very low, see the results presented in Table S-6 in the 
Supporting Information. Thus a good classification is possible for urines from treated and 
control bovines. It should be noted, however, that although the inherent biological 
variability was deliberately high, the number of bovines in both groups is still rather 
small. The reduction of equation 1 to equation 2 as described in the univariate statistical 
analysis section of the Supporting Information has larger validity for larger sample sizes. 
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 Therefore, larger groups are needed to improve the distributions, resulting in more 
accurate estimations of the number of false positives and false negatives. 
 
Table 2: Number of mass peak loadings with 0 to 7 false negatives observed in urine samples originating from 
DHEA (n= 6) and pregnenolone (n = 4) treated bovines compared to their corresponding control population. 
a The number of false negatives are within the parentheses as the percentage relative to the total number of 
DHEA (n = 48) and pregnenolone (n = 36) treated urine samples, respectively. 
 
Initial identification of steroid related candidate biomarkers 
Multivariate assigned mass peak loadings responsible for segregation between control and 
treated animals should be identified. Although complete identification cannot be 
performed solely on the basis of MS data, the accurate mass signals are very useful for 
initial identification purposes. Structural characteristics of natural occurring anabolic 
steroids generally consist of a saturated (androstane) or unsaturated (androstene) skeleton 
with hydroxyl and/or oxo-groups attached at the 3 and 17-positions (Figure 1). Although 
large similarities in structures are observed, their electrospray ionization behavior can be 
completely different. In positive ionization mode, it is observed that apart from [M+H]+ 
ions also abundant [M+H-H2O]+ or [M+H-2H2O]+ ions are formed. This is highly 
dependent on the groups attached at the C3 and C17 positions and the presence and 
position (C4-C5 or C5-C6 configuration) of the double bond [24]. Moreover phase I and 
phase II metabolism can cause steroid hydroxylation, oxidation, reduction, and 
glucuronidation. With administration of DHEA, a minimum of C19 for phase I and C25 
for phase II glucuronides is expected for steroid metabolites in urine. Typical elemental 
DHEA   
false negativesa no. of mass peak loadings (p = 180)  
false 
negativesa 
no. of mass peak 
loadings (p = 163) 
0 3  0 0 
1 (2%) 1  1 (3%) 0 
2 (4%) 3  2 (6%) 0 
3 (6%) 4  3 (8%) 3 
4 (8%) 2  4 (11%) 3 
5 (10%) 2  5 (14%) 0 
6 (13%) 3  6 (17%) 1 
7 (15%) 2  7 (19%) 2 
>> 160  >> 154 
 pregnenolone   
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 compositions of these steroid ions are listed in Table 3. Taking into account losses of 
water, adduct formation, and combinations thereof, the elemental composition of most of 
the mass peak loadings listed in Table S-1 in the Supporting Information can be directly 
linked to steroidal structures. Because of in-source fragmentation and adduct formation, a 
single compound can produce several m/z signals at the same retention time. 
 
Table 3: Elemental compositions and theoretical accurate masses of some androstane and androstene steroid 
related ions. 
ax and y are denoting the position (C3 or C17) of the keto- as well as the hydroxygroup, of which the latter could 
be in the α- or β-configuration. 
 
Combined analysis of the obtained differential mass peak loadings can therefore provide 
insight into the identity of the differential regulated urinary metabolites. For example, 
multivariate analysis yielded several signals at retention time 13.06 min (Figure 6). The 
most abundant ion is observed at m/z 484.2903 (C25H42NO8). This is probably a NH4+ 
adduct of the compound, explaining the fragment and adduct ions observed at 489.2457 
[M+Na]+, m/z 431.2408 [M+H-2H2O]+, m/z 291.2301 [M+H-Gluc]+, m/z 273.2224 [M+H-
Gluc-H2O]+, and m/z 255.2145 [M+H-Gluc-2H2O]+. Note that the ion observed at m/z 
660.3133 is probably the result of in-source adduct formation yielding a [M+NH4+Gluc]+ 
ion and not a diglucuronide (which would be expected at a shorter retention time). 
Together, this suggests a molecule with a mass of 466 which could be a glucuronide of 
androstane-ol-one or androstenediol (Table 3). Relative retention time comparison of 
commercially available standards versus the deuterium labeled internal standards revealed 
that this compound is most likely etiocholanolone glucuronide. This is in accordance with 
literature stating that ionization of etiocholanolone-glucuronide is yielding mainly 
[M+NH4]+ and [M+Na]+ ions due to lower proton affinity as compared to some 
 [M+H-2H2O]+ [M+H-H2O]+  [M+H]+  [(M+O)+H]+  [(M+Gluc)+H]+ 
androstene-x-ol-y-onea C19H25 253.1956  
 C19H27O 
271.2062   
C19H29O2 
289.2168  
C19H29O3 
305.2117  
C25H37O8 
465.2488 
androstenediol C19H27  255.2113  
C19H29O 
273.2218  
 C19H31O2 
291.2324  
C19H31O3 
307.2273  
C25H39O8 
467.2645 
androstenedione C19H23     251.1800  
C19H25O 
269.1905  
C19H27O2 
287.2011  
C19H27O3 
303.1960  
C25H35O8 
463.2332 
androstane-x-ol-y-onea C19H27     255.2113  
C19H29O 
273.2218  
C19H31O2 
291.2324  
C19H31O3 
307.2273  
C25H39O8 
467.2645 
androstanediol C19H29 257.2269  
C19H31O 
275.2375  
C19H33O2 
293.2481  
C19H33O3 
309.2430  
C25H41O8 
469.2801 
androstanedione C19H25 253.1956  
C19H27O 
271.2062  
C19H29O2 
289.2168   
C19H29O3 
305.2117  
C25H37O8 
465.2488 
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 androstene glucuronides [25].  
Etiocholanolone is a relevant urinary metabolite known to originate from (exogenous) 
DHEA [26] and used as a parameter in steroid urine profiling [11]. Using intact steroid 
glucuronide metabolites in LC-MS/MS routine screening was proven to be an effective 
targeted analysis method [27]. Similarly, other potential biomarkers can be assigned, 
although the limited availability of steroidglucuronide standards is an obstacle for full 
confirmation of the hypothesized identity. 
Figure 6 - Differential mass peak loadings (p value <0.01 after ANOVA) obtained at retention time 13.06 min 
(combining scans 1543-1545). Signals showing >10-fold change compared to the mean of all controls are 
marked with an asterisk. Accurate mass values are the averages from aligned peaks of all urine samples. The 
mass error (in millidaltons) versus the theoretical mass of the displayed elemental composition is shown in 
parentheses. As confirmed by retention time and spectral comparison, this biomarker is most likely 
etiocholanolone glucuronide. 
 
LC-LTQ-Orbitrap identification  
A major candidate biomarker ion responsible for group separation in the pregnenolone 
experiment is m/z 285.3, eluting at retention time 14.35 min in the UPLC-TOFMS 
experiments. The possible identity of the molecule yielding this ion is not obvious from 
Table 3. Therefore this biomarker was characterized with LC-LTQ-Orbitrap tandem MS, 
showing a retention time shift of 2.1 min compared to the UPLC-TOFMS analysis. Figure 
7A shows the LTQ-Orbitrap full scan mass spectrum of a urine sample originating from a 
pregnenolone treated animal at retention time 16.47 min. The differentially regulated ion 
at m/z 285.25847 (C21H33) is a fragment ion probably originating from m/z 497.31152 
(C27H45O8) due to neutral losses of water, a glucuronide moiety (resulting in C21H34O at 
m/z 303.26911), and another water. LTQ-Orbitrap MS/MS analysis of m/z 285 (Figure 
7B) shows no fragment ions containing an oxygen atom. The fragmentation pattern is 
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 consistent with a precursor ion having hardly any favorable carbon atom for carrying the 
positive charge. A pregnane or androstane skeleton would be an obvious hypothesis. 
Although the LTQ-Orbitrap MS/MS findings cannot be confirmed by the lack of available 
standards, they support the hypothesis of a glucuronide of 3,20-dihydroxy-pregnane. 
Figure 7 - LTQ Orbitrap mass spectra of an unknown candidate biomarker obtained by untargeted screening of 
urine from a pregnenolone treated animal: (A) full scan mass spectrum at retention time 16.47 min and (B)     
MS/MS spectrum from precursor ion m/z 285.3 using a normalized collision energy of 50% and an isolation 
width of 2.0 m/z. 
 
Conclusions 
The present work has outlined a novel untargeted metabolomics based strategy for 
anabolic steroid urine profiling in the field of livestock production. Results show that full 
scan high-resolution UPLC-TOFMS analysis of bovine urine samples generated stable 
and reproducible profiles. Subsequent accurate mass data alignment combined with 
multivariate statistical analysis allowed comparison of urinary profiles and highlighted 
mass peak loadings differentially regulated as a consequence of DHEA or pregnenolone 
treatment. The mass peak loadings indicated potential biomarkers specific for DHEA or 
pregnenolone abuse in bovines. Statistical testing of individual mass peak loadings by 
false negative and false positive classification yielded several robust biomarkers for 
DHEA and pregnenolone treatment. Validation of those robust biomarkers using an 
independent test set showed no or limited numbers of misclassifications for the selected 
mass signals. However, it should be noted that larger control groups are needed to obtain a 
more complete description of the control group distribution.  
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 Moreover, information about the identity of regulated metabolites as a consequence of 
prohormone administration was obtained. Observed differences most likely are a direct 
result of treatment with the prohormones DHEA and pregnenolone, given the fact that 
most of the differentially mass signals could be ascribed to steroid related structures 
within 5 mDa mass measurement accuracy. Following an initial identification, some 
compounds were verified by the analysis of commercially available steroids and steroid 
glucuronides. In addition, the structure of an unknown steroid glucuronide was elucidated 
by Orbitrap tandem MS. Nevertheless, the identity of most prohormone derived 
metabolites remains unclear due to the lack of standards, hereby emphasizing the need for 
more commercially available standards of steroid metabolites to achieve proper 
identification.  
It is envisaged that application of this holistic methodology is suitable for general anabolic 
steroid screening purposes in livestock production and eventually in sports doping. Urine 
profiles of unknown individual animals can be compared with a library of control urine 
profiles. On the basis of the statistical deviation from this control population and identity 
of the observed differential mass signals, it can be decided to initiate appropriate follow-
up actions. Within this context, future work will be directed at acquisition of additional 
urine profiles from control animals, in order to obtain a good description of the normal 
distribution of the control population. 
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 Abstract 
 
Background. Within the European Union the use of growth promoting agents in animal 
production is prohibited. Illegal use of natural prohormones like dehydroepiandrosterone 
(DHEA) is hard to prove since prohormones are strongly metabolized in vivo. In the 
present study, we investigated the feasibility of a novel effect-based approach for 
monitoring abuse of DHEA. Changes in gene expression profiles were studied in livers of 
bull calves treated orally (PO) or intramuscularly (IM) with 1000 mg DHEA versus two 
control groups, using bovine 44K DNA microarrays. In contrast to controlled genomics 
studies, this work involved bovines purchased at the local market on three different 
occasions with ages ranging from 6 to 14 months, thereby reflecting the real life inter-
animal variability due to differences in age, individual physiology, season and diet. 
 
Results. As determined by principal component analysis (PCA), large differences in liver 
gene expression profiles were observed between treated and control animals as well as 
between the two control groups. When comparing the gene expression profiles of PO and 
IM treated animals to that of all control animals, the number of significantly regulated 
genes (p-value <0.05 and a fold change >1.5) was 23 and 37 respectively. For IM and PO 
treated calves, gene sets were generated of genes that were significantly regulated 
compared to one control group and validated versus the other control group using Gene 
Set Enrichment Analysis (GSEA). This cross validation showed that 6 out of the 8 gene 
sets were significantly enriched in DHEA treated animals when compared to an 
‘independent’ control group. 
 
Conclusions. This study showed that identification and application of genomic 
biomarkers for screening of (pro)hormone abuse in livestock production is substantially 
hampered by biological variation. On the other hand, it is demonstrated that comparison 
of pre-defined gene sets versus the whole genome expression profile of an animal allows 
to distinguish DHEA treatment effects from variations in gene expression due to inherent 
biological variation. Therefore, DNA-microarray expression profiling together with 
statistical tools like GSEA represent a promising approach to screen for (pro)hormone 
abuse in livestock production. However, a better insight in the genomic variability of the 
control population is a prerequisite in order to define growth promoter specific gene sets 
that can be used as robust biomarkers in daily practice. 
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 1. Background 
In the European Union the use of growth promoting substances in livestock production is 
prohibited according EC directive 96/22 [1]. To ensure compliance with this legislation, 
requirements for monitoring are described in EC directive 96/23 [2]. At national level, 
legislations are implemented in residue monitoring programs regulating sampling of 
animal matrices and residue analysis therein to guarantee fair trade, food safety and public 
health. Residue analysis in livestock production is in general based on chemical [3], 
immunochemical or biological [4,5] screening methods followed by mass spectrometry 
based confirmation methods. Although this strategy seems to work for synthetic anabolic 
steroids, problems arise when compounds that also occur naturally are used. 
Abuse of naturally occurring (pro)hormones is hard to prove since most of these 
substances are strongly metabolized in vivo. Moreover, metabolites are not always known 
or are present in levels not significantly different from highly fluctuating endogenous 
levels. This makes it difficult to prove fraudulent use based on quantification of natural 
occurring compounds. Nowadays, it is observed that misuse of growth promoters in cattle 
fattening moves towards these natural steroids and steroid esters. Moreover, inspections of 
livestock farms in The Netherlands occasionally result in the finding of feed or herbal 
additives and preparations containing so-called prohormones. Prohormones are 
compounds that exhibit limited or no hormonal action by themselves, however they are 
direct precursors of active hormones and indirectly affect natural hormone levels. 
Dehydroepiandrosterone (DHEA) is such a prohormone and is the most abundant 
occurring precursor of both androgens and estrogens in humans [6,7]. It is claimed that 
orally taken DHEA improves muscle strength and is therefore illicitly used in sports to 
enhance performance and appearance [8,9]. 
Looking for alternatives to support evidence of illegal use of growth promoting 
substances, gene expression analysis can be an attractive new approach. Several studies 
demonstrated changes in mRNA expression in bovine tissues upon treatment with growth 
promoters after performing real-time RT-PCR analysis on a limited number of preselected 
genes [10-14]. Untargeted transcriptomics approaches using microarrays allow gene 
expression analysis of thousands of genes simultaneously as well as identification of 
(new) biomarkers for screening [15,16]. Moreover, microarray data can provide 
mechanistic insights in cellular processes and pathways and can be used for classification 
of compounds with the same mode of action (gene expression finger prints) [17,18]. 
Comparative microarray analysis is therefore in potential a promising screening tool for 
growth promoter abuse and in particular for prohormones of which the mode of action in 
cattle is sometimes unclear. 
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 In recent work we used a metabolomics approach to compare urine profiles of control and 
DHEA exposed bovines [19]. This revealed several urinary steroid phase I and phase II 
metabolites which are potential biomarkers for DHEA treatment. In the present study we 
investigated the feasibility of monitoring prohormone abuse at the mRNA level using liver 
tissue from the same animal experiment. Gene expression profiles of control and DHEA 
treated animals were compared to determine differentially expressed genes and to identify 
biomarkers for DHEA treatment. 
 
2. Methods 
 
2.1. Animals and treatment 
Male Frisian bull calves were purchased at the local market and housed for 2-3 weeks 
before the start of the experiment. Treatment with DHEA was repeated in three 
independent experiments using identical treatment and sampling schedules. Each of the 
three experiments consisted of two animals of which one was orally (PO) treated with 
capsules containing 1000 mg DHEA (Sigma, St. Louis, MO, USA) and the other was 
injected intramuscularly (IM) with 1000 mg DHEA dissolved in 10 ml Miglyol 812 (Certa 
SA, Braine-l’Alleud, Belgium).  
 
Table 1: Experimental setup, age and weights of bovines included in the DHEA animal treatment experiment. 
  Treatment Age Weight 
Experiment #1 Intramuscular (IM 1) 9 months 290 kg 
  Oral (PO 1) 8 months 253 kg 
  Control (C 1-1) 6 months 174 kg 
  Control (C 1-2) 6 months 172 kg 
  Control (C 1-3) 6 months 153 kg 
Experiment #2 Intramuscular (IM 2) 9 months 262 kg 
  Oral (PO 2) 8 months 210 kg 
Experiment #3 Intramuscular (IM 3) 12 months 355 kg 
  Oral (PO 3) 13 months 410 kg 
  Control (C 3-1) 14 months 368 kg 
  Control (C 3-2) 14 months 386 kg 
  Control (C 3-3) 13 months 432 kg 
  Control (C 3-4) 13 months 350 kg 
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 Administrations were performed seven times, at 24-hour intervals. IM treated animals 
(n=3, 262-355 kg) were 9-12 months old and PO treated animals (n=3, 210-410 kg) 8-13 
months old. Control animals were included in the first (n=3, 6 months old, 153-174 kg) 
and third (n=4, 13-14 months old, 350-432 kg) experiment. An overview of the 
experimental setup, age and weights of the bovines is shown in Table 1. Twenty-four 
hours after the last treatment, the animals were sacrificed and liver tissue was collected, 
snap-frozen in liquid nitrogen and stored at -80°C until use. The experimental work was 
approved by the Animal Ethics Committee of Ghent University, Belgium, in accordance 
with local ethical requirements. 
 
2.2. Microarray analysis 
Total RNA was extracted from tissues by homogenization in Trizol (Invitrogen Life 
Technologies, Breda, The Netherlands) and mixed with chloroform. The lysate was 
centrifuged at 12000 x g for 15 minutes at 4°C and the aqueous phase was transferred to 
be mixed with isopropanol which precipitates total RNA. After centrifuging (10 minutes, 
12000 x g at 4°C) the pellet was washed with 75% ethanol and resuspended in RNase free 
water. Upon extraction the RNA was purified according to the RNeasy mini kit protocol 
(Qiagen, Westburg bv, Leusden, The Netherlands). After purification, RNA integrity was 
determined spectroscopically (Nanodrop technologies) and by gel electrophoresis. Only 
RNA with A260/280 and A260/230 ratios above 1.8 was used for amplification. To 
generate fluorescently-labelled cRNA, the Agilent Low RNA Input Fluorescent Linear 
Amplification Kit (Agilent Technologies, Palo Alto, CA, USA) was used according to the 
manufacturer’s protocol. In short, 1 µg of total RNA was reverse transcribed using T7 
tagged oligo-dT primer and labelled with Cy3 or Cy5 (Perkin Elmer/NEN Life Sciences, 
Boston, MA, USA). Liver RNAs of the treated and control animals were individually 
labelled with Cy5 and RNA of all 7 control animals was pooled and labelled with Cy3. 
After purification with the RNeasy mini kit (Qiagen), label efficiency and yield were 
determined using a Nanodrop spectrophotometer (Nanodrop technologies). A mixture of  
1 µg of Cy3-labeled cRNA and 1 µg of Cy5-labeled cRNA was hybridized onto a 44k 
bovine oligo microarray (Agilent Technologies), using Agilent’s gene expression 
hybridization kit. Hybridization was performed at 65°C for 17 hours in a hybridization 
oven with rotation function (Agilent Technologies). Upon hybridization, microarrays were 
washed and dried according to the Agilent’s instructions and fluorescence measurements 
were performed using an Agilent Technologies G2565B microarray scanner. 
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 2.3. Data processing 
Fluorescence intensities were quantified using Feature Extraction 8.5 software (Agilent 
Technologies). Data were imported in GeneMaths XT 1.6 (Applied Maths, St. Martens-
Latem, Belgium) and signals below two times background were excluded from further 
analysis. Subsequently, the data was normalized as described by Pellis et al. [20]. This 
normalization included correction for the random error, with the median Cy3 signal for 
each individual spot. Secondly, correction for the systematic error was performed with the 
median value of the overall Cy5 signal. After normalization, principal component analysis 
(PCA) was performed to visualize differences between groups and t-test statistics were 
performed to test for differential expression. Microarray data was floored by adjusting low 
intensity spots to a threshold value of 130, hereby reducing the number of less reliable 
genes. Next, spot intensities were 2log transformed and each gene was mean centered 
versus all samples. Based on these 2log transformed data differentially regulated genes 
were selected with a p-value <0.05 and a fold change >1.5 (> 2log 0.6) in each of the three 
treatment replicates versus the average from the control animals. Hierarchical clustering 
of the differentially regulated genes was performed using Cluster and Treeview software 
[21]. Raw microarray data of the present study have been submitted to ArrayExpress 
(available at: http://www.ebi.ac.uk) and are stored under experiment accession number    
A-MEXP-1810. 
 
2.4. Gene set enrichment analysis (GSEA) 
Gene set enrichment analysis (GSEA) is a tool to identify and analyse the differential 
expression of biologically relevant sets of genes that share common biological functions 
[22]. Using GSEA, the differentially regulated genes observed in DHEA treated animals 
versus one control group (e.g. controls of experiment 1) were validated by evaluating this 
gene set by comparing the same DHEA treated animals versus the other control group 
(e.g. controls of experiment 3). Therefore, separate gene sets were generated of the 
differentially expressed genes of respectively IM treated animals (n=3) and OS treated 
animals (n=3) versus the controls of experiment 1 as well as the controls of experiment 3. 
For example, the transcripts found significantly up-regulated when comparing DHEA IM 
versus control group 1 were included in the gene set ‘DHEA_IM_vs_CTR1_UP’. In a 
similar way other gene sets were created for up- as well as down-regulated genes. Next, 
GSEA ranks all genes on the microarray on differential expression between DHEA 
exposed and controls using signal to noise statistics, resulting in a list with up-regulated 
genes at the top and down-regulated genes at the lower end of the list. Each of the pre-
defined gene sets was tested against this list and GSEA calculated whether the genes in 
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 the gene set are randomly distributed, enriched at the top or at the lower end of the ranked 
list. Permutations were performed on gene sets and gene sets were considered 
significantly affected when the p-value was below 0.05 and the false discovery rate (FDR) 
below 0.25, accordingly to GSEA recommendations [22]. 
 
3. Results and Discussion 
 
3.1. Principal component analysis (PCA) and selection of differentially regulated 
genes 
In the present study the potential strengths as well as the pitfalls of microarray 
experiments using calves from real-life practice were investigated. Three small animal 
experiments were performed independently using bull calves purchased at the local 
market. In this way the experimental setup was taking into account the inherent variability 
needed to investigate the usefulness of bovine-specific microarrays as a screening tool for 
prohormone abuse in veterinary control. For obvious ethical reasons larger numbers of 
bovines treated with banned substances could not be justified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Principal component analysis (PCA) of bovine liver gene expression profiles. PCA-plot showing the 
three principal components of greatest variation which cover 22% (x-axis),  14% (y-axis) and 13% (z-axis) of 
the total variance respectively. Spheres in the PCA are representing profiles of control animals of experiment 1 
(green, C1 1-3), control animals of experiment 3 (red, C3 1-4), orally treated (blue, PO 1-3) and intramuscular 
treated animals (yellow, IM 1-3) respectively.   
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Upon microarray hybridization and data normalization, unsupervised principal component 
analysis (PCA) was performed to visualize differences between liver profiles of control 
and treated animals. Figure 1 shows the PCA-plot which is based on the three largest 
components, representing 49.9% of the total variance. Although there is variation in gene 
expression profiles of livers of animals treated with DHEA, they are clearly discriminated 
from those of the controls. However, large differences are observed between the two 
control groups, whereas the exposed animals (IM 1-3 and PO 1-3) and the control animals 
of the first experiment (CTR1) are separated along the x-axis while the control bovines of 
experiment three (CTR3) and the exposed bovines are mainly separated along the z-axis. 
Based upon the outcome of this PCA, further analysis was focused on comparison of the 
IM and PO treated animals versus either the total control population as well as the two 
control groups separately. 
Figure 2 - Venn diagram comparison of differentially expressed genes. Differentially expressed genes (p-value 
<0.05 and fold change >1.5 observed in each of the three treated animals) in liver of intramuscular (IM) and 
oral (PO) treated animals versus the mean of all controls, the controls of experiment 1 (CTR 1) and experiment 
3 (CTR 3). For each comparison the number of unique and shared genes are presented.  
 
Differentially regulated genes were selected using t-test statistics. A p-value <0.05 and a 
difference of at least 1.5 (>2log0.6) fold change, versus the control average, observed in 
all three biological treatment replicates (either IM or PO) were used as criteria for the 
selection of differentially expressed genes. An overview of the differentially regulated 
genes found in the IM and PO treated animals is shown in Figure 2. A total of 37 and 23 
genes were found to be regulated in IM and PO treated animals as compared to the total 
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 control group, respectively. Only one of these genes (DMBT) was found differentially 
expressed (down-regulated) in IM as well as PO treated animals. A hierarchical cluster 
diagram of all differentially regulated genes is presented in Figure 3. Since many probes 
were spotted twice or more on the microarray the 37 and 23 genes found regulated are 
represented by 66 and 39 spots respectively. A detailed description of all regulated genes 
is listed in Additional file 1. 
Figure 3 - Hierarchical cluster analysis of significant regulated genes. Hierarchical cluster analysis (HCA) of 
genes with a p-value <0.05 and a fold change >1.5 (fold changes calculated for each individual DHEA exposed 
animal versus the mean of all control animals) for (A) intramuscularly and (B) orally treated animals. Based on 
2log mean centered ratios, HCA was performed on genes only using average linkage clustering. Colour scales 
are ranging from bright red to bright green which correspond with respectively up- or down-regulated genes. 
Maximum brightness represents a fold change of ≥ 2 (2log mean centered ratios of ≤ -1 or ≥ 1).   
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 Of the 37 differentially expressed genes in response to the IM DHEA treatment, 4 
represented unidentified transcripts and 7 were encoding for proteins with poorly known 
or unknown function (LOC617652, LOC527553, LOC515784, LOC617667, LOC515640, 
LOC497203 and LOC521795). Among the 26 transcripts that encode for known proteins, 
10 transcripts are involved in immune response and inflammatory processes. Of these 
latter transcripts XBP1, MX1, LBP, SERPINA3, CCL24, CARD14 and PIGR were found 
up-regulated and ANKRD1, LYZ and DMBT were down-regulated. The remaining 
transcripts are involved in various processes like cell growth and proliferation (INHBE), 
formation of tight-junctions (CLDN7), tumor suppression (DIRAS3), cell proliferation 
and cell adhesion (CYR61) intra-cellular signalling (JAG2) and cell-cell interactions 
(LGALS4). Regarding metabolism, the GSTP1 gene was found to be down regulated >1.6 
fold in all IM treated animals. GSTP1 mediates glutathione conjugation and plays an 
important role in detoxification of xenobiotics as well as in uptake and transport of 
numerous hydrophobic endogenous compounds like steroids [23] Moreover, it has been 
observed in mouse that the GSTP1 gene contains androgen receptor binding sites which 
regulate GSTP1 activity in response to androgens [24]. 
Comparison of PO treated animals versus all control animals revealed a total of 23 
differentially expressed genes of which 7 represent unidentified transcripts or encoded for 
proteins with an unknown function. Again a substantial number of the differentially 
regulated genes are involved in immune response of which LILRA5, THBS, CLEC6A and 
FUT1 were found up-regulated and CCL14 and DBMT were down-regulated. Other 
differentially regulated genes are involved in peptidase inhibition (SERPINB8, WFDC1), 
G-protein signalling (RGS5) and amino acid transport (SLC6A14). Also regulated is the 
short/branched chain acyl-CoA dehydrogenase (ACADSB) gene, a member of the acyl-
CoA dehydrogenase enzyme family which is involved in fatty acid metabolism. This 
could point towards regulation of fatty acid metabolism and is supported by a study in 
which DHEA administration to rats showed significant regulation of genes involved in 
fatty acid metabolism, including the very long chain acyl-CoA gene which is also a 
member of the acyl-CoA dehydrogenase enzyme family [25]. Overall it can be stated that 
the majority of regulated genes are involved in immune response for both PO as well as 
IM treated animals which is in line with numerous studies reporting the significant 
immune modulatory properties of DHEA [26]. 
In principle the above listed genes are potential biomarkers for DHEA treatment. On the 
one hand, we are aware of the small number of animals used in this study which hampers 
proper statistics and substantially increases the chance of missing DHEA-responsive 
genes or detecting false-positive genes. On the other hand, combining and comparing the 
Feasibility of a liver transcriptomics approach 
  
153 
 data of three independently performed experiments will limit the risk of false-positive 
genes considerably and results in identification of only the most robustly regulated genes. 
Therefore, we assessed whether the genes differentially expressed in animals treated with 
DHEA via one administration route versus animals of one control group would also be 
affected when compared 1) to other control animals and 2) by the other administration 
route. To deal with these issues we applied the statistics of gene set enrichment analysis 
(GSEA). In this way statistical power could be improved and regulated gene sets were 
tested for their robustness. 
 
3.2. Gene set enrichment analysis (GSEA) 
For GSEA we used the genes found to be differentially expressed when the exposed 
animals are compared with the two control groups separately. For DHEA IM, 306 and 65 
genes were differentially regulated versus CTR1 and CTR3, respectively, whereas for 
DHEA PO, 138 and 65 genes were regulated. As shown in Figure 2, a relatively small 
number of genes was affected per treatment in both comparisons versus CTR1 and 
comparisons versus CTR3. Apparently, only a low proportion of genes showed a 
significant up-regulation or down-regulation of 1.5 or more in both comparisons. GSEA 
was used as a tool to discriminate DHEA treated animals from non-treated animals on the 
basis of gene sets generated from genes found to be differentially regulated (Figure 2). 
Gene sets were compared to the whole experimental dataset and GSEA calculated whether 
genes within a gene set are randomly distributed, enriched at the top or at the bottom of 
the ranked list [22]. The advantage of this GSEA approach is that no cut-off is used for 
determination of differentially regulated genes. Using the whole experimental data set 
makes that alterations are viewed for as a group of genes instead for individual genes. 
Gene sets can be significantly affected while changes in expression of individual genes 
are relatively subtle. For example, the transcripts found to be significantly up-regulated 
when comparing DHEA IM versus control group 3 (Figure 4A) were included in the gene 
set ‘DHEA_IM_vs_CTR3_UP’. GSEA analysis, using this gene set, showed that the 
genes where highly enriched in DHEA IM treated animals when comparing versus the 
CTR1-group (Figure 4B). As shown in Figure 4C, most of the genes are distinctly up-
regulated in DHEA IM treated animals, although also variation in gene expression of the 
individual animals is observed. In a similar way, the other gene sets were compared versus 
the other ‘independent’ control group and results are summarized in Table 2. This cross 
validation showed that 6 out of 8 gene sets were significantly enriched (p-value <0.05 and 
FDR < 0.25) when DHEA treated animals were compared versus an ‘independent’ control 
group. Moreover, gene sets generated on the basis of DHEA IM treated animals showed 
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 significant enrichment in DHEA PO treated animals and vice versa. In total 12 out of 16 
gene set comparisons showed significant enrichment, suggesting an overlap in gene 
expression profiles from IM and PO treated animals which most likely include genes that 
are differentially expressed irrespective of the manner of DHEA administration. 
 
Figure 4 - Overview of the GSEA method applied. (A) Heat map of the gene set ‘DHEA_IM_vs_CTR3’ 
containing all genes found significantly up-regulated (> 1.5 fold and p-value <0.05) when comparing DHEA IM 
treated animals versus the control population of experiment 3. Colours range from dark red to dark blue 
representing respectively the highest and lowest expression of a gene. (B) This gene set was compared to the 
ranked list of the total microarray expression data set of DHEA IM treated and CTR1 animals showing a 
significant (p-value 0.000 and FDR of 0.000) enrichment of genes in DHEA IM treated animals when compared 
to the control group of experiment 1. (C) Heat map displaying the genes of gene set ‘DHEA_IM_vs_CTR3’ in 
DHEA IM and CTR1 animals. 
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 Although in vivo transcriptomics data of DHEA in liver is limited [25,27], Depreter et al. 
identified 13 genes which were found to be up-regulated in rat liver [25]. GSEA analysis 
showed significant enrichment of this gene set in DHEA IM and PO treated animals when 
these were compared with the controls of experiment 1 (Table 2). These results illustrate 
that GSEA is a powerful approach for comparative analysis of gene expression data 
obtained in different settings. 
Controlled experiments with bovines have resulted in the identification of genomics based 
biomarkers which potentially can be used for screening for hormones [10-14,28]. 
However, when examining bovines from real-life practice, one is dealing with biological 
variation like age, genetic background, environment, nutrition and disease history. In the 
current study, this biological variation was deliberately included and was mainly reflected 
by the large differences in gene expression profiles of the control populations tested. The 
two control groups in this study showed substantial age differences i.e. the animals in the 
CTR1, CTR3 and DHEA-treated groups are 6 months, 13-14 months and 8-13 months in 
age, respectively. Nevertheless, for the DHEA IM and PO treated animals, sets of 
respectively 37 and 23 genes were found differentially expressed when compared to all 
controls using standard statistics. These two groups of genes are specific for IM and PO 
treatment, respectively, and independent from biological factors like age. However, GSEA 
results showed a correlation between gene expression profiles of IM and PO treated 
animals, suggesting that there are also effects independent from the route of 
administration. This is in line with our earlier performed metabolomics study showing 
large similarities in urine metabolite profiles of IM and PO treated animals as well as 
metabolites specific for the route of administration [19]. 
Hence, for application of transcriptomics based screening of bovines for (pro)hormones in 
practice, the treatment effect should be filtered out from differences in gene expression 
due to inherent biological variation. Here it was shown that microarray gene expression 
profiling in combination with statistical methods like GSEA are able to distinguish gene 
expression profiles of DHEA-treated animals from non-treated control animals. It should 
be noted that this experiment comprised small numbers of animals and follow up 
experiments are required to gain statistical power and to obtain a better description of 
DHEA specific gene sets. Furthermore, the behaviour of such a growth promoter specific 
gene set should be studied in a broad spectrum of untreated control animals from daily 
practice, to assure the robustness of the gene set. This underlines the need to obtain more 
liver gene expression profiles of control animals from slaughterhouses. 
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 Table 2: Significance of gene set regulation after GSEA analysis. 
* Significantly regulated gene set. 
 
  DHEA IM group  compared to CTR1 
DHEA IM group  
compared to CTR3 
Name gene set  # Genes p-value FDR p-value FDR 
DHEA_IM_vs_CTR1_up 98 - - 0.000* 0.000 
DHEA_IM_vs_CTR1_down 208 - - 0.000* 0.071 
DHEA_IM_vs_CTR3_up 46 0.000* 0.000 - - 
DHEA_IM_vs_CTR3_down 19 0.826 0.823 - - 
            
DHEA_PO_vs_CTR1_up 65 0.000* 0.000 0.751 0.887 
DHEA_PO_vs_CTR1_down 73 0.000* 0.000 0.861 0.899 
DHEA_PO_vs_CTR3_up 31 0.032* 0.073 0.000* 0.000 
DHEA_PO_vs_CTR3_down 34 0.312 0.413 0.000* 0.000 
            
Depreter_et_al_up 11 0.015* 0.031 0.381 0.657 
            
    DHEA PO group   compared to CTR1 
DHEA PO group   
compared to CTR3 
Name gene set  # Genes p-value FDR p-value FDR 
DHEA_PO_vs_CTR1_up 65 - - 0.000* 0.000 
DHEA_PO_vs_CTR1_down 73 - - 0.007* 0.002 
DHEA_PO_vs_CTR3_up 31 0.173 0.292 - - 
DHEA_PO_vs_CTR3_down 34 0.015* 0.014 - - 
            
DHEA_IM_vs_CTR1_up 98 0.000* 0.000 0.000 0.479 
DHEA_IM_vs_CTR1_down 208 0.000* 0.000 0.000* 0.000 
DHEA_IM_vs_CTR3_up 46 0.706 0.738 0.000* 0.000 
DHEA_IM_vs_CTR3_down 19 0.009* 0.006 0.002* 0.001 
            
Depreter_et_al_up 11 0.029* 0.030 0.887 1.000 
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 4. Conclusion 
The present study showed that identification of genomic biomarkers for DHEA treatment 
in cattle is hampered by the large biological variability as compared to genomics 
experiments with inbred strains of rodents under well-defined laboratory conditions. 
However, gene expression profiling using whole genome microarrays in combination with 
predefined gene sets and statistical methods like GSEA showed to be a promising 
approach to screen for (pro)hormone abuse in livestock production. For application in 
practice however, a better genomic description of the control population as well as growth 
promoter specific gene set are needed. 
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 Introduction 
Within the European Union the surveillance on veterinary growth promoter abuse is 
strictly regulated by several legislations. Council Directive 96/22/EC lays down the 
prohibition of the use of growth promoting agents such as steroid hormones in livestock 
production [1]. Interestingly there is no list of prohibited substances but 96/22/EC states 
that all substances having a thyrostatic, oestrogenic, androgenic or gestagenic action and 
beta-agonists are prohibited in livestock production. In addition Council Directive 96/23/
EC encloses specific requirements to monitor anabolic steroids in farm animals and their 
products [2]. This Directive primarily includes sampling and investigation procedures 
while technical guidelines and performance criteria for methods in residue analysis are 
described in Commission Decision 2002/657/EC [3]. In hormone residue analysis, 
methodologies based on gas and liquid chromatography in combination with mass 
spectrometric detection (GC- and LC-MS/MS) are presently considered state-of-the-art 
and are extensively used for screening as well as confirmation purposes. However, most 
of these methods are limited to screening of a predefined list of hormone residues and can 
thus not fully meet the legislation 96/22/EC. In this way some kind of discrepancy arises 
between the bioactivity based ban, as described in 96/22/EC on the one hand and the 
measures to monitor on targeted (groups) of substances on the other. Therefore, to fully 
meet the legislation, screening methods should be based on bioactivity rather than on 
targeted screening of a list of compounds. Within this scope, in recent years significant 
efforts have been invested in development and implementation of novel effect based 
methods such as bioassays to detect hormone abuse in the field of livestock production 
[4].  
During inspections at livestock farms in The Netherlands, inspection services are 
occasionally confronted with animals growing suspiciously fast. Besides these 
observations also syringes, feed supplements and herbal preparations have been found 
containing so-called prohormones such as dehydroepiandrosterone (DHEA) and 
pregnenolone. Prohormones show no or limited direct hormonal activity but might have 
hormonal effects upon in vivo bioactivation. However, knowledge about metabolism, the 
mode of action and excretion profiles of prohormones is often unclear, in particular in 
cattle. This thesis research investigated the bioactivity of prohormones upon their 
metabolism in vitro as well as in vivo with the goal to develop effective screening and 
detection methods to detect prohormone abuse in livestock production and to meet 
Directive 96/22/EC.  
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 Effect based screening of (pro)hormones in supplements and 
animal feed 
Supplements and preparations containing (pro)hormones used in sports also turn up in 
livestock production and vice versa. As a consequence, the nature of the samples and the 
methods and requirements for screening are highly similar. In Chapter 2 we investigated 
18 dietary supplements which were previously screened for the presence of 49 prohibited 
steroids by state-of-the-art LC-MS/MS analysis. After screening by a yeast androgen 
bioassay two of the supplements which were found negative by LC-MS/MS analysis did 
show a response. Upon application of the same bioassay as an off-line LC detector in 
combination with UPLC-TOFMS we were able to identify 4-androstene-3ß,17ß-diol,     
5α-androstane-3ß,17ß-diol and 1-testosterone in the bioactive fractions. Because these 
compounds were not included in the predefined list of 49 compounds they were missed in 
this targeted LC-MS/MS procedure. This clearly demonstrates the added value of an 
effect based screening approach where virtually all compounds with androgenic activity 
are taken into account. This together with bioassay guided identification sets a new 
benchmark for the analysis of supplements and preparations used in livestock production 
and sports.    
 
For supplements containing solely prohormones the value of bioactivity based screening 
seems to be limited. When testing the endogenous prohormones DHEA and 5-androstene-
3ß,17ß-diol in the yeast androgen bioassay they showed no direct androgenic activity 
while 4-androstenedione showed an EC50 of 6900 nM (Chapter 3). To detect these 
inactive prohormones in animal feed, supplements and injection preparations, a modified 
in vitro bioassay test system was developed. In order to mimic the in vivo metabolic 
activation, standards as well as sample extracts were incubated with bovine liver S9 
fractions and different cofactors before application to the yeast androgen assay. 
Depending on the cofactor used, this resulted in an increase in androgenic activity for 
DHEA, 5-androstene-3ß,17ß-diol and 4-androstenedione. After incubation of DHEA with 
bovine liver S9, UPLC-TOFMS analysis showed that 4-androstene-3,17-dione, 7α-OH-
DHEA and an initially unknown oxo-metabolite of DHEA were the most abundant 
metabolites formed when using NAD(P)+ as a cofactor. The unknown keto-metabolite 
later turned out to be 7-oxo-DHEA. When using NAD(P)H as a cofactor, metabolism was 
mainly guided in the direction of 5-androstene-3ß,17ß-diol but again also 7α-OH-DHEA 
and 7-oxo-DHEA were observed to be major metabolites. In addition also minor amounts 
of other metabolites are observed which were, based on their accurate mass and retention 
time, most likely hydroxy- and oxo- metabolites of DHEA, 4-androstenedione or even  
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 17ß-testosterone. An overview of the metabolism of DHEA by bovine liver S9 is shown 
in Figure 1. Regarding bioactivity, 4-androstenedione and 17ß-testosterone are most likely 
the main compounds contributing to the bioactivity read-out, as 17α-testosterone,             
5-androstene-3ß,17ß-diol and the hydroxy-metabolites of DHEA (data not shown in this 
thesis) and 17ß-testosterone [5] showed no or limited androgenic activity. 
Figure 1: DHEA metabolites observed after incubation with bovine liver S9 and various cofactors.  Enzymatic 
activities involved are: (a) 3ß-dehydrogenase/isomerase (b) 17ß-hydroxysteroid dehydrogenase (c) 17α-oxido-
reductase (d) 7α-hydroxylase (e) 7-hydroxy dehydrogenase.  
 
Metabolic conversion of unknown supplement samples claiming to contain DHEA 
resulted in successful bioactivation and positive screening results in the androgen yeast 
bioassay. However, the bioassay read-out was strongly hampered by the androgen 
antagonistic properties of one of the compounds present in the supplements, most likely 
DHEA. This antagonistic activity was confirmed by co-exposure of 17ß-testosterone with 
increasing concentrations of DHEA showing a clear dose dependent inhibition (Figure 2). 
The activity of 17ß-testosterone was even completely inhibited when the yeast cells were 
exposed to 70 nM 17ß-testosterone and more than 10 µM of DHEA. This illustrates the 
necessity to include spike-in controls in bioactivity screening procedures to test for 
antagonistic action and to rule out that high levels of antagonists, such as DHEA, can 
mask the presence of direct agonists.  
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Figure 2: Anti-androgenic action of DHEA. Shown are the inhibition of the response of 17ß-testosterone at half 
maximum (70 nM) and full response (1000 nM) at increasing levels of DHEA. Fluorescence signals are the 
mean of an assay triplicate (± SD) and corrected for the signal at t=0 hours and the reagent blank. 
 
Interestingly, after incubation of a supplement containing DHEA and 4-androstenedione 
with bovine liver S9, also high levels of 17α-testosterone were observed in particular 
when using NAD(P)H as a cofactor. Because this supplement contained apart from DHEA 
also high levels of 4-androstenedione, these findings are supporting the hypothesis that 
17α-testosterone could be formed by 17α-hydroxysteroid dehydrogenase reduction of       
4-androstenedione [6,7]. However further research is needed to confirm this observation. 
In conclusion it can be stated that bovine liver S9 successfully mimicked the in vivo 
hydroxysteroid dehydrogenase and cytochrome P450 mediated metabolic conversions. 
Using the screening protocol described in Chapter 3, 50 µg of DHEA resulted already in a 
significant signal in the yeast androgen bioassay. For supplements, application of 100 mg 
to the proposed screening method is amply sufficient to obtain a positive screening result 
as they contain in general high levels of prohormones. For example DHEA supplements 
intended for human use for example contain in general 50-200 mg DHEA per capsule 
which is equal to the daily intake recommended on the label.  
 
From a bioactivity point of view, steroid derivatives can also be considered as 
prohormones. Due to the lack of affinity for steroid receptors, intact steroid esters and 
glycosilated compounds show no or limited direct hormonal activity. Consequently these 
compounds can be missed in receptor based screening procedures. Chapter 4 describes 
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 the concept of a yeast bioassay based method for screening of esters and glycosides in 
animal feed and supplements. To optimize hydrolysis and deconjugation procedures a 
comparison was made between different in vitro activation methods for hormone esters 
and glycosides. For testosterone esters, the efficiency of alkaline hydrolysis was almost 
100% and much better compared to enzymatic hydrolysis by esterase. As a result 1 µg 
testosterone ester per gram of animal feed could be readily detected by the yeast androgen 
bioassay. When comparing different enzyme fractions for deglycosilation the glycoside 
mimic genistin was shown to be deconjugated most efficiently by ß-glucuronidase/
arylsulfatase from Helix pomatia. In conclusion, chemical and enzymatic deconjugation 
procedures for ester and glycoside conjugates respectively resulted in a significant 
increase in hormonal activity and allowed effective screening of these derivatives in 
animal feed and supplements. 
Figure 3: Effect based screening strategies for androgens, androgen prohormones, steroid esters and glycosides. 
Similar approaches can be foreseen for estrogen and corticosteroid (pro)hormones, esters and glycosides.  
 
To summarize, it can be stated that the previously developed androgen yeast bioassay 
allowed an effective screening for androgens in animal feed and supplements but is less 
suited to detect hormonally inactive prohormones. The use of either bovine liver S9, pure 
enzymes or alkaline hydrolysis showed that prohormones could be activated, resulting in a 
significant increase in bioactivity as determined by the androgen or estrogen yeast 
bioassay. Combined, this results in a panel of screening methods for (pro)hormonal 
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 activity that better meets Council Directive 96/22/EC (Figure 3). However, before 
application in routine use, the proposed qualitative screening methods need to be validated 
according EC Decision 2002/657.  
 
Compared to enzyme fractions, whole cell systems such as liver slices have the advantage 
that phase I and phase II enzymes are present together with natural levels of cofactors. 
Moreover, in liver slices all liver cell types are present maintaining their original 
interactions and spatial arrangement thus resembling the real in vivo situation more 
closely. In Chapter 5 the feasibility of bovine liver slices as a model for the bioactivation 
of prohormones was investigated. After incubation of DHEA with bovine liver slices, 
UPLC-TOFMS analysis showed that 4-androstenedione, 7α-OH-DHEA and 7-oxo-DHEA 
were the most abundant metabolites formed, while also minor amounts of 5-androstene-
3ß,17ß-diol, 17ß-testosterone and 17α-testosterone were observed. Compared to the 
earlier performed bovine liver S9 experiments described in Chapter 3, DHEA phase I 
metabolism observed in liver slices is highly similar to liver S9 incubations using NAD+ 
or NADH+ as a cofactor. Application of medium extracts, originating from incubations of 
liver slices with DHEA, to the androgen yeast assay showed an increase in androgen 
activity as well as a decrease in androgen antagonistic activity, confirming metabolism of 
DHEA into more androgen active compounds such as 4-androstenedione and                 
17ß-testosterone. In this way liver slices can be used as a complementary tool to screen 
for biologically inactive steroids. On the other hand, because liver slices resemble the in 
vivo situation more closely also a substantial amount of phase II metabolites are formed. 
Compared to bovine liver S9, bioactivation of DHEA with liver slices is therefore less 
efficient and can be considered to be a less suitable bioactivation model for screening 
purposes. Moreover, since preparation of liver slices is very laborious, and the fact that for 
each screening experiment liver slices have to be prepared freshly, other bioactivation 
models such as bovine liver S9 are more suitable to use in high through-put screening 
procedures. Alternatively, the lifespan of liver slices could be extended by cryo-
preservation thereby facilitating that one single batch of liver slices could be used for 
multiple screening procedures. Although this is shown to be a feasible approach for 
human and rat liver slices, success of these cryopreservation procedures is variable, seems 
dependent on animal species and often still results in a significant decrease in enzyme 
activity and cell viability compared to freshly isolated liver slices [8].  
At this stage a more feasible application of liver slices is foreseen in evaluation of both 
metabolism and bioactivation of (new) compounds showing up in the illegal circuit of 
which the in vivo mode of action is unclear. Currently, these compounds are tested in 
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 small scale animal experiments to obtain knowledge about absorption, distribution, 
metabolism and excretion kinetics in bovines. In this process, exposure of liver slices 
could be included to gather knowledge about metabolism and identification of (new) 
metabolite biomarkers that could be used for in vivo urine screening.   
 
Metabolomics based steroid profiling in urine 
Urine profiling of endogenous steroid concentrations is an established method to identify 
abuse of natural hormones in human doping control. In livestock production however, 
misuse of natural occurring (pro)hormones is hard to prove. Urinary metabolites are either 
unknown or profiling parameters which are relevant in humans are failing in cattle due to 
highly fluctuating endogenous steroid levels or differences in metabolism. Chapter 6 
outlined a novel metabolomics based strategy for anabolic steroid urine profiling in the 
field of livestock production. Urine profiles of controls and bull calves treated with DHEA 
or pregnenolone were analyzed in triplicate by UPLC-TOFMS. The quality and 
reproducibility of the analytical procedure was assessed by application of two deuterium 
labeled internal standards. This demonstrated that the data acquisition was highly stable, 
both in retention time as well as mass accuracy, within as well as between measurement 
series. Also the signal intensities were considered as stable since most fluctuations in 
signal amplitudes were within a factor 2. As a result, changes in metabolite profiles by 
more than a factor 2 (e.g. the applied thresholds of >5 and >10 times fold change) can be 
considered to be differential from random variations in the analytical procedure.  
Comparison of the urinary profiles using MetAlign™ and multivariate statistics revealed 
large differences between the urinary profiles of control and DHEA as well as 
pregnenolone treated animals. For DHEA, cutoff based selection revealed 180 mass 
signals that were significantly different (fold change >10, p-value <0.01) between 
untreated controls and DHEA treated animals. In addition, PCA and hierarchical cluster 
analysis revealed also large differences between days and the route of administration. 
However, because potential application in control and enforcement programs is performed 
without a priori knowledge about the route of administration it was decided to determine 
potential biomarkers independent from the route of administration. Consequently 
biomarkers for DHEA treatment were selected by comparing urine samples of all controls 
versus all treated animals. In analogy with the DHEA experiment, a similar data selection 
procedure was performed for the pregnenolone experiment. Here the differences in urine 
profiles were less distinct since biomarker selection yielded 163 m/z values (fold change 
>5, p-value <0.01). Interestingly also mass signals were observed to be significantly down
-regulated suggesting negative feedback mechanisms induced by pregnenolone 
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 administration. Yet, within this thesis research no further attempts were made to identify 
the compounds belonging to those differentially down-regulated masses.  
In order to determine if the mass peak loadings selected by multivariate statistics can be 
used as biomarker for DHEA or pregnenolone administration respectively, all mass 
signals were evaluated individually by univariate statistics. Hereby the control as well as 
the treated population was assumed to be normally distributed. Initially the number of 
false negatives was determined for each mass peak loading individually, by comparing the 
DHEA and pregnenolone treated bovines to their corresponding control population. For 
DHEA already seven mass peak loadings showed a false negative rate below 5% hereby 
complying with Commission Decision 2002/657/EC [3]. Next, the mass peak loadings 
showing the least false negatives, respectively 12 (for DHEA) and 7 (for pregnenolone), 
mass peaks were selected and tested for false positives using a small but independent test 
set of control urines. For DHEA, 10 out of the 12 biomarkers tested showed no false 
positives, while for pregnenolone 5 out of the 7 potential biomarkers showed no false 
positives. Although these results are promising, the robustness of these potential 
biomarkers should be tested against a larger control population of bovine urines to obtain 
a more accurate estimation of the number of false positives. Apart from identification of 
biomarkers for treatment by specific prohormones, it is envisaged that application of this 
holistic methodology is also suitable for general anabolic steroid screening. A possible 
scenario for implementation of such a steroid urine profiling approach in practice is 
outlined in Figure 4: upon sampling at the farm, urine samples are measured in triplicate 
by UPLC-TOFMS according to the method described in Chapter 6. After preprocessing 
and alignment of the data, the obtained urine profiles are compared to a library of control 
urines by using multivariate statistics. Based on the statistical deviation from this control 
population it then can be decided whether a sample could be classified as “compliant” or 
“suspect”. This inherently raises the need to define thresholds to decide when an urine 
profile is considered to be differential from a control population. This threshold could e.g. 
be based on a p-value derived by multivariate statistics (e.g. p-value <0.05) or by use of 
classification tools such as Orthogonal Partial Least Squares analysis (OPLS).  
When a sample is classified as “suspect” the observed differential masses can provide 
extra information about the possible identity of the compound administered and it can be 
decided to initiate appropriate follow-up actions. When suspecting abuse of synthetic 
steroids the screening procedure can be followed by confirmatory mass spectrometry 
analysis to unambiguously confirm the presence of these xenobiotic steroids. When abuse 
of natural (pro)hormones is suspected follow-up actions are currently limited to 
investigations at the farm since classical mass spectrometry methodologies are incapable 
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 of discriminating synthetic hormones from the biosynthesized congeners. Nevertheless, 
based on the screening results, inspection services could focus on farms showing 
suspicious results by intensifying the sample frequency or perform more detailed 
investigations in search for suspicious supplements and preparations. These in turn, could 
be subjected to the yeast androgen bioassay procedures described in Chapter 3 and 4.  
 
Figure 4: Proposed metabolomics based steroid urine profiling strategy to monitor for prohormone abuse in 
cattle.  
 
Ideally, suspicion of natural (pro)hormone abuse should be followed by gas 
chromatography/combustion/isotope ratio mass spectrometry (GC/C/IRMS) analysis of 
the suspect urine sample to unambiguously confirm the presence of exogenous 
administered (pro)hormones [9,10]. Although this sophisticated confirmation procedure is 
successful in discriminating synthetic and natural hormones, this GC/C/IRMS 
methodology is very complex, laborious and costly. Therefore, unfortunately, this 
approach is no common practice in veterinary growth promoter control and is currently 
used in only one National Reference Laboratory in Europe [11]. Another prerequisite for 
such a holistic screening approach is an ever growing library of control urine profiles 
reflecting the total control population, thus with inclusion of inherent biological variability 
such as differences in origin, age, feeding regime and medical history.  
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 Feasibility of a transcriptomics approach for prohormone 
screening 
Surveillance of growth promoter abuse is mainly based on residue analysis in urine, 
blood, tissue or hair. Alternatively, monitoring differences in transcript levels is in 
potential a promising screening method to detect abuse of (natural) (pro)hormones, 
perhaps even when metabolites already have been excreted. In Chapter 7 we investigated 
changes in liver gene expression profiles of bovines treated orally (n=3) or 
intramuscularly (n=3) with 1000 mg DHEA versus two control groups (n=3 and n=4), 
using bovine 44K oligonucleotide microarrays. In contrast to controlled genomics studies 
these bull calves were purchased at the local market on three different occasions and aged 
from 6 to 14 months, thereby reflecting the real-life inter-animal variability.  
The significance of the gene expression data obtained from orally (PO) and 
intramuscularly (IM) treated calves versus all controls were evaluated using t-test 
statistics. Significant (p-value <0.05) more than 1.5 fold differential regulation of 37 and 
23 transcripts for respectively intramuscularly and orally treated animals was shown. In 
principle these regulated genes could be considered potential biomarkers for DHEA 
treatment. However we are also aware of the small number of animals used which 
hampers proper statistics and substantially increases the chance of detecting false-positive 
genes as well as missing typical DHEA target genes. In addition, for screening purposes 
this raises the question how specific these genes are for DHEA treatment and 
consequently the percentage of false positive animals obtained when using these genes for 
screening purposes. Overall it can be stated that the majority of the regulated genes are 
involved in immune response for both PO as well as IM treated animals. Although DHEA 
is reported to have significant immunomodulatory properties it can be expected that these 
genes are not specific for DHEA treatment nor represent a typical androgenic or 
prohormonal effect. Moreover, the question is whether the gene expression profiles of the 
DHEA treated animals in this study will remain differential when they are compared to 
other groups of control animals. To deal with these issues we applied the statistics of gene 
set enrichment analysis (GSEA). For IM and PO treated calves, gene sets were generated 
of genes that were significantly regulated compared to one control group and validated 
versus the other control group using GSEA. This cross validation showed that 6 out of the 
8 gene sets were significantly enriched in DHEA treated animals when compared to an 
independent control group. This study showed that identification and application of 
genomic biomarkers for DHEA treatment is strongly hampered by biological variation. 
On the other hand, it is demonstrated that comparison of defined gene sets versus the 
whole expression profile allows to distinguish DHEA treatment effects from variations in 
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 gene expression due to inherent biological variation. This observation is a first hint that it 
is possible to use gene expression patterns to discriminate DHEA treated from control 
animals and opens the possibility to develop a screening method to control the misuse of 
(pro)hormones in cattle. 
However, as already concluded by Carraro et al. [12], gene expression analysis is not yet 
the “magic bullet” to detect illicit treatment with growth promoters. Currently, in the field 
of growth promoter control, gene expression analysis is at the stage of providing proof of 
principle by performing in vivo experiments under controlled settings, ideally resulting in 
identification of “potential” biomarkers specific for illicit treatment, but application of 
these genomics based biomarkers for screening in practice is still far away. The next 
question is then whether the suggested biomarkers are robust and not influenced by 
biological factors like differences in breed, nutrition, age and medical history and should 
therefore be tested against a large control population. This can be achieved by obtaining 
more liver gene expression profiles of “control” animals from the slaughterhouse or, 
alternatively, even could be retrieved from rapidly growing genome databases such as 
ArrayExpress or the Gene Expression Omnibus (GEO) [13,14]. Apart from difficulties in 
identification of robust biomarkers it is foreseen that implementation of such a 
transcriptomics approach in practice can also be hampered by technical difficulties during 
e.g. sampling. First of all, for proper comparison of gene expression profiles tissues 
should be sampled consequently at the same anatomic location of the liver to obtain a 
homogenous sample without irregularities e.g. the presence of endothelial cells when 
sampling liver. Moreover, due to sub-optimal sampling conditions at the slaughterhouse, 
breakdown of mRNA could occur which in turn could cause differences in gene 
expression analysis. Nonetheless, preliminary evidence from analysis of RNA stability 
and qRT-PCR repeatability on skeletal muscle samples stored at 4°C suggests that reliable 
measures of gene expression can be obtained up to 10 days after slaughtering [12]. 
However, it is not very likely that this long term stability can be obtained in organs which 
contain high levels of RNases such as liver.  
 
Towards a new control system for prohormones 
The fight against growth promoter abuse in livestock production continues to be a major 
fair trade and food safety related issue. To facilitate efficient control and to try to keep up 
with the abusers, there is a continuous need for development of new screening and 
detection methods to cover the broad range of compounds used for treatment. The basis 
for control on hormone abuse is laid down in Directive 96/23/EC which outlines the 
measures to monitor certain (groups of) substances and residues while the ban described 
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 in Directive 96/22/EC is based on bioactivity and prohibits the use of all compounds 
showing androgenic and other hormone-like activity. Within this scope the attention in 
this thesis has been focused on development of novel effect based screening methods for 
prohormone abuse. Hereby it is important to realize that according to Commission 
Decision 2002/657/EC [3], screening methods are used to detect the presence of a 
substance at relevant levels and with the capability for high sample throughput. Therefore 
typical screening methods are optimized to examine large numbers of samples in search 
for non-compliant results and hereby avoiding false compliant results.  
Based on the outcomes of this thesis research we propose to implement two methods to 
screen for prohormones: (1) screening for prohormones in feed and (feed) supplements 
and (2) a holistic screening method for screening on prohormones in urine. Regarding 
screening of prohormones in animal feed and supplements we used bioactivation models 
in combination with an androgen yeast transcription activation bioassay. This allowed 
effective screening as well as detection of the (indirect) androgenic action of prohormones 
simultaneously hereby better meeting legislation 92/22/EC. The number of false 
compliant results in those methods is largely depending on the efficiency of the 
bioactivation procedures and the sensitivity of the yeast androgen bioassay readout 
system. For androgens this yeast androgen bioassay was validated according to 
Commission Decision 2002/657/EC [3] at a level of 50 or 100 ng per gram of animal feed 
[15]. Hereby the number of false negatives was shown to be less than 5%. Also the 
percentage of false positives was only 5% but this percentage could be lowered when 
conformation analysis would include more androgenic metabolites [15]. For DHEA the 
current level of detection is around 12.5 µg per gram of feed/supplement, and for steroid 
esters a level of 1 µg per gram of animal feed could be easily detected.  
As stated above the second outcome of this thesis research focused on the development of 
a holistic screening method for screening on (pro)hormones in urine. For introduction of 
new screening strategies, such as profiling methods, in official control, specific criteria 
should be discussed as well as an estimation for false positive and negative rates should be 
made. For the developed steroid urine metabolomics approach samples can be sifted based 
on the statistical deviation from the control population classifying a sample to be either 
“compliant” or “suspect”. This inherently raises the need to define thresholds to decide 
when a urine profile is considered to be differential from a control population. This 
threshold could e.g. be based on a number of mass peak loadings observed to be 
significantly (p-value <0.01) above an arbitrary set fold change or by use of more 
sophisticated classification tools such as Orthogonal Partial Least Squares analysis 
(OPLS). It should be noted that apart from (pro)hormone administration other compounds/
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 medicines might disrupt the endogenous steroid profile as well. So occasionally a targeted 
chemical confirmation (focused on a priori known substances) following a suspect result 
from a more holistic screening approach might be negative. In such a case it might be 
questioned whether the initial screening should be classified as “false suspect” since a less 
obvious compound/medicine causing a biological effect can still be considered to violate 
the ban on hormonal activity as laid down in Directive 96/22/EC indirectly. The number 
of false negative screening results will depend on the time of sampling following 
administration, the initial dose administered, the intrinsic bioactivity of the compound and 
the sensitivity of the current UPLC-TOFMS profiling method. Under de current 
experimental settings even seven individual mass peak loadings showed a false negative 
screening rate lower than 5%, which is considered adequate according Commission 
Decision 2002/657/EC. However, these biomarkers should be tested for their robustness 
against a larger control population (see also the Future perspectives section). Moreover, 
combining individual biomarkers could increase statistical power. 
Although transcriptomics based screening for (pro)hormone abuse is only in the early 
phase of providing the proof of principle, gene expression analysis has the potential to 
discriminate between DHEA treated and control animals based on gene sets. Based on a 
statistical derived p-value retrieved by statistical analysis tools like GSEA it can be 
determined whether a gene expression profile deviates from gene expression profiles 
obtained from a library with control animals. Although the number of animals we used as 
a test set was limited, 6 out of the 8 genesets were found significantly different from the 
controls using a p-value < 0.05. In such a genomics approach the number of false 
positives obtained plays an important role and the question is how specific the identified 
gene sets are for a treatment with the prohormone DHEA. Based on the current results this 
question is hard to answer and further research is needed. 
All together, the current developed methods should be viewed as a screening tool to 
complement and further improve the testing programs rather than replacing current 
(confirmatory) tools. This, since current EU legislation still requires unambiguous 
evidence of drug administration which can only be achieved by classical targeted mass 
spectrometric based confirmation approaches. On the other hand, it should be noted that 
legislations in horse racing and human doping control are not ruling out indirect 
biomarkers. For instance legislations in human doping control state that sufficient proof of 
an anti-doping rule violation is established by either of the following: “presence of a 
prohibited substance or its metabolites or markers in the athlete’s sample” [16]. While 
legislations in horse racing state that: “The finding of any scientific indicator of 
administration or other exposure to a prohibited substance is also equivalent to the finding 
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 of a substance” [17]. In this way also biology-based approaches such as bioassays and 
measuring levels of genes or proteins could be used as direct indicators of hormone 
treatment. 
 
Future perspectives  
 
Bioactivation and effect based screening of prohormones  
Within this thesis research we investigated the usefulness of bioactivation models making 
use of pure enzymes, bovine liver S9 and liver slices in combination with a yeast based 
androgen reporter system. This has resulted in effect based methods to screen for 
prohormones and steroid derivatives in animal feed, supplements and preparations, which 
complement the already existing bioassays for screening androgens, estrogens and 
corticosteroids. However, the most ideal model for bioactivation of prohormones is still 
the in vivo situation where they pass through the complex dynamic processes of 
absorption, distribution, metabolism and excretion (also known as ADME) directly within 
the bovine’s body. Consequently the prohormone can be extensively metabolized leading 
to a target site concentration of the parent compound and/or its metabolites which can 
differ largely from what was expected from the administered dosage. The usage of in vitro 
liver models only highlights one aspect of bio(in)activation, and hence can only partly 
mimic the in vivo situation. Therefore, future research should be focused on investigating 
other organs to better describe metabolism and bio(in)activation of (pro)hormones. For 
instance, after oral administration, the acidic environment in the stomach can hydrolyze 
steroid esters or other steroid derivatives. Moreover, compared to liver, phase I and phase 
II metabolism in other tissues is often underestimated, this is for example shown in human 
intestine slices where metabolism of 17ß-testosterone by CYP2C9, CYP2C19 and         
17ß-hydroxysteroiddehydrogenase is observed to be at metabolic rates comparable to 
those in the liver [18]. For other compounds it has been shown that even 60% of the total 
phase I and phase II metabolism already takes place in the intestine [19]. For this purpose, 
a wide variety of in vitro model systems based on cells or tissue slices have been 
developed to mimic these biotransformation pathways as well as models for the 
gastrointestinal tract including the stomach. The latter range from relatively simple in 
vitro digestion models simulating gastrointestinal incubations [20,21] up to complex 
dynamic gastrointestinal tract models [22]. Ideally, such in vitro models for stomach, 
intestine and liver should be combined to get a better overall impression of metabolism 
and bioactivation after (oral) administration of (pro)hormones.  
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 Recent advances in microfluidic systems makes it possible to mimic multi-organ 
interactions which has been termed as a “body-on-a-chip” approach [23,24]. These 
approaches make it possible to perform inter-organ studies simply by integration of 
multiple organ models into one single microfluidic device. Together with e.g enzyme 
fractions or cell cultures this contributes to more realistic in vitro systems that can mimic 
the whole-body response. Using this concept, several microfluidic approaches for testing 
metabolism-dependent drug toxicity are developed [25] even making use of enzyme 
fractions such as microsomes which are integrated in a sol-gel bioreactor [26]. Drugs 
introduced into this microfluidics system diffuse into the layer containing the liver 
microsomes where subsequent metabolism takes place. In a similar way other in vitro 
bioactivation models such as liver slices [27] as well as slices of other organs such as 
intestine [17,28] are shown to be easily integrated in those microfluidics systems. It is 
envisaged that such approaches could be of great value for (pro)hormone screening as 
they could be used; (1) to mimic the in vivo bovine situation allowing to investigate 
metabolism of (new) (pro)hormones, which eventually may result in new metabolite 
biomarkers that could be used for urine screening; (2) for screening purposes especially 
when androgen reporter cells could integrated on those chips allowing to screen for 
androgenic activity, with and without bioactivation, using a “bovine-on-a-chip” approach 
(Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Bovine-on-a-chip. 
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 Screening based on steroid urine profiles  
Steroid profiling metabolomics approaches, similar to those discussed in Chapter 6, are 
considered nowadays with great interest by several European control laboratories as a 
potential holistic screening tool in hormone control programs [29]. As discussed in one of 
the above mentioned paragraphs, such an untargeted approach is not only a suitable tool 
for general anabolic screening purposes but also allows identification of potential 
candidate biomarkers for specific treatments. For application in practice, additional 
experiments are essential to assess the robustness of the candidate biomarkers. Therefore, 
in a follow up study, the 12 biomarkers for DHEA as determined in Chapter 6 were tested 
against a large control population of bovine urines (>140) sampled at 50 farms throughout 
The Netherlands [30]. Comparison of the TOFMS signal intensity of each of the 12 
selected masses in the samples of the treated animals and the control population resulted 
in the selection of 5 mass signals as the most robust biomarkers for DHEA treatment 
(Table 1). All of these 5 biomarkers could be attributed to glucuronidated steroid 
metabolites. For the most robust biomarker (m/z 255.2108 at retention time 10.98 min.) a 
confidence interval of 4.2 σ is demonstrated between treated and control animals. 
Combination of the 5 selected biomarkers results in a separation between treated and 
controls with a confidence interval of 3.47 σ, corresponding to a false positive/negative 
rate of 0.05%. Consequently, future screening for DHEA abuse could be limited to a 
targeted LC-MS/MS analysis of those 5 biomarkers, instead of measuring a complete 
urine profile.  
  
Table 1: Robust biomarkers for DHEA treatment of bovines (extracted and modified from ref  [30]). 
Another prerequisite in this process is the identification of these robust biomarkers. 
Although TOFMS analysis can provide already a tentative identity (Table 1, column 6), 
the exact identity of the most robust biomarkers remains unclear due to the lack of 
RT 
(min) 
  
m/z 
value 
(Da) 
  
Deviation 
(ppm) 
  
Elemental  
composition  
biomarker 
Fragment assigned Tentative identity of  metabolite 
5.47 481.2423 -3.0 C25H3709 [M+H]+ OH-androstene-ol-one-gluc 
7.50 305.2138 -15.0 C19H2903 [M-gluc+H]+ OH-androstene-ol-one-gluc 
10.62 271.2056 -2.2 C19H270 [M-gluc-2H20+H]+ 
OH-androstene-diol-gluc or 
OH-androstane-ol-one-gluc 
10.70 255.2095 6.5 C19H27 [M-gluc-3H20+H]+ OH-androstane-diol-gluc 
10.98 255.2108 11.8 C19H27 [M-gluc-3H20+H]+ OH-androstane-diol-gluc 
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 standards. Hereby emphasizing the need for more commercially available standards to 
achieve proper identification of the biomarkers. Another potential drawback which 
remains to be investigated may lie in the limited window of detection i.e. the time after 
prohormone administration during which biomarkers are still significantly different from 
levels in control urines.   
In analogy with steroid profiling for human doping control purposes, investigations are 
ongoing regarding steroid profiling in cattle urine [31]. This profiling approach is based 
on the quantitative determination of almost all natural hormones (aglycons as well as 
glucuronide and sulphate conjugates) present in the steroid hormone biosynthesis and 
metabolism pathway. While single parameters may not be significantly different from 
undisrupted control urines, analyzing the whole pathway could increase statistical power 
allowing to discriminate urine samples from animals treated with (natural) (pro)hormones. 
By using statistical models such as SIMCA or Discriminant Analysis an unknown urine 
sample could be tested against a library of control urine profiles, and depending on the 
outcome classified as “compliant” or “suspect”.  
Furthermore, to follow-up these urine profiling screening techniques, there is a need for 
techniques to confirm the abuse of natural prohormones. Therefore, control laboratories 
should focus on implementation of GC/C/IRMS analysis methods for natural 
prohormones allowing to unambiguously confirm the presence of exogenous administered 
natural prohormones.  
 
Transcriptomics based screening 
Although application of transcriptomics based screening for hormone abuse is only in the 
early phase of providing the proof of principle [12,32], gene expression analysis offers the 
possibility for the implementation of (long lasting) effect-based toxicological endpoints. 
Because surveillance mainly occurs at the holdings, future gene expression analysis 
should be focused at samples originating from holdings rather than sampling of organs at 
slaughter. Within this scope, easy to collect sample matrices such as blood [33] or hair 
follicles [34] are attractive target tissues to sample for gene expression analysis. Although, 
for anabolic steroids the proof of principle is already demonstrated for these sample 
matrices, it remains to be investigated whether gene expression analysis in these matrices 
is suitable to detect effects of prohormones, as well as whether the methods are applicable 
in practice. In this process, it is foreseen that whole genome microarrays are used for 
holistic screening as well as identification of biomarkers for a certain treatment. 
Application of transcriptomics based biomarkers for screening however, most likely will 
move to low cost methods such as targeted RT-PCR or small scale multiplex 
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 transcriptome analysis. An example of such an approach is the transcriptomics-based 
detection of type A trichothecenes in food [35]. For that purpose,  human MCF7 breast 
carcinoma cells are exposed to food sample extracts followed by quantification of 28 
selectively amplified target sequences by hybridization on a miniaturized microchip 
platform which could be scanned with a portable miniaturized USB camera. A similar 
array based on estrogen-dependent genes is currently employed for the detection of 
compounds with estrogenic activity [36]. Another low cost/high-throughput procedure is 
developed by Eppendorf allowing detection of multiple DNA targets (~30-50) in one tube 
[36]. By integrating multiplex target amplification, amplicon hybridization and real-time 
detection in one cartridge, this technology combines the multiplex capabilities of a 
microarray with the wide dynamic range of real-time RT-PCR resulting in a sample-to-
result time of less than 6 hours. Although these proposed methods are still more laborious 
than most reporter gene assays, this is a first step towards application of transcriptomics 
based methods to screen food and feed for residues and contaminants at low costs and 
allowing high-throughput.  
 
All together, the results of the current thesis increased our knowledge on the metabolism 
and bioactivation of prohormones in vitro as well as in vivo. Moreover, based on this 
knowledge, we revealed new effect based concepts and prohormone screening methods 
that complement and improve the current testing programs. Meanwhile the bioactivation 
concepts described have been validated and fully implemented for the screening of illicit 
preparations and feed supplements at RIKILT - Institute of Food Safety. These new 
concepts better meet the European ban on growth promoters in livestock production as 
described in Directive 96/22/EC. Moreover the in vitro concepts developed allow a 
reduction in animal testing since new unknown (pro)hormone compounds can be tested in 
vitro for bioactivity at the transcript, the androgenic bioactivity and the metabolite level, 
thereby limiting the need for in vivo bovine trials to verification of the in vitro 
experiments only. 
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 Summary 
Within the European Union the surveillance on veterinary growth promoter abuse is 
strictly regulated by several legislations. Council Directive 96/22/EC lays down the 
prohibition of the use of growth promoting agents such as steroid hormones in livestock 
production [1]. However, there is no list of prohibited substances but 96/22/EC states that 
all substances having a thyrostatic, oestrogenic, androgenic or gestagenic action and beta-
agonists are prohibited in livestock production. In addition Council Directive 96/23/EC 
encloses specific requirements to monitor anabolic steroids in farm animals and their 
products [2]. This Directive primarily includes sampling and investigation procedures 
while technical guidelines and performance criteria for methods in residue analysis are 
described in Commission Decision 2002/657/EC [3]. In hormone residue analysis, 
methodologies based on gas and liquid chromatography in combination with mass 
spectrometric detection (GC- and LC-MS/MS) are presently considered state-of-the-art 
and are extensively used for screening as well as confirmation purposes. However, most 
of these methods are limited to screening of a predefined list of hormone residues and can 
thus not fully meet the legislation 96/22/EC. In this way some kind of discrepancy arises 
between the bioactivity based ban, as described in 96/22/EC on the one hand and the 
measures to monitor on targeted (groups) of substances on the other. Therefore, to fully 
meet the legislation, screening methods should be based on bioactivity rather than on 
targeted screening of a list of compounds. Within this scope, in recent years significant 
efforts have been invested in development and implementation of novel effect based 
methods such as bioassays to detect hormone abuse in the field of livestock production 
[4]. During inspections at livestock farms in The Netherlands, inspection services are 
occasionally confronted with animals growing suspiciously fast. Besides these 
observations also syringes, feed supplements and herbal preparations have been found 
containing so-called prohormones such as dehydroepiandrosterone (DHEA) and 
pregnenolone. Prohormones show no or limited direct hormonal activity but might have 
hormonal effects upon in vivo bioactivation. However, knowledge about metabolism, the 
mode of action and excretion profiles of prohormones is often unclear, in particular in 
cattle. This thesis research investigated the bioactivity of prohormones upon their 
metabolism in vitro as well as in vivo with the goal to develop effective screening and 
detection methods to detect prohormone abuse in livestock production and to meet 
Directive 96/22/EC.  
 
In Chapter 2 we investigated 18 dietary supplements which were previously screened for 
the presence of 49 prohibited steroids by state-of-the-art LC-MS/MS analysis. After 
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 screening by a yeast androgen bioassay two of the supplements which were found 
negative by LC-MS/MS analysis did show a response. Upon application of the same 
bioassay as an off-line LC detector in combination with UPLC-TOFMS we were able to 
identify 4-androstene-3ß,17ß-diol, 5α-androstane-3ß,17ß-diol and 1-testosterone in the 
bioactive fractions. Because these compounds were not included in the predefined list of 
49 compounds they were missed in this targeted LC-MS/MS procedure. This clearly 
demonstrates the added value of an effect based screening approach where virtually all 
compounds with androgenic activity are taken into account. This together with bioassay 
guided identification sets a new benchmark for the analysis of supplements and 
preparations used in livestock production and sports.    
 
For supplements containing solely prohormones the value of bioactivity based screening 
seems to be limited. When testing the endogenous prohormones DHEA and 5-androstene-
3ß,17ß-diol in the yeast androgen bioassay they showed no direct androgenic activity 
while 4-androstenedione showed an EC50 of 6900 nM. To detect these inactive 
prohormones in animal feed, supplements and injection preparations, a modified in vitro 
bioassay test system was developed (Chapter 3).  In order to mimic the in vivo metabolic 
activation, standards as well as sample extracts were incubated with bovine liver S9 
fractions and different cofactors before application to the yeast androgen assay. 
Depending on the cofactor used, this resulted in an increase in androgenic activity for 
DHEA, 5-androstene-3ß,17ß-diol and 4-androstenedione. After incubation of DHEA with 
bovine liver S9, UPLC-TOFMS analysis showed that 4-androstene-3,17-dione, 7α-OH-
DHEA and an initially unknown oxo-metabolite of DHEA were the most abundant 
metabolites formed when using NAD(P)+ as a cofactor. The unknown keto-metabolite 
later turned out to be 7-oxo-DHEA. When using NAD(P)H as a cofactor, metabolism was 
mainly guided in the direction of 5-androstene-3ß,17ß-diol but again also 7α-OH-DHEA 
and 7-oxo-DHEA were observed to be major metabolites. In addition also minor amounts 
of other metabolites are observed which were, based on their accurate mass and retention 
time, most likely hydroxy- and oxo- metabolites of DHEA, 4-androstenedione or even  
17ß-testosterone.  Regarding bioactivity, 4-androstenedione and 17ß-testosterone are most 
likely the main compounds contributing to the bioactivity read-out, as 17α-testosterone,    
5-androstene-3ß,17ß-diol and the hydroxy-metabolites of DHEA (data not shown in this 
thesis) and 17ß-testosterone [5] showed no or limited androgenic activity. Also metabolic 
activation of unknown supplement samples claiming to contain prohormones resulted in 
successful bioactivation and positive screening results in the androgen yeast bioassay. 
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 From a bioactivity point of view, steroid derivatives can also be considered as 
prohormones that need to be deconjugated to become biologically active. Chapter 4 
describes the concepts for screening of esters and glycosides in animal feed and 
supplements. These methods are based on alkaline hydrolysis or enzymatic deconjugation 
followed by screening on bioactivity using yeast bioassays. For testosterone esters, the 
efficiency of alkaline hydrolysis was much better compared to enzymatic hydrolysis by 
esterase. As a result 1 µg testosterone ester per gram of animal feed could be readily 
detected by the yeast androgen bioassay. When comparing different enzyme fractions for 
deglycosilation the glycoside mimic genistin was shown to be deconjugated most 
efficiently by ß-glucuronidase/arylsulfatase from Helix pomatia.  
 
To summarize, it can be stated that the bioactivation procedures described in Chapter 3 
and 4 of this thesis complement and improve the current effect based screening 
procedures, resulting in a panel of methods for screening on compounds with androgenic 
activity as well as prohormones and steroid derivatives. In this way the bioactivity based 
ban described in Council Directive 96/22/EC can be better met in future. 
 
Compared to enzyme fractions, whole cell systems such as liver slices have the advantage 
that phase I and phase II enzymes are present together with natural levels of cofactors. 
Moreover, in liver slices all liver cell types are present maintaining their original 
interactions and spatial arrangement thus resembling the real in vivo situation more 
closely. In Chapter 5 the feasibility of bovine liver slices as a model for the bioactivation 
of prohormones was investigated. After incubation of DHEA with bovine liver slices 
showed that 4-androstenedione, 7α-OH-DHEA and 7-oxo-DHEA were the most abundant 
metabolites formed, while also minor amounts of 5-androstene-3ß,17ß-diol, 17ß-
testosterone and 17α-testosterone were observed. This resulted in an increase in androgen 
activity as well as a decrease in androgen antagonistic activity. This confirms metabolism 
of DHEA into more androgen active compounds such as 4-androstenedione and 17ß-
testosterone. On the other hand, because liver slices resemble the in vivo situation more 
closely also a substantial amount of phase II metabolites are formed. Compared to bovine 
liver S9, bioactivation of DHEA with liver slices is therefore less efficient and can be 
considered to be a less suitable bioactivation model for screening purposes. Moreover, 
since preparation of liver slices is very laborious, and the fact that for each screening 
experiment liver slices have to be prepared freshly this method is less suitable for use as a 
high through-put screening procedure.  
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 Chapter 6 outlined a novel metabolomics based strategy for anabolic steroid urine 
profiling. Urine profiles of controls and DHEA or pregnenolone treated bull calves were 
analyzed by UPLC-TOFMS and compared by using MetAlign™ and multivariate 
statistics. These comparisons revealed large differences between the urinary profiles of 
control and DHEA or pregnenolone treated animals as well as between days of sampling 
and the route of administration. Data analysis showed that dozens of mass peak loadings 
were responsible for the significant differences (fold change >5x or >10x and a p-value 
<0.01) observed between urine profiles of controls and DHEA or pregnenolone treated 
animals. In order to determine if the mass peak loadings selected by multivariate statistics 
can be used as biomarker for DHEA or pregnenolone administration respectively, all mass 
signals were evaluated individually by univariate statistics. For DHEA already seven mass 
peak loadings showed a false negative rate below 5% hereby complying with Commission 
Decision 2002/657/EC [3]. Next, the mass peak loadings showing the least false 
negatives, respectively 12 (for DHEA) and 7 (for pregnenolone), mass peaks were 
selected and tested for false positives using a small but independent test set of control 
urines. For DHEA, 10 out of the 12 biomarkers tested showed no false positives, while for 
pregnenolone 5 out of the 7 potential biomarkers showed no false positives. Although 
these results are promising, the robustness of these potential biomarkers should be tested 
against a larger control population of bovine urines to obtain a more accurate estimation 
of the number of false positives.  
For future application of this holistic methodology in practice, urine profiles could be 
statistically compared to a “control population” i.e. an ever growing library of urine 
profiles of untreated control animals. Based on the statistical deviation from this control 
population it then can be decided whether a sample could be classified as “compliant” or 
“suspect”. Based on these screening results, inspection services could focus on farms 
showing suspicious results by intensifying the sample frequency or perform more detailed 
investigations in search for suspicious supplements and preparations. Another option is 
analyzing the urine sample with gas chromatography/ combustion/isotope ratio mass 
spectrometry (GC/C/IRMS) to unambiguously confirm the presence of exogenous 
administered (pro)hormones.  
 
In Chapter 7 the feasibility of a transcriptomics approach for screening on DHEA was 
investigated. Liver gene expression profiles of bovines treated orally or intramuscularly 
treated with DHEA were compared versus two control groups. Large differences in gene 
expression profiles were observed between treated and control animals as well as between 
the two separate groups of control animals. Nevertheless, significant (p<0.05) more than 
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 1.5 fold differential regulation of 37 and 23 transcripts for respectively intramuscularly 
and orally treated animals was shown. The majority of the regulated genes are involved in 
immune response for both PO as well as IM treated animals. It should be noted that the 
small number of animals used can hamper proper statistics and substantially increases the 
chance of detecting false-positive genes as well as missing typical DHEA target genes. In 
addition, for screening purposes this raises the question how specific these genes are for 
DHEA treatment and consequently the percentage of false positive animals obtained when 
using these genes for screening purposes. Moreover, the question is whether the gene 
expression profiles of the DHEA treated animals in this study will remain differential 
when they are compared to other groups of control animals. To deal with these issues we 
applied the statistics of gene set enrichment analysis (GSEA). For IM and PO treated 
calves, gene sets were generated of genes that were significantly regulated compared to 
one control group and validated versus the other control group using GSEA. This cross 
validation showed that 6 out of the 8 gene sets were significantly enriched in DHEA 
treated animals when compared to an independent control group.  
On the one hand this study showed that identification and application of genomic 
biomarkers for DHEA treatment is strongly hampered by biological variation. On the 
other hand, it is demonstrated that comparison of defined gene sets versus the whole 
expression profile allows to distinguish DHEA treated animals from controls. 
 
In the last chapter (Chapter 8) the results obtained in this research are summarized and 
discussed and also the future perspectives of the developed concepts set forth. To 
summarize it can be concluded that this thesis contributes to the knowledge about 
metabolism and bioactivation of prohormones in vitro as well as in vivo. The new effect 
based concepts for prohormone screening described in this thesis complement and 
improve the current testing programs as well as meeting better the European bioactivity 
based ban on growth promoters as described in Council Directive 96/22/EC. Moreover the 
in vitro concepts developed allow a reduction in animal testing since new unknown (pro)
hormone compounds can be tested in vitro for bioactivity at the transcript, the androgenic 
bioactivity and the metabolite level, thereby limiting the need for in vivo bovine trials to 
verification of the in vitro experiments only. 
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 Samenvatting 
Zoals vastgelegd in Richtlijn 96/22/EG [1] is in de Europese Unie het gebruik van 
groeibevorderaars in de veeteelt bij wet verboden. Er is echter geen lijst met verboden 
stoffen, maar 96/22/EG stelt dat alle stoffen met thyrostatische, estrogene, androgene of 
gestagene activiteit en bèta-agonisten verboden zijn. Daarnaast beschrijft Richtlijn 96/23/
EG de specifieke eisen om vee en dierlijke producten te monitoren op anabole steroïden 
[2]. Deze wet behelst voornamelijk monstername- en onderzoeksprocedures terwijl 
technische richtlijnen en criteria voor residu-analyses zijn beschreven in Beschikking 
2002/657/EG [3]. In hormoon residu-analyse zijn methodes over het algemeen gebaseerd 
op gas- of vloeistofchromatografie in combinatie met massaspectrometrische detectie (GC
- en LC-MS/MS) welke worden gebruikt voor zowel het screenen als het bevestigen van 
hormoonmisbruik. De meeste van deze screeningsmethodes zijn echter beperkt tot een 
korte lijst van vooraf bekende groeibevorderaars en kunnen dus niet volledig voldoen aan 
de essentie in Richtlijn 96/22/EG. Op deze manier is er dus een discrepantie tussen het op 
bioactiviteit gebaseerde verbod beschreven in 96/22/EG aan de ene kant en de technische 
middelen om te monitoren op gerichte (groepen) stoffen aan de andere kant. Om volledig 
aan de wetgeving te voldoen zouden screeningsmethodes op bioactiviteit gebaseerd 
moeten zijn. De laatste jaren is daarom veel tijd geïnvesteerd in de ontwikkeling en 
implementatie van nieuwe effectgebaseerde methodes, zoals bioassays, om misbruik van 
groeibevorderaars in de veehouderij op te sporen [4].  
Tijdens controles van veeteeltbedrijven in Nederland worden inspectiediensten echter 
soms geconfronteerd met dieren die op een onverklaarbare manier verdacht snel groeien. 
Naast deze observaties worden ook spuiten, supplementen en kruidenpreparaten 
aangetroffen die zogenaamde prohormonen, zoals dehydroepiandrosterone (DHEA) en 
pregnenolone, bevatten. Prohormonen hebben geen of geringe directe hormonale 
activiteit, maar hebben mogelijk wel hormonale effecten na in vivo-bioactivering. Kennis 
over metabolisme, werkingsmechanisme en excretieprofielen zijn echter vaak onduidelijk, 
met name in vee. Dit proefschrift beschrijft het onderzoek naar de bioactiviteit van 
prohormonen, zowel voor als na in vitro- en in vivo-metabolisme, met als doel het 
ontwikkelen van effectieve screenings- en detectiemethodes om prohormoon misbruik in 
de veeteelt aan te kunnen tonen en om te kunnen voldoen aan het op bioactiviteit 
gebaseerde verbod beschreven in Richtlijn 96/22/EG. 
 
In Hoofdstuk 2 zijn 18 voedingssupplementen, die vooraf met LC-MS/MS waren 
gescreend op de aanwezigheid van 49 verboden steroïdhormonen, getest op hormonale 
activiteit met behulp van een androgenen gist-assay. Na het screenen van deze 
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 supplementen, gaven twee eerder negatief verklaarde supplementen een respons in de 
androgenen gist-assay. Gebruik makend van dezelfde gist-assay in combinatie met ultra 
performance vloeistofchromatografie time-of-flight massaspectrometrie (UPLC-TOFMS) 
was het mogelijk om 4-androstene-3ß,17ß-diol, 5α-androstane-3ß,17ß-diol en 1-
testosteron in de bioactieve fracties aan te tonen. Omdat deze verbindingen niet in de lijst 
met 49 vooraf bekende steroïden stonden werden ze gemist door de eerder gebruikte LC-
MS/MS procedure. Dit illustreert duidelijk de toegevoegde waarde van een effect-
gebaseerde aanpak, waar in principe alle verbindingen met androgene activiteit kunnen 
worden opgepikt. Samen met bioassay-geleide identificatie is dit een nieuwe maatstaf 
voor de analyse van supplementen en preparaten die worden gebruikt in zowel de veeteelt 
als in de sport.  
 
Voor supplementen die alleen prohormonen bevatten, lijkt het gebruik van een op 
bioactiviteit gebaseerde screeningsmethode van beperkte waarde. De endogene 
prohormonen DHEA en 5-androstene-3ß,17ß-diol vertonen geen directe activiteit in de 
androgenen gist-assay, terwijl 4-androstenedion een EC50 van 6900 nM geeft. Om deze 
inactieve prohormonen in diervoeder, supplementen en injectiepreparaten op te sporen, is 
een alternatief in vitro-bioassay testsysteem ontwikkeld (Hoofdstuk 3). Om de in vivo-
metabole activering na te bootsen, zijn standaarden en monsterextracten geïncubeerd met 
runderlever S9-fracties, gevolgd door een screening in de androgenen gist-assay. 
Afhankelijk van de gebruikte cofactor resulteerde dit in een toename van de androgene 
activiteit voor DHEA, 5-androstene-3ß,17ß-diol en 4-androstenedion. Na incubatie van 
DHEA met runderlever S9, laat UPLC-TOFMS analyse zien dat 4-androstene-3,17-dion, 
7α-OH-DHEA en een in eerste instantie nog onbekende oxo-metaboliet van DHEA de 
meest voorkomende metabolieten van DHEA zijn wanneer NAD(P)+ als een cofactor 
word gebruikt. De onbekende oxo-metaboliet bleek later 7-oxo-DHEA te zijn. Wanneer 
NAD(P)H als een cofactor wordt gebruikt, word DHEA voornamelijk in 5-androstene-
3ß,17ß-diol omgezet, maar opnieuw zijn 7α-OH-DHEA en 7-oxo-DHEA de meest 
voorkomende metabolieten. Daarnaast worden ook kleine hoeveelheden onbekende 
metabolieten waargenomen die, gebaseerd op hun accurate massa, waarschijnlijk hydroxy
- en oxo-metabolieten van DHEA, 4-androstenedion of zelfs 17ß-testosteron zijn. Met 
betrekking tot bioactiviteit, zijn 4-androstenedion en 17ß-testosteron de verbindingen die 
het meeste bijdragen aan de androgene respons, terwijl 17α-testosteron, 5-androstene-
3ß,17ß-diol en de hydroxy-metabolieten van DHEA en 17ß-testosteron geen of zeer 
geringe androgene activiteit vertonen [5]. Ook metabole activering van prohormoon 
bevattende supplementen uit de praktijk resulteerde met succes in bioactivering en een 
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 positief screenings resultaat in de androgenen gist-assay. 
 
Vanuit het oogpunt van bioactiviteit zijn steroïd-conjugaten in principe ook prohormonen. 
Deze verbindingen moeten eerst gedeconjugeerd worden alvorens ze biologisch actief 
kunnen worden. In Hoofdstuk 4 worden methodes beschreven voor het screenen op esters 
en glycosiden in diervoeder en diervoedersupplementen. Deze methodes zijn gebaseerd op 
alkalische hydrolyse en enzymatische deconjugatie, gevolgd door screening op 
bioactiviteit met behulp van gist-bioassays. Voor testosteron-esters blijkt alkalische 
hydrolyse efficiënter te werken dan enzymatische hydrolyse met behulp van esterase. Na 
alkalische hydrolyse resulteerde een spike van 1 µg testosteron-ester per gram diervoeder 
al in een positief signaal in de androgenen gist-bioassay. Voor deglycosylering blijkt β-
glucuronidase/arylsulfatase van Helix pomatia het meest efficiënt te werken, resulterend 
in een significante toename van de hormonale activiteit.     
 
Samenvattend kan worden vastgesteld dat de bioactiveringsprocedures beschreven in 
Hoofdstuk 3 en 4 van dit proefschrift de huidige op effect gebaseerde screenings-
procedures aanvullen en verbeteren, wat resulteert in een panel van methodes dat geschikt 
is voor screening op zowel verbindingen met directe androgene activiteit als van 
prohormonen en steroïd-conjugaten. Hierdoor kan in de toekomst beter worden voldaan 
aan het op bioactiviteit gebaseerde verbod zoals beschreven in Richtlijn 96/22/EG.  
 
Vergeleken met lever enzymfracties hebben modellen gebaseerd op cellen, zoals 
leverslices, het voordeel dat alle fase I- en fase II-enzymen aanwezig zijn samen met de 
natuurlijke hoeveelheden aan cofactoren. Bovendien zijn in slices alle leverceltypen 
aanwezig met behoud van natuurlijke interacties en ruimtelijke ordening, wat in theorie 
een betere benadering van de in vivo-situatie geeft. In Hoofdstuk 5 is de bruikbaarheid 
van runderleverslices voor de bioactivering van het prohormoon DHEA beschreven. Na 
incubatie van DHEA met runderleverslices, worden voornamelijk de metabolieten            
4-androstenedion, 7α-OH-DHEA en 7-oxo-DHEA gevormd, maar ook kleine hoeveel-
heden van 5-androstene-3ß,17ß-diol, 17ß-testosteron en 17α-testosteron. Dit resulteerde 
zowel in een toename van androgene activiteit als in een afname van anti-androgene 
activiteit en bevestigt het metabolisme van DHEA in meer androgene verbindingen zoals 
4-androstenedion en 17ß-testosteron. Daar leverslices meer op de in vivo-situatie lijken, 
wordt er waarschijnlijk ook een substantieel deel aan fase II-metabolieten gevormd. Mede 
door dit fase II-metabolisme is incubatie van DHEA met runderleverslices vergeleken met 
runderlever-S9 een minder efficiënt bioactiverings model voor screeningsdoeleinden. 
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 Bovendien is het maken van deze leverslices zeer arbeidsintensief en ook daarom minder 
geschikt voor routinematige screeningsprocedures.  
 
In Hoofdstuk 6 is een nieuwe, op metabolomics gebaseerde, strategie voor urine-
steroïdprofilering beschreven. Urineprofielen van controle en DHEA of pregenenolone 
behandelde runderen zijn gemeten met UPLC-TOFMS en vervolgens vergeleken met 
behulp van MetAlignTM-sofware en multivariate statistiek. Deze vergelijkingen laten grote 
verschillen zien tussen urineprofielen van controle en DHEA of pregnenolone behandelde 
dieren evenals tussen de dagen van monstername en de manier van toediening. Na 
statistische analyse blijkt dat tientallen massa’s verantwoordelijk zijn voor deze 
significante verschillen (>5 of >10x gereguleerd, p-waarde <0.01) tussen urineprofielen 
van controle en DHEA dan wel pregnenolone behandelde dieren. Om te bepalen of deze 
massa’s geschikt zijn als biomarkers voor DHEA of pregnenolone misbruik zijn al deze 
massa signalen ook individueel geëvalueerd met univariate statistiek. Voor DHEA 
vertoonde al zeven massa’s een percentage vals-negatieven lager dan 5% hetgeen voldoet 
aan de screeningsmethode eisen van Beschikking 2002/657/EG [3]. Vervolgens zijn op 
basis van het aantal vals negatieven, respectievelijk 12 (voor DHEA) en 7 (voor 
pregnenolone) massa’s geselecteerd die zijn getest op het aantal vals-positieven versus 
een kleine maar onafhankelijke set van controle-urines. Voor DHEA vertoonden 10 van 
de 12 biomarkers geen vals-positieven, terwijl voor pregnenolone 5 van de 7 potentiële 
biomarkers geen vals-positieve resultaten opleverden. Hoewel deze resultaten veel-
belovend zijn, moet de robuustheid van deze potentiële biomarkers versus een grotere 
controlepopulatie urines worden getest om een betere schatting van het aantal vals-
positieven te kunnen maken. 
Bij een toekomstige toepassing van deze holistische methode in de praktijk zouden 
urineprofielen statistisch vergeleken kunnen worden met een “normaal-populatie”, dat wil 
zeggen een groeiend bestand van urineprofielen van onbehandelde controledieren. Het 
analyseresultaat is dan een statistische waarschijnlijkheid dat het urinemonster afwijkt van 
een normaal profiel plus een indicatie van de biomarkers die daarvoor verantwoordelijk 
zijn. Op basis hiervan kan een opsporingsdienst gericht verder zoeken naar preparaten, 
voer, en andere monsters, dan wel besluiten tot een intensievere gerichte controle 
(opsporingsfocus). Een andere optie is analyse van urine met behulp van gas 
chromatography/combustie/isotoop ratio massaspectrometrie (GC/C/IRMS) om het 
gebruik van exogene toediening van natuurlijke (pro)hormonen onomstotelijk vast te 
kunnen stellen.  
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 In Hoofdstuk 7 is de bruikbaarheid van genexpressieprofilering als een screenings-
methode voor DHEA-misbruik onderzocht. Lever genexpressieprofielen van runderen die 
intramusculair of oraal waren behandeld met DHEA zijn vergeleken met gen-
expressieprofielen van (twee groepen) controledieren. Dit resulteerde in grote verschillen 
in genexpressieprofielen, zowel tussen de controle en de behandelde dieren als tussen de 
twee controlegroepen onderling. Desalniettemin resulteerde dit in 37 en 23 significant 
gereguleerde genen (>1.5x gereguleerd, p-waarde <0.05) specifiek voor respectievelijk de 
intramusculair en oraal behandelde dieren. De meeste van deze gereguleerde genen 
hebben betrekking op immuunrespons en de vraag is dan ook hoe typerend deze genen 
voor DHEA-behandeling zijn. Ook moet worden opgemerkt dat om ethische redenen 
slechts een klein aantal dieren in de proefopzet is meegenomen. Dit beïnvloedt de 
statistiek en hierdoor is de kans op identificatie van vals-positieve genen groter evenals de 
kans op het missen van DHEA-specifieke genen.  
Daarnaast is het de vraag of de gevonden genexpressieprofielen significant verschillend 
blijven wanneer ze worden vergeleken met andere groepen van controledieren. Daarom is 
gebruik gemaakt van de statistiek van gene set enrichment analysis (GSEA) waar naar 
verschillen in genexpressie wordt gekeken op basis van zogenaamde genensets. Voor 
zowel de intramusculair als oraal behandelde dieren zijn genensets gecreëerd versus de 
ene controlegroep die vervolgens zijn vergeleken met genexpressieprofielen van de andere 
controlegroep. Deze validatie toonde aan dat 6 van de 8 genensets statistisch significant 
waren verrijkt in DHEA-behandelde dieren wanneer deze worden vergeleken met een 
“onafhankelijke” controlegroep. Aan de ene kant laat dit onderzoek zien dat identificatie 
en toepassing van genbiomarkers sterk gehinderd wordt door biologische variatie, aan de 
andere kant is  het wel degelijk mogelijk om DHEA behandelde dieren te onderscheiden 
van controledieren op basis van hun genexpressieprofielen.  
 
In het laatste hoofdstuk (Hoofdstuk 8) worden de resultaten van het in dit proefschrift 
beschreven onderzoek samengevat en bediscussieerd en worden de toekomstperspectieven 
van de ontwikkelde concepten uiteengezet. Samenvattend kan worden geconcludeerd dat 
dit proefschrift bijdraagt aan de kennis van metabolisme en bioactivering van 
prohormonen zowel in vitro als in vivo. Bovendien kunnen de nieuwe op effect 
gebaseerde concepten en prohormoon screeningsmethodes beschreven in dit proefschrift 
de huidige testmethodes aanvullen en verbeteren en kunnen zij tevens beter voldoen aan 
het op bioactiviteit gebaseerde verbod beschreven in Richtlijn 96/22/EG. Daarnaast 
kunnen de ontwikkelde concepten bijdragen aan het terugdringen van het 
proefdiergebruik, daar nieuwe (pro)hormonen eerst in vitro kunnen worden geëvalueerd 
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 op bioactiviteit, metabolisme en genexpressie. De noodzaak voor in vivo-proeven blijft 
hierdoor beperkt tot verificatie van de resultaten van de in vitro-experimenten. 
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 Dankwoord 
 
Toen ik begin 2005 bij Maria, aan de met een Perzisch kleed bedekte tafel op 
sollicitatiegesprek zat, werd me verteld dat ze voor onderzoek naar prohormonen een 
duizendpoot zochten. Bioassays waren wel een beetje bekend terrein, maar LC-(TOF)MS 
en microarrays waren echt een “black box” voor me. Toch heb ik toen de keuze gemaakt 
om me te storten op een voor mij toentertijd compleet onbekend onderwerp. Het begin 
van een leerzame periode waarvan ik achteraf absoluut geen spijt heb gehad, integendeel! 
Het eindresultaat ligt nu voor je, “mijn proefschrift”. Naast mijn inzet werd dit mede 
mogelijk gemaakt door een aantal mensen die ik door middel van dit dankwoord wil 
bedanken. 
 
Allereerst wil ik mijn (co)-promotoren Michel, Ivonne, Maria en Ad bedanken. 
Michel, vooral dankzij jouw inzet en kennis heb ik de eindstreep gehaald. Bedankt voor 
het enthousiasme voor mijn promotieonderzoek en de razendsnelle commentaren en 
correcties van manuscripten en hoofdstukken. Maria, ik wil je hartelijk bedanken voor je 
steun en de begeleiding van het prohormonen-project. Altijd kon ik bij je binnen lopen om 
het werk en de voortgang van het onderzoek te bespreken, of zomaar, voor een praatje. Ik 
hoop dat in de toekomst nog vaak te kunnen doen. Ad, bedankt voor de begeleiding en het 
kritisch doorlezen van de (vele) concept manuscripten. Het microarray stuk was een harde 
noot om te kraken, maar uiteindelijk is het, zoals hoofdstuk 7 bewijst, toch gelukt. Met 
veel plezier blijf ik binnen jouw cluster werken. Ivonne, bedankt voor je input in de laatste 
fase van mijn promotietraject. Leuk dat ook jij mijn promotor wilt zijn. 
 
Verder wil ik alle collega’s van het cluster Toxicologie en Effect Analyse bedanken voor 
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